Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-12-460669.txt : 20121108 0001193125-12-460669.hdr.sgml : 20121108 20121108165502 ACCESSION NUMBER: 0001193125-12-460669 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121108 DATE AS OF CHANGE: 20121108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-09410 FILM NUMBER: 121190675 BUSINESS ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 10-Q 1 d398107d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-09410

PROVECTUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Nevada		90-0031917
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee		37931
(Address of principal executive offices)		(Zip Code)

866-594-5999

(Registrant’s telephone number, including area code)

N/A

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

The number of shares outstanding of the registrant’s common stock, par value $.001 per share, as of September 30, 2012 was 113,701,071. The number of shares outstanding of the issuer’s 8% convertible preferred stock, par value $.001 per share, as of September 30, 2012 was 2,941,665.

TABLE OF CONTENTS


PART I FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets			3
Condensed Consolidated Statements of Operations			4
Condensed Consolidated Statements of Stockholders’ Equity			5
Condensed Consolidated Statements of Cash Flow			9
Notes to Condensed Consolidated Financial Statements			10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			13
Item 3. Quantitative and Qualitative Disclosures About Market Risk			16
Item 4. Controls and Procedures			16

PART II OTHER INFORMATION

Item 1. Legal Proceedings			17
Item 1A. Risk Factors			17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			17
Item 3. Defaults Upon Senior Securities			17
Item 4. Mine Safety Disclosures			17
Item 5. Other Information			17
Item 6. Exhibits			18

SIGNATURES			19

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30, 2012 (Unaudited)			December 31, 2011
Assets
Current Assets
Cash and cash equivalents	$	1,842,118		$	7,705,773
Prepaid expenses and other current assets		16,284			—

Total Current Assets		1,858,402			7,705,773
Equipment and furnishings, less accumulated depreciation of $421,377 and $416,798		31,417			20,111
Patents, net of amortization of $6,621,717 and $6,118,377, respectively		5,093,728			5,597,068
Other assets		27,000			27,000

	$	7,010,547		$	13,349,952

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable — trade	$	280,615		$	101,102
Accrued compensation and payroll taxes		1,433,481			—
Accrued consulting expense		102,000			71,000
Other accrued expenses		139,000			90,622

Total Current Liabilities		1,955,096			262,724
Long-Term Liability
Warrant liability		1,631,590			3,067,488

Total Liabilities		3,586,686			3,330,212

Stockholders’ Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; 2,941,665 and 3,531,665 shares issued and outstanding, respectively, liquidation preference $0.75 per share (in aggregate $2,250,133 and $2,702,134, respectively)		2,941			3,531
Common stock; par value $.001 per share; 200,000,000 authorized; 113,701,071 and 110,596,798 shares issued and outstanding, respectively		113,701			110,597
Paid-in capital		119,739,223			115,690,334
Deficit accumulated during the development stage		(116,432,004	)		(105,784,722	)

Total Stockholders’ Equity		3,423,861			10,019,740

	$	7,010,547		$	13,349,952

See accompanying notes to condensed consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended Sept 30, 2012			Three Months Ended Sept 30, 2011			Nine Months Ended Sept 30, 2012			Nine Months Ended Sept 30, 2011			Cumulative Amounts from January 17, 2002 (Inception) Through Sept 30, 2012
Revenues
OTC product revenue	$	—		$	—		$	—		$	—		$	25,648
Medical device revenue		—			—			—			—			14,109

Total revenues		—			—			—			—			39,757
Cost of sales		—			—			—			—			15,216

Gross profit		—			—			—			—			24,541
Operating expenses
Research and development		1,129,921			3,442,344			4,352,940			6,971,816			42,446,334
General and administrative		2,296,637			3,860,755			7,228,225			9,568,240			64,753,074
Amortization		167,780			167,780			503,340			503,340			6,621,717

Total operating loss		(3,594,338	)		(7,470,879	)		(12,084,505	)		(17,043,396	)		(113,796,584	)
Gain on sale of fixed assets		—			—			—			—			55,075
Loss on extinguishment of debt		—			—			—			—			(825,867	)
Investment income		310			529			1,325			898			653,195
Gain on change in fair value of warrant liability		1,246,917			1,027,554			1,435,898			1,059,730			5,580,181
Net interest expense		—			—			—			—			(8,098,004	)

Net loss		(2,347,111	)		(6,442,796	)		(10,647,282	)		(15,982,768	)		(116,432,004	)
Dividends on preferred stock		(43,884	)		(59,465	)		(145,709	)		(193,623	)		(10,800,584	)

Net loss applicable to common shareholders	$	(2,390,995	)	$	(6,502,261	)	$	(10,792,991	)	$	(16,176,391	)	$	(127,232,588	)

Basic and diluted loss per common share	$	(0.02	)	$	(0.06	)	$	(0.10	)	$	(0.16	)

Weighted average number of common shares outstanding — basic and diluted		113,166,988			109,100,408			112,073,836			104,277,935

See accompanying notes to consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY


	Preferred Stock				Common Stock
	Number of Shares		Par Value		Number of Shares			Par Value			Paid in capital			Accumulated Deficit			Total
Balance, at January 17, 2002		—	$	—		—		$	—		$	—		$	—		$	—
Issuance to founding shareholders		—		—		6,000,000			6,000			(6,000	)		—			—
Sale of stock		—		—		50,000			50			24,950			—			25,000
Issuance of stock to employees		—		—		510,000			510			931,490			—			932,000
Issuance of stock for services		—		—		120,000			120			359,880			—			360,000
Net loss for the period from January 17, 2002 (inception) to April 23, 2002 (date of reverse merger)		—		—		—			—			—			(1,316,198	)		(1,316,198	)

Balance, at April 23, 2002		—	$	—		6,680,000		$	6,680		$	1,310,320		$	(1,316,198	)	$	802
Shares issued in reverse merger		—		—		265,763			266			(3,911	)		—			(3,645	)
Issuance of stock for services		—		—		1,900,000			1,900			5,142,100			—			5,144,000
Purchase and retirement of stock		—		—		(400,000	)		(400	)		(47,600	)		—			(48,000	)
Stock issued for acquisition of Valley Pharmaceuticals		—		—		500,007			500			12,225,820			—			12,226,320
Exercise of warrants		—		—		452,919			453			—			—			453
Warrants issued in connection with convertible debt		—		—		—			—			126,587			—			126,587
Stock and warrants issued for acquisition of Pure-ific		—		—		25,000			25			26,975			—			27,000
Net loss for the period from April 23, 2002 (date of reverse merger) to December 31, 2002		—		—		—			—			—			(5,749,937	)		(5,749,937	)

Balance, at December 31, 2002		—	$	—		9,423,689		$	9,424		$	18,780,291		$	(7,066,135	)	$	11,723,580
Issuance of stock for services		—		—		764,000			764			239,036			—			239,800
Issuance of warrants for services		—		—		—			—			145,479			—			145,479
Stock to be issued for services		—		—		—			—			281,500			—			281,500
Employee compensation from stock options		—		—		—			—			34,659			—			34,659
Issuance of stock pursuant to Regulation S		—		—		679,820			680			379,667			—			380,347
Beneficial conversion related to convertible debt		—		—		—			—			601,000			—			601,000
Net loss for the year ended December 31, 2003		—		—		—			—			—			(3,155,313	)		(3,155,313	)

Balance, at December 31, 2003		—	$	—		10,867,509		$	10,868		$	20,461,632		$	(10,221,448	)	$	10,251,052
Issuance of stock for services		—		—		733,872			734			449,190			—			449,923
Issuance of warrants for services		—		—		—			—			495,480			—			495,480
Exercise of warrants		—		—		132,608			133			4,867			—			5,000
Employee compensation from stock options		—		—		—			—			15,612			—			15,612
Issuance of stock pursuant to Regulation S		—		—		2,469,723			2,469			790,668			—			793,137
Issuance of stock and warrants pursuant to Regulation D		—		—		1,930,164			1,930			1,286,930			—			1,288,861
Beneficial conversion related to convertible debt		—		—		—			—			360,256			—			360,256


	Preferred Stock				Common Stock
	Numberof Shares		Par Value		Number of Shares		Par Value		Paid in capital			Accumulated Deficit			Total
Issuance of convertible debt with warrants		—		—		—		—		105,250			—			105,250
Repurchase of beneficial conversion feature		—		—		—		—		(258,345	)		—			(258,345	)
Net loss for the year ended December 31, 2004		—		—		—		—		—			(4,344,525	)		(4,344,525	)

Balance, at December 31, 2004		—	$	—		16,133,876	$	16,134	$	23,711,540		$	(14,565,973	)	$	9,161,701
Issuance of stock for services		—		—		226,733		227		152,058			—			152,285
Issuance of stock for interest payable		—		—		263,721		264		195,767			—			196,031
Issuance of warrants for services		—		—		—		—		1,534,405			—			1,534,405
Issuance of warrants for contractual obligations		—		—		—		—		985,010			—			985,010
Exercise of warrants and stock options		—		—		1,571,849		1,572		1,438,223			—			1,439,795
Employee compensation from stock options		—		—		—		—		15,752			—			15,752
Issuance of stock and warrants pursuant to Regulation D		—		—		6,221,257		6,221		6,506,955			—			6,513,176
Debt conversion to common stock		—		—		3,405,541		3,405		3,045,957			—			3,049,362
Issuance of warrants with convertible debt		—		—		—		—		1,574,900			—			1,574,900
Beneficial conversion related to convertible debt		—		—		—		—		1,633,176			—			1,633,176
Beneficial conversion related to interest expense		—		—		—		—		39,529			—			39,529
Repurchase of beneficial conversion feature		—		—		—		—		(144,128	)		—			(144,128	)
Net loss for the year ended 2005		—		—		—		—		—			(11,763,853	)		(11,763,853	)


	Preferred Stock				Common Stock
	Number of Shares		Par Value		Number of Shares		Par Value		Paid in capital		Accumulated Deficit			Total
Balance, at December 31, 2005		—	$	—		27,822,977	$	27,823	$	40,689,144	$	(26,329,826	)	$	14,387,141
Issuance of stock for services		—		—		719,246		719		676,024		—			676,743
Issuance of stock for interest payable		—		—		194,327		195		183,401		—			183,596
Issuance of warrants for services		—		—		—		—		370,023		—			370,023
Exercise of warrants and stock options		—		—		1,245,809		1,246		1,188,570		—			1,189,816
Employee compensation from stock options		—		—		—		—		1,862,456		—			1,862,456
Issuance of stock and warrants pursuant to Regulation D		—		—		10,092,495		10,092		4,120,329		—			4,130,421
Debt conversion to common stock		—		—		2,377,512		2,377		1,573,959		—			1,576,336
Beneficial conversion related to interest expense		—		—		—		—		16,447		—			16,447
Net loss for the year ended 2006		—		—		—		—		—		(8,870,579	)		(8,870,579	)

Balance, at December 31, 2006		—	$	—		42,452,366	$	42,452	$	50,680,353	$	(35,200,405	)	$	15,522,400
Issuance of stock for services		—		—		150,000		150		298,800		—			298,950
Issuance of stock for interest payable		—		—		1,141		1		1,257		—			1,258
Issuance of warrants for services		—		—		—		—		472,635		—			472,635
Exercise of warrants and stock options		—		—		3,928,957		3,929		3,981,712		—			3,985,641
Employee compensation from stock options		—		—		—		—		2,340,619		—			2,340,619
Issuance of stock and warrants pursuant to Regulation D		—		—		2,376,817		2,377		1,845,761		—			1,848,138
Debt conversion to common stock		—		—		490,000		490		367,010		—			367,500
Net loss for the year ended 2007		—		—		—		—		—		(10,005,631	)		(10,005,631	)

Balance, at December 31, 2007		—	$	—		49,399,281	$	49,399	$	59,988,147	$	(45,206,036	)	$	14,831,510
Issuance of stock for services		—		—		350,000		350		389,650		—			390,000
Issuance of warrants for services		—		—		—		—		517,820		—			517,820
Exercise of warrants and stock options		—		—		3,267,795		3,268		2,636,443		—			2,639,711
Employee compensation from stock options		—		—		—		—		1,946,066		—			1,946,066
Net loss for the year ended 2008		—		—		—		—		—		(10,269,571	)		(10,269,571	)

Balance, at December 31, 2008		—	$	—		53,017,076	$	53,017	$	65,478,126	$	(55,475,607	)	$	10,055,536
Issuance of stock for services		—		—		796,012		796		694,204		—			695,000
Issuance of warrants for services		—		—		—		—		1,064,210		—			1,064,210
Exercise of warrants and stock options		—		—		3,480,485		3,480		2,520,973		—			2,524,453
Employee compensation from stock options		—		—		—		—		870,937		—			870,937
Issuance of stock and warrants pursuant to Regulation D						10,116,653		10,117		6,508,571		—			6,518,688
Net loss for the year ended 2009		—		—		—		—		—		(12,322,314	)		(12,322,314	)

Balance, at December 31, 2009		—	$	—		67,410,226	$	67,410	$	77,137,021	$	(67,797,921	)	$	9,406,510
Issuance of stock for services		—		—		776,250		776		855,837		—			856,613
Issuance of warrants for services		—		—		—		—		1,141,593		—			1,141,593
Exercise of warrants and stock options		—		—		3,491,014		3,491		3,100,189		—			3,103,680
Issuance of common stock pursuant to Regulation S		—		—		559,000		559		418,691		—			419,250
Issuance of common stock and warrants pursuant to Regulation D		—		—		11,168,067		11,169		6,335,820		—			6,346,989


	Preferred Stock						Common Stock
	Number of Shares			Par Value			Number of Shares		Par Value		Paid in capital		Accumulated Deficit			Total
Issuance of preferred stock pursuant to Regulation D		13,283,324			13,283			—		—		4,204,107		—			4,217,390
Preferred stock conversions into common stock		(7,893,326	)		(7,893	)		7,893,326		7,893		—		—			—
Employee compensation from stock options		—			—			—		—		3,759,650		—			3,759,650
Net loss for the year ended 2010		—			—			—		—		—		(18,552,102	)		(18,552,102	)

Balance, at December 31, 2010		5,389,998		$	5,390			91,297,883	$	91,298	$	96,952,908	$	(86,350,023	)	$	10,699,573
Issuance of stock for services		—			—			350,000		350		332,400		—			332,750
Issuance of warrants for services		—			—			—		—		945,116		—			945,116
Exercise of warrants and stock options		—			—			7,185,522		7,185		6,616,126		—			6,623,311
Issuance of common stock and warrants pursuant to Regulation D		—			—			9,905,062		9,905		7,031,334		—			7,041,239
Sale of non-controlling interest in Pure-ific Corporation and warrants		—			—			—		—		443,500		—			443,500
Preferred stock conversions into common stock		(1,858,333	)		(1,859	)		1,858,331		1,859		—		—			—
Employee compensation from stock options		—			—			—		—		3,368,950		—			3,368,950
Net loss for the year ended 2011		—			—			—		—		—		(19,434,699	)		(19,434,699	)

Balance, at December 31, 2011		3,531,665		$	3,531			110,596,798	$	110,597	$	115,690,334	$	(105,784,722	)	$	10,019,740
Issuance of stock for services		—			—			475,000		475		408,775		—			409,250
Issuance of warrants for services		—			—			—		—		1,381,329		—			1,381,329
Issuance of common stock and warrants pursuant to Regulation D		—			—			2,039,273		2,039		2,075,757		—			2,077,796
Preferred stock conversions into common stock		(590,000	)		(590	)		590,000		590		—		—			—
Employee compensation from stock options		—			—			—		—		183,028		—			183,028
Net loss for the nine months ended September 30, 2012		—			—			—		—		—		(10,647,282	)		(10,647,282	)

Balance, at September 30, 2012 (Unaudited)		2,941,665		$	2,941			113,701,071	$	113,701	$	119,739,223	$	(116,432,004	)	$	3,423,861

See accompanying notes to condensed consolidated financial statements.

PROVECTUS PHARMACEUTICALS, INC.

(A Development-Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)


	Nine Months Ended September 30, 2012			Nine Months Ended September 30, 2011			Cumulative Amounts from January 17, 2002 (Inception) through September 30, 2012
Cash Flows From Operating Activities
Net loss	$	(10,647,282	)	$	(15,982,768	)	$	(116,432,004	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		4,579			5,737			444,378
Amortization of patents		503,340			503,340			6,621,717
Amortization of original issue discount		—			—			3,845,721
Amortization of commitment fee		—			—			310,866
Amortization of prepaid consultant expense		—			—			1,295,226
Amortization of deferred loan costs		—			—			2,261,584
Accretion of United States Treasury Bills		—			—			(373,295	)
Loss on extinguishment of debt		—			—			825,867
Loss on exercise of warrants		—			—			236,146
Beneficial conversion of convertible interest		—			—			55,976
Convertible interest		—			—			389,950
Compensation through issuance of stock options		183,028			3,368,950			14,397,729
Compensation through issuance of stock		—			—			932,000
Issuance of stock for services		409,250			268,500			9,006,261
Issuance of warrants for services		1,381,329			540,316			6,065,872
Issuance of warrants for contractual obligations		—			—			985,010
Gain on sale of equipment		—			—			(55,075	)
Gain on change in fair value of warrant liability		(1,435,898	)		(1,059,730	)		(5,580,181	)
(Increase) decrease in assets
Prepaid expenses and other current assets		(16,284	)		(42,415	)		(16,284	)
Increase (decrease) in liabilities
Accounts payable		179,513			(271,314	)		276,970
Accrued expenses		1,512,859			(588,369	)		1,824,111

Net cash used in operating activities		(7,925,566	)		(13,257,753	)		(72,681,455	)

Cash Flows From Investing Activities
Proceeds from sale of fixed assets		—			—			180,075
Capital expenditures		(15,885	)		(6,147	)		(89,920	)
Proceeds from sales of investments		—			—			37,010,481
Purchases of investments		—			—			(36,637,186	)

Net cash (used in) provided by investing activities		(15,885	)		(6,147	)		463,450

Cash Flows From Financing Activities
Net proceeds from loans from stockholder		—			—			174,000
Proceeds from convertible debt		—			—			6,706,795
Net proceeds from sales of preferred stock and warrants		—			—			8,908,131
Net proceeds from sales of common stock and warrants		2,077,796			9,486,071			40,101,773
Proceeds from exercises of warrants and stock options		—			6,504,209			21,078,014
Cash paid to retire convertible debt		—			—			(2,385,959	)
Cash paid for deferred loan costs		—			—			(747,612	)
Premium paid on extinguishments of debt		—			—			(170,519	)
Purchase and retirement of common stock		—			—			(48,000	)
Net proceeds from sale non-controlling interest in Pure-ific Corporation		—			—			443,500

Net cash provided by financing activities		2,077,796			15,990,280			74,060,123

Net change in cash and cash equivalents	$	(5,863,655	)	$	2,726,380		$	1,842,118
Cash and cash equivalents, at beginning of period		7,705,773			8,086,200			—

Cash and cash equivalents, at end of period	$	1,842,118		$	10,812,580		$	1,842,118


Supplemental Disclosure of Noncash Investing and Financing Activities:

During the nine months ended September 30, 2011, the Company reclassified $485,467 from warrant liability to equity due to the exercise of warrants.

See accompanying notes to condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

2. Recapitalization and Merger

Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.

On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.

On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

3. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2012 and 2011, respectively, relate to 26,042,116 and 24,575,302 from warrants, 15,140,956 and 15,390,956 from options, and 2,941,665 and 3,848,332 from convertible preferred shares.

4. Equity Transactions

(a) During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(b) During the three months ended March 31, 2012, the Company issued 1,003,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants expired. During the three months ended June 30, 2012, the Company issued 454,500 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants expired. During the three months ended September 30, 2012, the Company issued 1,732,135 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants expired. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $148,364. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $222,546. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $429,818.

During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

(d) The Company determined that warrants issued in March and April, 2010 with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $114,800. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $229,599. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $817,099.

Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock.

5. Related Party Transaction

The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2012. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2012 and issued 100,000 fully vested warrants in exchange for services. Consulting costs charged to operations were $47,520 for the services for which these warrants were issued. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2012.

6. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2012 for the 2010 warrants include a weighted average term of 3.0 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.51%. Significant assumptions used at June 30, 2012 for the 2010 warrants include a weighted average term of 2.7 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 64.2% to 65.8% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2010 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%.

Significant assumptions used at March 31, 2012 for the 2011 warrants include a weighted average term of 3.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.78%. Significant assumptions used at June 30, 2012 for the 2011 warrants include a weighted average term of 3.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2011 warrants include a weighted average term of 3.3 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%.

The warrant liability measured at fair value on a recurring basis is as follows:


	Total		Level 1		Level 2		Level 3
Derivative instruments:
Warrant liability at September 30, 2012	$	1,631,590	$	—	$	—	$	1,631,590
Warrant liability at December 31, 2011	$	3,067,488	$	—	$	—	$	3,067,488

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2012 to September 30, 2012 follows:


Balance at January 1, 2012	$	3,067,488
Net gain included in earnings		(1,435,898	)

Balance at September 30, 2012	$	1,631,590

7. Stock-Based Compensation

On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On July 6, 2011, the Company issued 250,000 stock options to its re-elected members of the board. On July 12, 2011, the Company issued 50,000 stock options to a newly appointed member of the board. On September 6, 2011, the Company issued 4,000,000 stock options to its employees. All of the stock options issued in 2011 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.

The compensation cost relating to stock options issued in 2012 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for both the three and nine months ended September 30, 2011 is $3,368,950 of stock-based compensation expense which relates to the fair value of stock options.

The following is a summary of nonvested stock option activity for the nine months ended September 30, 2012:


	Number of Shares			Weighted Average Grant-Date Fair Value
Nonvested at December 31, 2011		—		$	—
Granted		250,000		$	0.73
Vested		(250,000	)	$	0.73
Canceled		—			—

Nonvested at September 30, 2012		—		$	—

As of September 30, 2012, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited financial statements, our Annual Report on Form 10-K for the year ended December 31, 2011, which includes additional information about our critical accounting policies and practices and risk factors, and Item 1A of Part II of this report, which updates those risk factors. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

Plan of Operation

We have implemented our integrated business plan, including execution of the current and next phases in clinical development of our pharmaceutical products and continued execution of research programs for new research initiatives.

We intend to proceed as rapidly as possible with a licensure of our dermatology drug product candidate (PH-10) on the basis of our Phase 2 atopic dermatitis and psoriasis results, which are in process of being further developed. We intend to also proceed as rapidly as possible with a majority stake asset sale and subsequent licensure of our OTC products that can be sold with a minimum of regulatory compliance and with the further development of revenue sources through a majority stake asset sale and subsequent licensing of our existing medical device, imaging, and biotech intellectual property portfolio. On December 15, 2011, we concluded a private offering of securities, pursuant to which we issued 3,333,335 shares of common stock of Pure-ific Corporation, one of our wholly owned subsidiaries. Upon completion of the offering, we commenced the process to facilitate this spin-out transaction. Although we believe that there is a reasonable basis for our expectation that we will become profitable due to both the licensure of PH-10 and the asset sale of a majority stake via a spin-out transaction of the wholly-owned subsidiaries that contain the non-core assets and subsequent licensure of our non-core products, we cannot assure you that we will be able to achieve, or maintain, a level of profitability sufficient to meet our operating expenses.

Our current plans include continuing to operate with our four employees during the immediate future, as well as four primary consultants and various vendor relationships, and anticipate adding additional personnel if necessary in the next 12 months. Our current plans also include minimal purchases of new property, plant and equipment, and increased research and development for additional clinical trials.

We believe that our prescription drug candidates PV-10 and PH-10 provide us with two products in multiple indications, which have been shown in clinical trials to be safe to treat serious cancers and diseases of the skin. We continue to develop clinical trials for these products to show their safety and efficacy, which we believe will be shown based on data in previous studies. Together with our OTC products, medical device, biotech, imaging, and other non-core technologies, which we intend to sell or license in the future, we believe this combination represents the foundation for maximizing shareholder value this year and beyond.

Results of Operations

Comparison of Three and Nine Months Ended September 30, 2012 and September 30, 2011

Revenues

We had no revenue during the three and nine months ended September 30, 2012 and 2011.

Research and Development

Research and development costs of $1,129,921 for the three months ended September 30, 2012 included payroll of $302,064, consulting and contract labor of $670,449, legal of $62,568, insurance of $60,228, lab supplies and pharmaceutical preparations of $13,122, rent and utilities of $19,864, and depreciation expense of $1,626. Research and development costs of $3,442,344 for the three months ended September 30, 2011 included payroll of $2,843,840, consulting and contract labor of $469,051, legal of $41,162, insurance of $55,359, lab supplies and pharmaceutical preparations of $16,475, rent and utilities of $14,497, and depreciation expense of $1,960. The decrease in payroll is primarily the result of no bonuses and no stock-based compensation expense from stock options.

Research and development costs of $4,352,940 for the nine months ended September 30, 2012 included payroll of $2,258,622, consulting and contract labor of $1,737,376, legal of $178,236, insurance of $85,228, lab supplies and pharmaceutical preparations of $32,564, rent and utilities of $56,335, and depreciation expense of $4,579. Research and development costs of $6,971,816 for the nine months ended September 30, 2011 included payroll of $4,998,364, consulting and contract labor of $1,685,162, legal of $97,669, insurance of $84,606, lab supplies and pharmaceutical preparations of $50,339, rent and utilities of $49,939, and depreciation expense of $5,737. The decrease in payroll is primarily the result of a decrease in bonuses and stock-based compensation expense from stock options.

General and Administrative

General and administrative expenses decreased by $1,564,118 in the three months ended September 30, 2012 to $2,296,637 from $3,860,755 for the three months ended September 30, 2011. The decrease is primarily from lower payroll due to no bonuses and no stock-based compensation expense from stock options.

General and administrative expenses decreased by $2,340,015 in the nine months ended September 30, 2012 to $7,228,225 from $9,568,240 for the nine months ended September 30, 2011. The decrease is primarily from lower payroll due to a decrease in bonuses and stock-based compensation expense from stock options.

Investment Income

Investment income was insignificant in both the three and nine months ended September 30, 2012 and 2011.

Gain on change in fair value of warrant liability

Gain on change in fair value of warrant liability increased by $219,363 in the three months ended September 30, 2012 to $1,246,917 from $1,027,554 for the three months ended September 30, 2011. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d) and 6 to the financial statements.

Gain on change in fair value of warrant liability increased by $376,168 in the nine months ended September 30, 2012 to $1,435,898 from $1,059,730 for the nine months ended September 30, 2011. This activity results from accounting for the warrant liability described in Footnotes 4(c), 4(d) and 6 to the financial statements.

Liquidity and Capital Resources

Our cash and cash equivalents were $1,842,118 at September 30, 2012, compared with $7,705,773 at December 31, 2011. The decrease of approximately $5.9 million was due primarily to a substantial reduction of sales of common stock and

warrants as well as no exercises of warrants and stock options offset partially by approximately $5.3 million less cash that was used in operating activities. Additionally in October 2012, the Company received approximately $2.0 million in cash due to a private placement of its common stock at a premium to the fair market value of its common stock at the time of the sale.

By managing variable cash expenses due to minimal fixed costs, we believe our cash and cash equivalents on hand at September 30, 2012, together with cash proceeds received during October 2012, will be sufficient to meet our current and planned operating needs until well into 2013 without consideration being given to additional cash inflows that might occur from the exercise of existing warrants or future sales of equity securities, although we may, in our sole discretion, direct Lincoln Park Capital Fund, LLC (the “Fund”) to purchase up to an additional $29,950,000 of our common stock per an existing agreement with the Fund.

We are seeking to improve our cash flow through both the licensure of PH-10 on the basis of our Phase 2 atopic dermatitis and psoriasis results, and the geographic licensure of PV-10 on the basis of our Phase 2 metastatic melanoma and Phase 1 liver results in certain areas of the world, as well as pursuing a strategic investment strategy, including equity sales to potential pharmaceutical and or biotech partners, and continuing with the majority stake asset sale and licensure of our OTC products as well as other non-core assets.

However, we cannot assure you that we will be successful in either licensing of PH-10 or PV-10, any equity transaction, or selling a majority stake of the OTC and other non-core assets via a spin-out transaction and licensing our existing non-core products. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our long-term requirements in 2013 and beyond. We anticipate that these funds will otherwise come from the proceeds of private placements, the exercise of existing warrants outstanding, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to shareholders.

Critical Accounting Policies

Management’s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no material changes to the items that we disclosed as our critical accounting policies under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our 2011 Form 10-K.

New Accounting Pronouncements

None.

Contractual Obligations — Leases

We lease office and laboratory space in Knoxville, Tennessee. We have a lease commitment of $13,500 as of September 30, 2012. We are currently leasing until December 31, 2012, and then it will be either month-to-month or a lease for no longer than one year.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to differ materially from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011, and elsewhere in this Quarterly Report on Form 10-Q), and the following:

•

our ability to license our dermatology drug product candidate, PH-10, on the basis of our Phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed;

•

our determination, based on guidance of the FDA, whether to proceed with or without a partner with a Phase 3 trial of PV-10 to treat metastatic melanoma and the costs associated with such a trial;

•

our determination whether to license PV-10, our metastatic melanoma drug product candidate, and other solid tumors such as liver cancer, if such licensure is appropriate considering the timing and structure of such a license, or to commercialize PV-10 on our own to treat metastatic melanoma and other solid tumors such as liver cancer; and

•

our ability to raise additional capital if we determine to commercialize PH-10 and/or PV-10 on our own.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We had no holdings of financial or commodity instruments as of September 30, 2012, other than cash and cash equivalents, short-term deposits, money market funds, and interest bearing investments in U.S. governmental debt securities. We have accounted for certain warrants issued in March and April 2010 and January 2011 as liabilities at their fair value upon issuance, which are remeasured at each period end with the change in fair value recorded in the statement of operations. See note 4 to the interim financial statements contained in this Quarterly Report on Form 10-Q.

All of our business is transacted in U.S. dollars and, accordingly, foreign exchange rate fluctuations have not had a significant impact on us, and they are not expected to have a significant impact on us in the foreseeable future.

ITEM 4. CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures. Our chief executive officer and chief financial officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of September 30, 2012, the end of the fiscal quarter covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective.

(b) Changes in Internal Controls. There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company was not involved in any legal proceedings during the fiscal quarter covered by this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors listed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011. Such risk factors should be considered carefully with the information provided elsewhere in this report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended March 31, 2012, the Company issued warrants to purchase an aggregate of 1,003,000 shares of common stock to consultants in exchange for services, consisting of warrants to purchase 1,003,000 shares at an exercise price of $1.12 per share with a three year term. Consulting costs charged to operations for the warrants were $475,668.

During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended June 30, 2012, the Company issued warrants to purchase an aggregate of 454,500 shares of common stock to consultants in exchange for services, consisting of warrants to purchase 300,000 shares at an exercise price of $1.12 per share with a two year term, 54,500 shares at an exercise price of $1.12 per share with a three year term, and 100,000 shares at an exercise price of $1.25 per share with a four year term. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. During the three months ended September 30, 2012, the Company issued warrants to purchase an aggregate of 1,732,135 shares of common stock to consultants in exchange for services, consisting of warrants to purchase 288,501 shares at an exercise price of $1.12 per share with a three year term, 250,000 shares at an exercise price of $1.12 per share with a five year term, 160,000 shares at an exercise price of $1.15 per share with a three year term, 683,633 shares at an exercise price of $1.25 per share with a three year term, 80,000 shares at an exercise price of $1.45 per share with a three year term and 270,001 shares at an exercise price of $1.50 per share with a three year term. Consulting costs charged to operations were $721,753.

The issuances of the securities were exempt from the registration requirements of the Securities Act of 1933 by virtue of Section 4(2).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS


Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.*

The documents formatted in XBRL (Extensible Business Reporting Language) and attached as Exhibit 101 to this report shall not be deemed filed as part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act, shall not be deemed filed for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under these sections, except as shall be expressly set forth by specific reference in such filings.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PROVECTUS PHARMACEUTICALS, INC.

November 8, 2012	By:	/s/ Peter R. Culpepper
		Peter R. Culpepper
		On behalf of the registrant and as Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)

EXHIBIT INDEX


Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101		Interactive Data Files.*

EX-31.1 2 d398107dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, H. Craig Dees, Ph.D., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d398107dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Peter R. Culpepper, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32 4 d398107dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, H. Craig Dees, the Chief Executive Officer of Provectus Pharmaceuticals, Inc. (the “Company”), and Peter R. Culpepper, Chief Financial Officer and Chief Operating Officer of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is signed on November 8, 2012.


By:		/s/ H. Craig Dees
		H. Craig Dees, Ph.D.
		Chief Executive Officer

By:		/s/ Peter R. Culpepper
		Peter R. Culpepper
		Chief Financial Officer
		Chief Operating Officer

EX-101.INS 5 pvct-20120930.xml XBRL INSTANCE DOCUMENT 0000315545 us-gaap:SubsequentEventMember 2012-01-01 2012-09-30 0000315545 us-gaap:PreferredStockMember 2012-01-01 2012-09-30 0000315545 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2012-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000315545 us-gaap:RetainedEarningsMember 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0000315545 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0000315545 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0000315545 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0000315545 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0000315545 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-12-31 0000315545 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-12-31 0000315545 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-12-31 0000315545 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-04-23 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-23 0000315545 2002-04-23 0000315545 us-gaap:RetainedEarningsMember 2002-01-17 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-17 0000315545 2002-01-17 0000315545 us-gaap:PreferredStockMember 2012-09-30 0000315545 us-gaap:CommonStockMember 2012-09-30 0000315545 us-gaap:PreferredStockMember 2011-12-31 0000315545 us-gaap:CommonStockMember 2011-12-31 0000315545 us-gaap:PreferredStockMember 2010-12-31 0000315545 us-gaap:CommonStockMember 2010-12-31 0000315545 us-gaap:PreferredStockMember 2009-12-31 0000315545 us-gaap:CommonStockMember 2009-12-31 0000315545 us-gaap:PreferredStockMember 2008-12-31 0000315545 us-gaap:CommonStockMember 2008-12-31 0000315545 us-gaap:PreferredStockMember 2007-12-31 0000315545 us-gaap:CommonStockMember 2007-12-31 0000315545 us-gaap:PreferredStockMember 2006-12-31 0000315545 us-gaap:CommonStockMember 2006-12-31 0000315545 us-gaap:PreferredStockMember 2005-12-31 0000315545 us-gaap:CommonStockMember 2005-12-31 0000315545 us-gaap:PreferredStockMember 2004-12-31 0000315545 us-gaap:CommonStockMember 2004-12-31 0000315545 us-gaap:PreferredStockMember 2003-12-31 0000315545 us-gaap:CommonStockMember 2003-12-31 0000315545 us-gaap:PreferredStockMember 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-12-31 0000315545 us-gaap:PreferredStockMember 2002-04-23 0000315545 us-gaap:CommonStockMember 2002-04-23 0000315545 us-gaap:PreferredStockMember 2002-01-17 0000315545 us-gaap:CommonStockMember 2002-01-17 0000315545 pvct:ReElectedBoardMemberMember 2012-06-01 2012-06-30 0000315545 pvct:NewlyAppointedBoardMemberMember 2012-05-01 2012-05-31 0000315545 pvct:EmployeesMember 2011-09-01 2011-09-30 0000315545 pvct:ReElectedBoardMemberMember 2011-07-01 2011-07-31 0000315545 pvct:NewlyAppointedBoardMemberMember 2011-07-01 2011-07-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-09-30 0000315545 us-gaap:RetainedEarningsMember 2012-01-01 2012-09-30 0000315545 us-gaap:RetainedEarningsMember 2011-01-01 2011-12-31 0000315545 us-gaap:RetainedEarningsMember 2010-01-01 2010-12-31 0000315545 us-gaap:RetainedEarningsMember 2009-01-01 2009-12-31 0000315545 us-gaap:RetainedEarningsMember 2008-01-01 2008-12-31 0000315545 us-gaap:RetainedEarningsMember 2007-01-01 2007-12-31 0000315545 us-gaap:RetainedEarningsMember 2006-01-01 2006-12-31 0000315545 us-gaap:RetainedEarningsMember 2005-01-01 2005-12-31 0000315545 us-gaap:RetainedEarningsMember 2004-01-01 2004-12-31 0000315545 us-gaap:RetainedEarningsMember 2003-01-01 2003-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-04-24 2002-12-31 0000315545 us-gaap:RetainedEarningsMember 2002-01-18 2002-04-23 0000315545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2012-01-01 2012-09-30 0000315545 2012-01-01 2012-01-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-07-01 2012-09-30 0000315545 2012-07-01 2012-07-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-04-01 2012-06-30 0000315545 2012-04-01 2012-04-30 0000315545 2012-03-31 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2012-06-30 0000315545 2012-06-30 0000315545 2011-09-30 0000315545 2010-12-31 0000315545 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000315545 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-09-30 0000315545 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000315545 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2011-01-01 2011-09-30 0000315545 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2012-09-30 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member 2012-09-30 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member 2012-09-30 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2012-09-30 0000315545 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2011-12-31 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member 2011-12-31 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member 2011-12-31 0000315545 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2011-12-31 0000315545 pvct:TwoThousandTenWarrantsMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandElevenWarrantsMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandTenWarrantsMember 2012-01-01 2012-06-30 0000315545 pvct:TwoThousandElevenWarrantsMember 2012-01-01 2012-06-30 0000315545 pvct:TwoThousandElevenWarrantsMember 2012-01-01 2012-03-31 0000315545 pvct:TwoThousandTenWarrantsMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandTenWarrantsMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandElevenWarrantsMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandElevenWarrantsMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000315545 pvct:TwoThousandTenWarrantsMember us-gaap:MinimumMember 2012-01-01 2012-06-30 0000315545 pvct:TwoThousandTenWarrantsMember us-gaap:MaximumMember 2012-01-01 2012-06-30 0000315545 pvct:TwoThousandTenWarrantsMember 2012-01-01 2012-03-31 0000315545 us-gaap:PreferredStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:CommonStockMember 2009-01-01 2009-12-31 0000315545 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0000315545 us-gaap:CommonStockMember 2003-01-01 2003-12-31 0000315545 us-gaap:CommonStockMember 2002-01-18 2002-04-23 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-01-18 2002-04-23 0000315545 2002-01-18 2002-04-23 0000315545 us-gaap:AdditionalPaidInCapitalMember 2002-04-24 2002-12-31 0000315545 2002-04-24 2002-12-31 0000315545 us-gaap:CommonStockMember 2002-04-24 2002-12-31 0000315545 pvct:ThirdNonEmployeeMember 2012-09-30 0000315545 pvct:NonEmployeeMember 2012-09-30 0000315545 us-gaap:WarrantMember 2012-01-01 2012-03-31 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-03-31 0000315545 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000315545 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0000315545 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0000315545 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0000315545 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0000315545 us-gaap:CommonStockMember 2005-01-01 2005-12-31 0000315545 us-gaap:CommonStockMember 2004-01-01 2004-12-31 0000315545 us-gaap:WarrantMember 2012-07-01 2012-09-30 0000315545 pvct:SeriesAndCWarrantsMember 2012-07-01 2012-09-30 0000315545 us-gaap:WarrantMember 2012-04-01 2012-06-30 0000315545 pvct:SeriesAndCWarrantsMember 2012-04-01 2012-06-30 0000315545 2012-01-01 2012-03-31 0000315545 us-gaap:CommonStockMember 2012-07-01 2012-09-30 0000315545 us-gaap:CommonStockMember 2012-04-01 2012-06-30 0000315545 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0000315545 pvct:NetworkOneFinancialSecuritiesMember 2012-04-01 2012-06-30 0000315545 2012-04-01 2012-06-30 0000315545 2012-07-01 2012-09-30 0000315545 2011-07-01 2011-09-30 0000315545 2011-01-01 2011-09-30 0000315545 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000315545 2011-01-01 2011-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0000315545 2010-01-01 2010-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0000315545 2009-01-01 2009-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0000315545 2008-01-01 2008-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0000315545 2007-01-01 2007-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0000315545 2004-01-01 2004-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2003-01-01 2003-12-31 0000315545 2003-01-01 2003-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0000315545 2006-01-01 2006-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0000315545 2005-01-01 2005-12-31 0000315545 2002-01-18 2012-09-30 0000315545 us-gaap:ConvertiblePreferredStockMember 2012-09-30 0000315545 2012-09-30 0000315545 2012-01-01 2012-09-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD

1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

2. Recapitalization and Merger Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate. On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI. On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

3. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2012 and 2011, respectively, relate to 26,042,116 and 24,575,302 from warrants, 15,140,956 and 15,390,956 from options, and 2,941,665 and 3,848,332 from convertible preferred shares.

4. Equity Transactions (a) During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. (b) During the three months ended March 31, 2012, the Company issued 1,003,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants expired. During the three months ended June 30, 2012, the Company issued 454,500 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants expired. During the three months ended September 30, 2012, the Company issued 1,732,135 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants expired. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.   (c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $148,364. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $222,546. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. (d) The Company determined that warrants issued in March and April, 2010 with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $114,800. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $229,599. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock.

5. Related Party Transaction The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2012. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2012 and issued 100,000 fully vested warrants in exchange for services. Consulting costs charged to operations were $47,520 for the services for which these warrants were issued. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2012.

6. Fair Value of Financial Instruments The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2012 for the 2010 warrants include a weighted average term of 3.0 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.51%. Significant assumptions used at June 30, 2012 for the 2010 warrants include a weighted average term of 2.7 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 64.2% to 65.8% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2010 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%. Significant assumptions used at March 31, 2012 for the 2011 warrants include a weighted average term of 3.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.78%. Significant assumptions used at June 30, 2012 for the 2011 warrants include a weighted average term of 3.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2011 warrants include a weighted average term of 3.3 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%. The warrant liability measured at fair value on a recurring basis is as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="1%"> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Derivative instruments: </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Warrant liability at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Warrant liability at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2012 to September 30, 2012 follows:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="87%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Balance at January 1, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Net gain included in earnings </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,435,898</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Balance at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

7. Stock-Based Compensation On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On July 6, 2011, the Company issued 250,000 stock options to its re-elected members of the board. On July 12, 2011, the Company issued 50,000 stock options to a newly appointed member of the board. On September 6, 2011, the Company issued 4,000,000 stock options to its employees. All of the stock options issued in 2011 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.   The compensation cost relating to stock options issued in 2012 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for both the three and nine months ended September 30, 2011 is $3,368,950 of stock-based compensation expense which relates to the fair value of stock options. The following is a summary of nonvested stock option activity for the nine months ended September 30, 2012:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="65%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted  Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">250,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Canceled </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> As of September 30, 2012, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $148,364. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $222,546. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $429,818. During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. (d) The Company determined that warrants issued in March and April, 2010 with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $114,800. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $229,599. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $817,099. Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock.

<table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="1%"> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Derivative instruments: </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Warrant liability at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Warrant liability at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="87%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Balance at January 1, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 3,067,488</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Net gain included in earnings </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,435,898</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Balance at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,631,590</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="65%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted  Average Grant-Date Fair Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">250,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Vested </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Canceled </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nonvested at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

false --12-31 Q3 2012 2012-09-30 10-Q 0000315545 113701071 2941665 Accelerated Filer PROVECTUS PHARMACEUTICALS INC 373295 1433481 39529 39529 16447 16447 34659 34659 15612 15612 15752 15752 1862456 1862456 2340619 2340619 1946066 1946066 870937 870937 3759650 3759650 3368950 3368950 183028 183028 105250 105250 985010 985010 258345 258345 144128 144128 281500 281500 443500 443500 2702134 2250133 310866 1295226 485467 -0.16 -0.06 -0.10 -0.02 55976 747612 1.25 1.12 6680000 -932000 160000 64500 184750 475668 183908 721753 47520 389950 100000 490000 25000 5580181 1059730 1027554 1435898 1246917 5580181 1059730 1435898 222546 229599 429818 817099 16284 42415 16284 1930164 6221257 10092495 2376817 11168067 9905062 2039273 1288861 1286930 1930 6513176 6506955 6221 4130421 4120329 10092 1848138 1845761 2377 6346989 6335820 11169 7041239 7031334 9905 2077796 2075757 2039 -9006261 -268500 -409250 -985010 -6065872 -540316 -1381329 114800 148364 236146 14109 174000 40101773 9486071 2077796 2077796 8908131 0.20 1 P5Y 170519 16284 21078014 6504209 1.12 75000 75000 0.73 0.73 250000 1500 4368644 122833 1003000 454500 1732135 25000 27000 26975 25 196031 195767 264 183596 183401 195 1258 1257 1 360000 359880 120 5144000 5142100 1900 239800 239036 764 449923 449190 734 152285 152058 227 676743 676024 719 298950 298800 150 390000 389650 350 695000 694204 796 856613 855837 776 332750 332400 350 409250 408775 475 -3645 -3911 266 6518688 6508571 10117 4217390 4204107 13283 380347 379667 680 793137 790668 2469 419250 418691 559 263721 194327 1141 120000 1900000 764000 733872 226733 719246 150000 350000 796012 776250 350000 475000 265763 10116653 13283324 679820 2469723 559000 1571849 1245809 3928957 3267795 3480485 3491014 7185522 510000 6000000 932000 931490 510 -6000 6000 1439795 1438223 1572 1189816 1188570 1246 3985641 3981712 3929 2639711 2636443 3268 2524453 2520973 3480 3103680 3100189 3491 6623311 6616126 7185 12226320 12225820 500 500007 452919 132608 453 453 5000 4867 133 145479 145479 495480 495480 1534405 1534405 370023 370023 472635 472635 517820 517820 1064210 1064210 1141593 1141593 945116 945116 1381329 1381329 3067488 1631590 0.664 0.658 0.642 0.647 0.571 0.647 0.571 0.664 0.646 0.0051 0.0041 0.0031 0.0023 0.0031 0.0023 0.0078 0.0041 0.05 0.05 0.05 0.05 0.05 0.05 P3Y9M18D P3Y P3Y6M P2Y8M12D P3Y3M18D P2Y6M 3067488 3067488 1631590 1631590 104277935 109100408 112073836 113166988

101102

280615

71000

102000

416798

421377

115690334

119739223

601000

360256

1633176

126587

1574900

3368950

183028

3845721

2261584

6621717

503340

167780

503340

167780

3848332

15390956

24575302

2941665

15140956

26042116

13349952

7010547

7705773

1858402

8086200

10812580

7705773

1842118

2726380

-5863655

1855176

371035

0.001

200000000

113701071

110596798

110597

113701

100000

490000

15216

444378

5737

4579

10800584

193623

59465

50631

145709

58490

51194

61424

43884

64183

-1435898

3067488

1631590

6118377

6621717

5597068

5093728

55075

-825867

64753074

9568240

3860755

7228225

2296637

24541

276970

-271314

179513

1824111

-588369

1512859

8098004

653195

898

529

1325

310

3330212

3586686

13349952

7010547

262724

1955096

74060123

15990280

2077796

463450

-6147

-15885

-72681455

-13257753

-7925566

-1316198

-116432004

-5749937

-3155313

-4344525

-11763853

-8870579

-10005631

-10269571

-12322314

-18552102

-15982768

-19434699

-6442796

-10647282

-2347111

-127232588

-16176391

-6502261

-10792991

-2390995

-113796584

-17043396

-7470879

-12084505

-3594338

90622

139000

27000

48000

36637186

89920

6147

15885

0.08

0.75

0.001

25000000

2941665

3531665

3531

2941

6706795

443500

37010481

180075

20111

31417

48000

2385959

42446334

6971816

3442344

4352940

1129921

-105784722

-116432004

25648

39757

50000

250000

4000000

250000

50000

200000

175000

75000

225000

6680000

9423689

10867509

16133876

27822977

42452366

49399281

53017076

67410226

91297883

5389998

110596798

3531665

113701071

2941665

802

1310320

6680

-1316198

11723580

18780291

9424

-7066135

10251052

20461632

10868

-10221448

9161701

23711540

16134

-14565973

14387141

40689144

27823

-26329826

15522400

50680353

42452

-35200405

14831510

59988147

49399

-45206036

10055536

65478126

53017

-55475607

9406510

77137021

67410

-67797921

10699573

96952908

91298

5390

-86350023

10019740

115690334

110597

3531

-105784722

3423861

119739223

113701

2941

-116432004

3405541

2377512

490000

7893326

-7893326

1858331

-1858333

590000

-590000

1855176

100000

50000

3049362

3045957

3405

1576336

1573959

2377

367500

367010

490

7893

-7893

1859

-1859

590

-590

25000

24950

14397729

3368950

183028

400000

48000

47600

400

EX-101.SCH 6 pvct-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 0404 - Disclosure - Equity Transactions (Policies) link:presentationLink link:calculationLink link:definitionLink 06071 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0507 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Recapitalization and Merger (Details) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Related Party Transaction (Details) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 06061 - Disclosure - Fair Value of Financial Instruments (Details 1) link:presentationLink link:calculationLink link:definitionLink 06062 - Disclosure - Fair Value of Financial Instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0506 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Basic and Diluted Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Related Party Transaction link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Basic and Diluted Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Recapitalization and Merger link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0140 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pvct-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pvct-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pvct-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Statement [Table] Statement, Equity Components [Axis] Equity Component [Domain] 8% convertible preferred stock Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash and Cash Equivalents, at Carrying Value Total Current Assets Assets, Current, Total Equipment and furnishings, less accumulated depreciation of $421,377 and $416,798 Property, Plant and Equipment, Net Patents, net of amortization of $6,621,717 and $6,118,377, respectively Finite-Lived Intangible Assets, Net Other assets Other Assets, Noncurrent Total Assets Assets Liabilities and Stockholders' Equity Liabilities and Stockholders' Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Accounts payable - trade Accounts Payable, Trade, Current Accrued Compensation and Payroll Taxes Accrued compensation and payroll taxes Accrued compensation and payroll taxes. Accrued consulting expense Accrued Professional Fees, Current Other accrued expenses Other Accrued Liabilities, Current Total Current Liabilities Liabilities, Current, Total Warrant liability Warrant liability Warrant liability. Total Liabilities Liabilities Stockholders' Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; par value $.001 per share; 25,000,000 shares authorized; 2,941,665 and 3,531,665 shares issued and outstanding, respectively, liquidation preference $0.75 per share (in aggregate $2,250,133 and $2,702,134, respectively) Preferred Stock, Value, Issued Common stock; par value $.001 per share; 200,000,000 authorized; 113,701,071 and 110,596,798 shares issued and outstanding, respectively Common Stock, Value, Issued Paid-in capital Additional Paid in Capital Deficit accumulated during the development stage Retained Earnings (Accumulated Deficit) Total Stockholders' Equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent, Total Total Liabilities and Stockholders' Equity Liabilities and Stockholders' Equity Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation on equipment and furnishings Amortization on patents Finite-Lived Intangible Assets, Accumulated Amortization Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, shares outstanding Aggregate Liquidation Preference Aggregate liquidation preference Aggregate liquidation preference. Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common stock, shares authorized Common stock, shares issued Common stock, shares issued Common stock, shares outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations [Abstract] Revenues Sales Revenue, Net [Abstract] OTC product revenue Sales Revenue, Goods, Net Medical Device Revenue Medical device revenue Medical device revenue. Total revenues Sales Revenue, Net, Total Cost of sales Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative General and Administrative Expense Total operating loss Operating Income (Loss), Total Gain on sale of fixed assets Gain on sale of equipment Gain (Loss) on Sale of Property Plant Equipment Loss on extinguishment of debt Loss on extinguishment of debt Gains (Losses) on Extinguishment of Debt Investment income Investment Income, Interest Gain Loss on Change in Fair Value of Warrant Liability Gain on change in fair value of warrant liability Gain loss on change in fair value of warrant liability. Net interest expense Interest Expense Net loss Net loss Net Income (Loss) Attributable to Parent Net loss applicable to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Basic and Diluted Loss Per Common Share Basic and diluted loss per common share Basic and diluted loss per common share. Weighted Average Number of Common Shares Outstanding Basic and Diluted Weighted average number of common shares outstanding - basic and diluted Weighted average number of common shares outstanding - basic and diluted. Consolidated Statements of Stockholders' Equity [Abstract] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Common Stock [Member] Paid in capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Beginning Balance, Shares Ending Balance, Shares Shares, Issued Stock Issued During Period to Founding Shareholders Value Issuance to founding shareholders Stock issued during period to founding shareholders value. Stock Issued During Period Shares to Founding Shareholders Issuance to founding shareholders, Shares Stock issued during period shares to founding shareholders. Sale of stock Stock Issued During Period, Value, New Issues Sale of stock, Shares Stock Issued During Period, Shares, New Issues Stock Issued During Period to Employees Value Issuance of stock to employees Stock issued during period to employees value. Stock Issued During Period Shares to Employees Issuance of stock to employees, Shares Stock issued during period shares to employees. Stock Issued During Period in Reverse Merger Value Shares issued in reverse merger Stock issued during period in reverse merger value. Stock Issued During Period Shares in Reverse Merger Shares issued in reverse merger, Shares Stock issued during period shares in reverse merger. Stock Issued During Period for Services Value Issuance of stock for services Stock issued during period for services value. Stock Issued During Period Shares for Services Issuance of stock for services, Shares Stock issued during period shares for services. Stock Issued During Period for Interest Payable Value Issuance of stock for interest payable Stock issued during period for interest payable value. Stock Issued During Period Shares for Interest Payable Issuance of stock for interest payable, Shares Stock issued during period shares for interest payable. Warrant Issued During Period for Services Value Issuance of warrants for services Warrant issued during period for services value. Stock Issued During Period Warrants and Stock Options Exercised Value Exercise of warrants and stock options Stock issued during period warrants and stock options exercised value. Stock Issued During Period Shares Stock Options and Warrants Exercised Exercise of warrants and stock options, Shares Stock issued during period shares stock options and warrants exercised. Purchase and retirement of stock Stock Repurchased and Retired During Period, Value Purchase and retirement of stock, Shares Stock Repurchased and Retired During Period, Shares Stock Issued for Acquisition Stock issued for acquisition of Valley Pharmaceuticals Stock issued for acquisition. Stock Issued for Acquisition Shares Stock issued for acquisition of Valley Pharmaceuticals, Shares Stock issued for acquisition shares. Warrant Exercised During Period Value Exercise of warrants Warrant exercised during period value. Warrant Exercised During Period Shares Exercise of warrants, Shares Warrant exercised during period shares. Warrants issued in connection with convertible debt Adjustments to Additional Paid in Capital, Warrant Issued Stock and Warrant Issued During Period Value Stock and warrants issued for acquisition of Pure-ific Stock and warrant issued during period value. Stock and Warrant Issued During Period Shares Stock and warrants issued for acquisition of Pure-ific, Shares Stock and warrant issued during period shares. Adjustments to Additional Paid in Capital Issuance of Warrants for Contractual Obligations Value Issuance of warrants for contractual obligations Adjustments to additional paid in capital issuance of warrants for contractual. Adjustments to Additional Paid in Capital Stock to be Issued for Services Value Stock to be issued for services Adjustments to additional paid in capital stock to be issued for services value. Adjustments to Additional Paid in Capital Employee Compensation from Stock Options Value Employee compensation from stock options Adjustments to additional paid in capital employee compensation from stock options value. Stock Issued During Period Pursuant to Regulation S Value Issuance of common stock pursuant to Regulation S Stock issued during period pursuant to regulation S value. Stock Issued During Period Shares Pursuant to Regulation S Issuance of common stock pursuant to Regulation S, Shares Stock issued during period shares pursuant to regulation S. Issuance of Common Stock and Warrants Pursuant to Regulation D Value Issuance of stock and warrants pursuant to Regulation D Issuance of common stock and warrants pursuant to regulation D value. Issuance of Common Stock and Warrants Pursuant to Regulation D Shares Issuance of stock and warrants pursuant to Regulation D, Shares Issuance of common stock and warrants pursuant to regulation D. Stock Issued During Period Pursuant to Regulation D Value Issuance of stock and warrants pursuant to Regulation D Stock issued during period pursuant to regulation D value. Stock Issued During Period Shares Pursuant to Regulation D Issuance of stock and warrants pursuant to Regulation D, Shares Stock issued during period shares pursuant to regulation D. Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock conversion into common stock Preferred stock conversion into common stock, Shares Stock Issued During Period, Shares, Conversion of Convertible Securities Beneficial conversion related to convertible debt Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Adjustments to Additional Paid in Capital Beneficial Conversion Related to Interest Expense Value Beneficial conversion related to interest expense Adjustments to additional paid in capital beneficial conversion related to interest expense value. Adjustments to Additional Paid in Capital Issuance of Convertible Debt with Warrants Value Issuance of convertible debt with warrants Adjustments to additional paid in capital issuance of convertible debt with warrants value. Adjustments to Additional Paid in Capital Repurchase of Beneficial Conversion Feature Value Repurchase of beneficial conversion feature Adjustments to additional paid in capital repurchase of beneficial conversion feature value. Condensed Consolidated Statements of Cash Flow [Abstract] Cash Flows From Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of original issue discount Amortization of Debt Discount (Premium) Amortization of Commitment Fee Amortization of commitment fee Amortization of commitment fee. Amortization of Prepaid Consultant Expense Amortization of prepaid consultant expense Amortization of prepaid consultant expense. Amortization of deferred loan costs Amortization of Financing Costs Accretion of United States Treasury Bills Accretion of United States Treasury Bills Accretion of united states treasury bills. Loss on Exercise of Warrants Loss on exercise of warrants Loss on exercise of warrants. Beneficial Conversion of Convertible Interest Beneficial conversion of convertible interest Beneficial conversion of convertible interest. Convertible Interest Convertible interest Convertible interest. Compensation through issuance of stock options Stock Option Plan Expense Compensation Through Issuance of Stock Compensation through issuance of stock Compensation through issuance of stock. Issuance of Stock for Services Issuance of stock for services Issuance of stock for services. Issuance of Warrants for Services Issuance of warrants for services Issuance of warrants for services. Issuance of Warrants for Contractual Obligations Issuance of warrants for contractual obligations Issuance of warrants for contractual obligations. Gain Loss on Fair Value of Warrant Liability Gain on change in fair value of warrant liability Gain loss on fair value of warrant liability. Increase Decrease in Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets Prepaid expenses and other current assets. Accounts payable Increase (Decrease) in Accounts Payable, Trade Accrued expenses Increase (Decrease) in Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Proceeds from sale of fixed assets Proceeds from Sale of Property, Plant, and Equipment Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from sales of investments Proceeds from Sale, Maturity and Collections of Investments Purchases of investments Payments to Acquire Investments Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash Flows From Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net Proceeds from Loans from Stockholder Net proceeds from loans from stockholder Net proceeds from loans from stockholder. Proceeds from convertible debt Proceeds from Convertible Debt Net Proceeds from Sales of Preferred Stock and Warrants Net proceeds from sales of preferred stock and warrants Net proceeds from sales of preferred stock and warrants. Net Proceeds from Sales of Common Stock and Warrants Net proceeds from sales of common stock and warrants Gross proceeds from private offering of common stock and warrants to accredited investors Net proceeds from sales of common stock and warrants. Proceeds from Exercises of Warrants and Stock Options Proceeds from exercises of warrants and stock options Proceeds from exercises of warrants and stock options. Cash paid to retire convertible debt Repayments of Convertible Debt Cash Paid for Deferred Loan Costs Cash paid for deferred loan costs Cash paid for deferred loan costs. Premium Paid on Extinguishments of Debt Premium paid on extinguishments of debt Premium paid on extinguishments of debt. Purchase and retirement of common stock Payments for Repurchase of Common Stock Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Supplemental Disclosure of Noncash Investing and Financing Activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Amount Reclassified from Warrant Liability to Equity Amount reclassified from warrant liability to equity Amount reclassified from warrant liability to equity. Dividends on preferred stock Dividends on preferred stock Dividends, Preferred Stock Basis of Presentation [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Recapitalization and Merger [Abstract] Recapitalization and Merger Business Combination Disclosure [Text Block] Basic and Diluted Loss Per Common Share [Abstract] Basic and Diluted Loss Per Common Share Earnings Per Share [Text Block] Equity Transactions [Abstract] Related Party Transaction [Abstract] Related Party Transaction Related Party Transactions Disclosure [Text Block] Equity Transactions [Text Block] Equity Transactions Equity transactions. Fair Value of Financial Instruments [Abstract] Recapitalization and Merger (Textual) [Abstract] Recapitalization and Merger (Textual) [Abstract] Recapitalization and merger. Basic and Diluted Loss Per Common Share (Textual) [Abstract] Basic and Diluted Loss Per Common Share (Textual) [Abstract] Basic and diluted loss per common share. Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Equity Transactions (Textual) [Abstract] Equity Transactions (Textual) [Abstract] Equity transactions. Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Line Items] Loss on Change in Fair Value of Warrant Liability Loss on change in fair value of warrant liability Loss on change in fair value of warrant liability. Rate of convertible preferred stock Preferred Stock, Dividend Rate, Percentage Redeemable preferred stock converted into shares Convertible Preferred Stock, Shares Issued upon Conversion Convertible Preferred Stock Shares to be Converted to Common Stock Shares Converted redeemable preferred stock Convertible preferred stock shares to be converted to common stock shares. Reconciliation of the warranty liability measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value by Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] EX-101.PRE 10 pvct-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	May 31, 2012 Newly Appointed Board Member [Member]	Jul. 31, 2011 Newly Appointed Board Member [Member]	Jun. 30, 2012 Re Elected Board Member [Member]	Jul. 31, 2011 Re Elected Board Member [Member]	Sep. 30, 2011 Employees [Member]
Stock Based Compensation (Textual) [Abstract]
Stock option issued			250,000		50,000	50,000	200,000	250,000	4,000,000
Stock Based Compensation (Additional Textual) [Abstract]
Stock-based compensation expense	$ 0	$ 3,368,950	$ 183,028	$ 3,368,950
Unrecognized stock-based compensation expense	$ 0		$ 0

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References+ Details

XML 13 R9.htm IDEA: XBRL DOCUMENT

Basic and Diluted Loss Per Common Share

9 Months Ended

Sep. 30, 2012

Basic and Diluted Loss Per Common Share [Abstract]

Basic and Diluted Loss Per Common Share

3. Basic and Diluted Loss Per Common Share

- Definition

The entire disclosure for earnings per share.

+ References+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S,#-E,V4V.%]D8F0P7S0V-31?860R-%\V.64P M8F5D-6$S9&$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7U-T M;SPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)KF%T:6]N7V%N9%]-97)G97(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E M;%=O5]4#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L M7TEN#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K0F%S961?0V]M<&5N#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)KF%T:6]N7V%N9%]-97)G97)?1&4\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O5]4#I%>&-E M;%=O#I% M>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN M86YC:6%L7TEN#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@ M(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S,P,V4S938X7V1B9#!?-#8U-%]A9#(T7S8Y M93!B960U83-D80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,#-E M,V4V.%]D8F0P7S0V-31?860R-%\V.64P8F5D-6$S9&$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!296=I"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^4V5P(#,P+`T*"0DR,#$R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^,C`Q,CQS<&%N/CPO M'0^+2TQ,BTS,3QS<&%N/CPO2!#;VUM;VX@4W1O8VLL(%-H87)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S M,#-E,V4V.%]D8F0P7S0V-31?860R-%\V.64P8F5D-6$S9&$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S`S93-E-CA?9&)D,%\T-C4T7V%D,C1? M-CEE,&)E9#5A,V1A+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$7)O;&P@=&%X M97,\+W1D/@T*("`@("`@("`\=&0@8VQAF5D.R`R+#DT,2PV-C4@86YD M(#,L-3,Q+#8V-2!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9RP@2D\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S,#-E,V4V.%]D8F0P7S0V-31?860R-%\V.64P8F5D-6$S9&$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S`S93-E-CA?9&)D,%\T M-C4T7V%D,C1?-CEE,&)E9#5A,V1A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0^)FYB'0^)FYB M'0^)FYB'0^)FYB M'0^)FYB'0^)FYB'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)FYB'0^)FYB'0^ M)FYB'0^)FYB7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)FYB'0^ M)FYB'0^)FYB'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!0:&%R;6%C975T:6-A;',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!0:&%R;6%C975T:6-A;',L(%-H M87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES92!O9B!W87)R86YT'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4L(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4L(%-H87)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O M9B!W87)R86YT65E(&-O M;7!E;G-A=&EO;B!F'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!O9B!W87)R86YT65E(&-O;7!E;G-A=&EO;B!F'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES M92!O9B!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O M9B!W87)R86YT65E(&-O M;7!E;G-A=&EO;B!F'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65E(&-O;7!E;G-A=&EO;B!F'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!":6QL'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB&5R8VES92!O9B!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!I M;G9E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'1I;F=U M:7-H;65N=',@;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA MF%T:6]N0V]N&)R;"QN&)R;"QN>"`M M+3X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4] M,T0R/CPO9F]N=#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6EN9R!U;F%U9&ET960@8V]N9&5N2P@=&AE>2!D M;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!F;V]T M;F]T97,@2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D#0H@("!3=&%T97,@;V8@06UE M2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!H879E(&)E M96X@:6YC;'5D960N($]P97)A=&EN9R!R97-U;'1S(&9O2!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F M(S$V,#LS,2P@,C`Q,BX@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!S=6)S M97%U96YT(&5V96YT7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA MF%T:6]N(&%N9"!-97)G97(\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]LF%T:6]N M(&%N9"!-97)G97(@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&%N9"!-97)G M97(\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN M+6)O='1O;3HP<'@^/&9O;G0@2!K;F]W;B!A2!T:&4@=W)I='1E;B!C;VYS96YT(&]F(&$@;6%J;W)I M='D@;V8@=&AE(&]U='-T86YD:6YG('-H87)E2UO M=VYE9"!S=6)S:61I87)Y(&]F(%!R;W9E8W1UF%T:6]N(&]F(%!022X@ M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@2!0:&%R;6%C M975T:6-A;',L($EN8RXL(&$@<')I=F%T96QY+6AE;&0@5&5N;F5S2!M97)G:6YG(%!022!W:71H(&%N9"!I;G1O(%9A;&QE>2!A;F0@;F%M:6YG M('1H92!S=7)V:79I;F<@8V]R<&]R871I;VX@)B,X,C(P.UAA;G1E8V@-"B`@ M(%!H87)M86-E=71I8V%L2!S:&%R96AO;&1E2X@0GD@86-Q=6ER:6YG(%9A;&QE>2P@=&AE($-O;7!A;GD- M"B`@(&%C<75I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1";&]C:RTM M/@T*("`@/'`@6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP M<'@^/&9O;G0@&-L=61E2!A&-L=61E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/CQB/CPO8CXT+B`\8CY%<75I='D@5')A M;G-A8W1I;VYS(#PO8CX\+V9O;G0^/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/BAA*2!$=7)I M;F<@=&AE('1H2!I2!D971E6QE M/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!V97-T960@=V%R2!I2!V97-T960@=V%RF4Z,7!X M.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@28C,38P.S$S+"`R,#$Q(&%N9"!R969E M&5R8VES92!P2!R96QA=&5D(&EN2!O9B`D,C(R M+#4T-BX@1F]R('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q M-C`[,S`L(#(P,3(@=&AEF5D(&9R;VT@ M=&AE(')E=F%L=6%T:6]N(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!O9B`D M-#(Y+#@Q."X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O M<#HQ,G!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!A8V-E<'1E9`T*("`@'!E;G-E&5R8VES92!P2!R96QA=&5D(&EN2!W87,@9&5T97)M:6YE9"!B87-E9"!O;B!T:&4@36]N=&4M M0V%R;&\@4VEM=6QA=&EO;B!M;V1E;"!A="!T:&4@9&%T92!T:&4@=V%R XML 15 R8.htm IDEA: XBRL DOCUMENT

Recapitalization and Merger

9 Months Ended

Sep. 30, 2012

Recapitalization and Merger [Abstract]

Recapitalization and Merger

2. Recapitalization and Merger

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 67-73

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph F4

-Subparagraph e

-Appendix F

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 88-16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51, 52

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

XML 16 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 1,842,118	$ 7,705,773
Prepaid expenses and other current assets	16,284
Total Current Assets	1,858,402	7,705,773
Equipment and furnishings, less accumulated depreciation of $421,377 and $416,798	31,417	20,111
Patents, net of amortization of $6,621,717 and $6,118,377, respectively	5,093,728	5,597,068
Other assets	27,000	27,000
Total Assets	7,010,547	13,349,952
Current Liabilities
Accounts payable - trade	280,615	101,102
Accrued compensation and payroll taxes	1,433,481
Accrued consulting expense	102,000	71,000
Other accrued expenses	139,000	90,622
Total Current Liabilities	1,955,096	262,724
Long-Term Liability
Warrant liability	1,631,590	3,067,488
Total Liabilities	3,586,686	3,330,212
Stockholders' Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; 2,941,665 and 3,531,665 shares issued and outstanding, respectively, liquidation preference $0.75 per share (in aggregate $2,250,133 and $2,702,134, respectively)	2,941	3,531
Common stock; par value $.001 per share; 200,000,000 authorized; 113,701,071 and 110,596,798 shares issued and outstanding, respectively	113,701	110,597
Paid-in capital	119,739,223	115,690,334
Deficit accumulated during the development stage	(116,432,004)	(105,784,722)
Total Stockholders' Equity	3,423,861	10,019,740
Total Liabilities and Stockholders' Equity	$ 7,010,547	$ 13,349,952

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended		128 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows From Operating Activities
Net loss	$ (10,647,282)	$ (15,982,768)	$ (116,432,004)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	4,579	5,737	444,378
Amortization of patents	503,340	503,340	6,621,717
Amortization of original issue discount			3,845,721
Amortization of commitment fee			310,866
Amortization of prepaid consultant expense			1,295,226
Amortization of deferred loan costs			2,261,584
Accretion of United States Treasury Bills			(373,295)
Loss on extinguishment of debt			825,867
Loss on exercise of warrants			236,146
Beneficial conversion of convertible interest			55,976
Convertible interest			389,950
Compensation through issuance of stock options	183,028	3,368,950	14,397,729
Compensation through issuance of stock			932,000
Issuance of stock for services	409,250	268,500	9,006,261
Issuance of warrants for services	1,381,329	540,316	6,065,872
Issuance of warrants for contractual obligations			985,010
Gain on sale of equipment			(55,075)
Gain on change in fair value of warrant liability	(1,435,898)	(1,059,730)	(5,580,181)
(Increase) decrease in assets
Prepaid expenses and other current assets	(16,284)	(42,415)	(16,284)
Increase (decrease) in liabilities
Accounts payable	179,513	(271,314)	276,970
Accrued expenses	1,512,859	(588,369)	1,824,111
Net cash used in operating activities	(7,925,566)	(13,257,753)	(72,681,455)
Cash Flows From Investing Activities
Proceeds from sale of fixed assets			180,075
Capital expenditures	(15,885)	(6,147)	(89,920)
Proceeds from sales of investments			37,010,481
Purchases of investments			(36,637,186)
Net cash (used in) provided by investing activities	(15,885)	(6,147)	463,450
Cash Flows From Financing Activities
Net proceeds from loans from stockholder			174,000
Proceeds from convertible debt			6,706,795
Net proceeds from sales of preferred stock and warrants			8,908,131
Net proceeds from sales of common stock and warrants	2,077,796	9,486,071	40,101,773
Proceeds from exercises of warrants and stock options		6,504,209	21,078,014
Cash paid to retire convertible debt			(2,385,959)
Cash paid for deferred loan costs			(747,612)
Premium paid on extinguishments of debt			(170,519)
Purchase and retirement of common stock			(48,000)
Net proceeds from sale non-controlling interest in Pure-ific Corporation			443,500
Net cash provided by financing activities	2,077,796	15,990,280	74,060,123
Net change in cash and cash equivalents	(5,863,655)	2,726,380	1,842,118
Cash and cash equivalents, at beginning of period	7,705,773	8,086,200
Cash and cash equivalents, at end of period	1,842,118	10,812,580	1,842,118
Supplemental Disclosure of Noncash Investing and Financing Activities:
Amount reclassified from warrant liability to equity		$ 485,467

XML 18 R22.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Details 1) (Recurring [Member], Level 3 [Member], Warrants [Member], USD $)	9 Months Ended
	Sep. 30, 2012
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]
Reconciliation of the warranty liability measured at fair value on a recurring basis
Balance at January 1, 2012	$ 3,067,488
Net gain included in earnings	(1,435,898)
Balance at September 30, 2012	$ 1,631,590

XML 19 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) (USD $)	9 Months Ended
Stock-Based Compensation (Details) (USD $)	Sep. 30, 2012
Summary of nonvested stock option activity
Number of Share Nonvested at December 31, 2011
Weighted Average Grant-Date Fair Value Nonvested at December 31, 2011
Number of Shares, Granted	250,000
Weighted Average Grant-Date Fair Value Granted	$ 0.73
Number of Shares, Vested	(250,000)
Weighted Average Grant-Date Fair Value Vested	$ 0.73
Number of Shares Canceled
Weighted Average Grant-Date Fair Value Canceled
Number of Share Nonvested at September 30, 2012
Weighted Average Grant-Date Fair Value Nonvested at September 30, 2012

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References+ Details

ZIP 20 0001193125-12-460669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-460669-xbrl.zip M4$L#!!0````(`.F&:$'WQ'@1:%(``*AK!``1`!P`<'9C="TR,#$R,#DS,"YX M;6Q55`D``T8JG%!&*IQ0=7@+``$$)0X```0Y`0``[%U;<]LXLGX_5><_8'UF MIV:J=*/N>#Q6'QW0<,OY,0/IB$?C6/RT\G/Y'9* MKJ[(J>]YS'79E%2K:2?'-()G?4_VUJQ9ZK?'V]`E0(\7?3@8QW%P6*\_/#S4 M\.N:'X[JS4:C5>=>%%//9@>RY:'+O2_/-,>?;V&\M/GCD_8/+=':&@P&=?%K MVC2XM^.L)7ZHV?X$>K6:C4&KD;;BD=]N6KWG*)8MT@=`J"-*@^R!.QK=BL;J M!S%"M6%56U9&-/3'OT$F^*LS>R#?N%N7/V9-([Y,&M#2JO]U\?':'K,)K2X. MX+"%WB-FUT;^?1U^R-,/J!+R'H5Z&(F>KM@=$4(^C*$]^+V6-,KID=@\Y*U8'?;/4]=SXNX#/ MX^C,H&O>#Q5G^`S=_"; M.\Y"(AA@<\)*N3XY_]^#7QKPKV5U.NW.^_KLL5E7$1M-X-OL"_A*0G'('@.7 MVSR6M!"'0SMICTHE#F=D"ZIO0'9'CSPZ^&5%`]G3^_K2`68DU>=I>E^?8_]] MP$+N.SD.8AK&IV#XOZ00-RSH(_LV:\@\)]=L4&TUL&LGU^A]/=?Y^[H"[UN0 MO`1=86$(WUW'OOUE5X",00;X]-G7!.@[\2>![\'':![.C#G!V]Z@>?/`W/MY M/*U39D/'EL&S4#RM]?"TJ@!IRWHMGL?4Q:AP%'V^RUGF%8LIF*TS/*.A!WE$ MM%]8INREW)6#IHRX\9S1I=\5`=*1XW",G]0=7E+N#,^]X0D->`R?]PJM&9_( MYKFGF-PIT#(?:2RK6)`R]U(Z"E;!?!DC&<^P>:#IYCA+XZQG/4;`2]LH`R7B. MW0--)\]1`G]=XSD*5L)N&2`9S[%[H.GD.4K@KV,\1\%*V"D#).,Y=@\TG3Q' M"?RUC>8_=`T\MS%,:?U?N= M>L9SE*.$5M7J%0N2\1R[!YIFGJ,H_LR[?KJ_F)(!!+Q-?&\?T9&<[1XTYKW* MW7CUQ#*VHRLT#6,[6K]<`@`9V]$3FL;`V([FKX\8V]$5FKZQ'WH"DW+ MV([FI<3&=G2%QM05Z%Y,:VQ'-VAF):;&=O0N)S6VHQLTLR)+8SMZ%U0:V]$! MFL^+5S_\GGCJ@/GAFFW)XQ91DA&`D$>7@ M'"U<']%=[_J([ANNCUA4".N"3H5"?&(/[G1X%`0^]XQ6/-4*(9],/!M7CM/&=N5=TU*58-,&!N`W<):YG4N('G3A3(+L%N_ M)^Y4W91@0H1>(0*0[JVG$+WB_,!,(4R(T#=$;$8U5E\E=N)[]RR,^:W+5DS- MAN6_8U54^G_BT@@F,X+ZQ=0_8W-/[Q=;#;%Y]W0W$7WNQCB#Z6[>&K<:4W,/ M3_&8-M;#M%$2IN8&F.(Q%3.KES&=O9M0-*;F;H[B,>VOAVF_+$S-K0G%8]I; M#]->69B:\^R+Q[2['J;=LC`U)XT7CVEG/4P[96%JSH`N'M/V>IBVR\+4G,Y; M/*:M]3!MO0W3,SX:Q\L@-3X4$YC4C:R2%)&6TGGJ\DJR$>?9T!4UY8#)[3=!'3JU]"?H%TEL=AK M^WR7&M$E"^7^VG1Y!_-,*37:FS7Y)WNL5)1E;?T4PE>*PBHRKGS+IJ+N#D7_ M+<5U=HV+5G994*"?MJ\IB[?LH"_1]K0DTVA[^=K>WER%90HO),G]""4W' M\<./;$3=,T'77(638`SXRMB:<55V+?S,,`O$2C-=+(X_5;VK$W]6\6?S-G3B M[XUG0*Z>C>_6)-I,"`M=BI$)X.<`I:5[Y-BH"@C!*+E\!WJP^].#C6C%]UNA M:YDXL?M!:VQW9P%^^GI3^M*'@5@CB%NEG`'[DG\>7G"/3Y+)7J+]S>[Z M6TBYP@.*YU-Q)4NMU&H#>=U2M:*/1JV*4BLIR^]-K9;'H[UV6*\)3\9G%:E< M>^RVMJ%<>^:Y7CT-WFNO9=*L3T_7L&S*6=A2"IP>T"!LEBD-SVG0(M@^1.G7S\S#&Y!LAB@-S,X;C/ M`'GD.!S+:*@[O*3<&9Y[PQ,:\!@^[Q6L,SZ1S7-/,?D=0+SU8Z6V((UGSFPW M"K\!A=_`&>ZK(=9.X;3/FH3/\!#"FEW;O"))7S`49.)<@ ML>E-2+V(VN+PFN-I_I?\`A1R"HRF?)9>GUO**ZO?`U([!-(S:[J[5;:_QJG4 M.IXF^:8EV]78[?[Q4/J?,K[5*CR3NFP:Q[(NYS9(%H/D]J_D-D@6@^2V-\AZ M!LF")H;;O];7(%D,DMN_S-<@60R2V[_"UR!9#)(;NKAW]B^6*Y];@-[P4N5V`XP!*K\9<7SVV&^)YX3,.?(< MD(T73\_X*![K7XBPYD%1;]VK6WY\QQX=+/#2JSP;/5R@Y&-7MJ[`Q?'W._50 M_U79?``]5;7@<$/;Z7^K5O_P>$RNF3B$IEJ57R?X'8KG,@E9)HN)O)7T%]15 M?AC`G^_KZ7>R;WQNH8<_KD_/+J^S/AQ^#[*8D8_M/B43%M+8GSLJ/>V81WZ[ M:?4.H9_YT21KRY\7W9XRSY]P;U7'DHL(+S*-5O7\M(OW]1P'2QD65Z-&*X2V M;+A58GO2Q4I1Y'L`1,F9*UQ2BBI)8<7?CMF(>^38!=]#;NAHQ!SRR8]9UB;U M6)_#$?7X?\35K^"](M_ECO@``0Y<6`3]JVMA9[65J2^,3GEDNS[2=P.J)@=3 M>G?%[IZQNA_=^!U0>?KYY.;_+L_(.)ZXY/*/XX_G)^2@6J__V3JIUT]O3LE? MO]U"C\NWI' M)]R='L80PR+BL0<2^A/J'9"(_P>:-`_P:7SP-OVC?OO,5W7LLY@!GW85I/U, M:`CBK\9^<&@U@\=WZO.M'\?^Y+`1/&:=%,6NM>2[6O8=.:81CXA_1_*XDA6B M$1^"%SGK%L_8S9@1:MN0C%!ORKT123R:P(0$M!?,$&)1)/]2J@H?[E+-A+%2 MU21C>L_(+6,>"4(6@.=R"!@#=APZF!60!QZ/Q><$@AD,$X0<.@E<%@F.1\P# MQ^RZ4VS#@E@^'P-Q&'3@DS`#(<\C<.'`X4^+XQ//!I7KB3FL"Q.!H2$*^3^J! M!'P_AJ9`#E[.S9'9V^ERYEYD3'"_G#D$Q67@099)O$;.93=^P#TD#!X&<.E( M_%P1Y%/GWTD42X!^0@QY),B#IAXRY`+]ZL9PI"Y,J!O]+,"&L(5<>(QC4$*4Z"( M0'X,,0WU50T^9324HQ*8?BX.:,D!:P0-XD2:`W`'=-Y3-Q&*'R6WD;B,/29X M_908+_23T5ATC\8A_O@6LWD`,0L9\"A*4'8KO0($[I)B2"X9`-U>'>Z_)24X M3B*`.HI`D+>8%`$Y^Q_HF[E`OYX`%CI?&LSZ&PEFS>>#V16SY:J4TCOA!B]8 M.(+)C78A[3+T[\'TDXA<0@X]H39+8G`8;E0!GVG7*N@1P,V")_GB^0_`2T2D M(^@WFXV53\N'LX;6.R&#W(/7EQ?DG^`/`C5,OND#E6$.G*0?!GXH/$("?B($ M7^/"9P@^+GT@(-D+.IVY)?!*UJ#7KY&L(N2:;92T5#X;10R.85%IBY=*E"_8GXN2H)1Q`^8HZPB6CY[ M>8YV2F@08#.1TZ'V/(0\CN%AC.8X#G1/(A@IOXO MP!GF,&^RQ25Q\7+LQSY,8=*.P"30>:/:"',1DSH/O0<`KFC`SZ`#V`9)A83G MGM_CI_Q0.>7X"V9HS!Y+*UA&?UXUY@D2"$?25V&*#0+-6@"/]MB#X#H284@: M$3`%TPFO"A9>A6<723N:) M4#,K(`"D/)%S%&4].#T,,N\$4@(SP95]U$MQ@C<."\,)YN$!"&""=X(:?(_^ M!9_#64).D6-L"1,Q,1O#V0F3!&8^*4\[4J*`$=V`5&507=DZ9U'JP3$%1'V@ M`&8]"=`.;.*<2O;S)#+D]+-&CE,=1060W8B_*C?U1NZZ!IXK%/`JE)/^F(%UHC/,SS`S6FE&MEZR7,4\ZHR',B4?1 M)0O%8O"^3HU:N:G12I[UF0VU7E[:LX7.G7(W02O^Z$,^>BFR>1&+!6/ZS8QF MA#N*\#UEWE*%24J>H@%'.K:Z5HAC9]?G@)R M\%6]"N9R@9Q5X8*B].[H(IO=2J/=K%A6%QL+WIOM2J?7J;0:33EFRAS,O3H5 MJ]VH##JB,7YL#>1'T5!)1$[TFI5!VZITNQWQJ57IM_N55DMUN4)$@N.U7.)* M(RW2"XJ3-^1N>/YZBWUU@FUP@B^QK(\/;$L]$7]+@DF>8OV M&>-Y%G.+S>2"AO;XZ9KO?$JMT@L++/29:198-J9],'T3;FEAUB58CQ@DOC;: MVXEL*7/@")I#RW`DD[_<(H;(SWX`RG#@V@N\_)YX[*E#6LK*6SAY'1>"_Q^Z MX.=>9N09][J4FV9SX^P`*/UVI==IB-DQTB12;]#?+RR6&;A*^",V![V8G^#V M1EN(ND]&JV0=X3)BE$KWV*7@0:YM2.91 M,B):P%2'V]A@XCO,U6>B*Q=^;@LU6="+EM"-NP0WW.Z9F)1EN4,YJM$&\^IV M^S7!T"N9L=!09H2RQP"G0P6Z@'9'V&*)@A'L+[&;5F70Z+^6DW:EU>U7NNWV M-\OF6[V*5>FU($MK=5XEHK?X^UX3QNZTWL20U6Q6^JW6$BF]Z*_>[JL$\]OW M5\+SH(ZB7OEVW/.24IL9V>8*DU]NF,MJ.HZN3TC?ZHC%VB226^`SFCWR-0%3$CLO(!$J#(>%-H]P8@*JA!,G4),[ M)O9XU!:^*JN02VCSS=7"6C8"D"O+''#YZ.ZI:8/QP40(Q_5Q?4U./F4ZFR[! M83EHF,@->1BK-B@@R_H2AI=4!-TL'Y<+&/5R?D\D#=,:H/`&DU M\JNJB%@_1(FU22:W1^2:`2Y'CCS0X]S$.52U$KFMMZ?4P@\_6#A7[;:?I61Y M3)@C9(2PKD>($,!R8IK@/#OM[K/$/+<&\$J*5E#3;@XJ?:NO6:+VFO`]9XMI M+9,SVXL`=L%7J7JDN1Q^;L4''9EM@TOCTE8Q,ONAK"D:A6)E*?1MQIQ(HEEI M]'J5WJ`[7\F3%E_)2`UV88<\74U1]5@P4P_9"`@3!0*0$?0[G8K5ZZZ8:517F"@P2L"&S_Q4ZPBBME"-2&\7N6[W-E+I(-D`3XT6HT_IZJU6Q% M3@V9ME6!>JI*VM)A%?-S%^.8%X2RKU20:*JXWM:"P'YGCH\EE@DJ[@B ML]-CU2X1IDXRH`:0]J@MZQ'^GQ:HS2`X%]'28PN[*FF#I1GLZ*>;3:VEL./!JWOQ;;%?(PYJ``(5-E@Q'XADQ78Q^%_$1C%VF)?%=N ME&5*BT5OMG`(H,]+Z%`IS@($NKC4GYQO2_FX)^.R4$=1#"$\;&.F&?V_/[LJ MGJ5V@M4]3N^>3^WD9N,>IG?KI':"^0VE=U:[TL>5OXVE=RM3NT&E,QADA*AM M]BVF=WVK5VD@1;KXHE/QCA+$5+F`XZ7N)/<:(LG>0R37,C_#6G$FYDI8">KA M3GTH,SI\-"V)"CD0BB7YJ-[*WM"#82H0T*G:J2>,"\NU:30F?KB8'LF^'$4E M&D-`N7")\\G8TM3G:5!S77010!2V_YKXX/9$25=:@$'H!(OXQ9-(4#IPI/[* MJL+4\L:A4)3:28M&F M"@\OY+=>#`$Q$*\10(=ILCX;:4%@MS:WC2-K_Q57SD[5;I6=(6Z\ MY.QLE>/8LS[O3.R-/;.UGUR,1-O+K1:#0:?3'Q*;!10V1;,7X8;&UR]/<+WUM731T35O[";><)24+0DMC_\Y6< MPUE0`0(DNKR)<6HBD-H\_"8]S8IH19_.>2EE($\4X%?CN>.PS578HN39'_3` M4+Y$R>4_)3&+N0+6_[+-8.YY+VZ59<'W\]3T\-(XL*V7U[YX\RB4&#?U`D+L M4^PTA3[V%9#*0%SSM!`/&9][O72`4^!@[=+!EMIZT;3.P"F&N)Z-G`O]UQK% M4,-%:>]\+2LQ.K5M+:S#"=`)%B!`HDA)PPBD0XT6F%RXB6D_R_+1?C*UKF7F9-L27T.W6A.%8^=W#!S2S6_YLOOQ:C>X%'4\U0)-J@';H)Q MJDLPW"`YR;9#2>,Z!H"21">G-Z'I[EWM>QSLTOR40"._.N7&>/IU/YJ/.O&#W*\VJ)G*^]4BRK"#OM.QZ5S1*?V=364Q MWL$&'YK"-M-(M\3&HN$6O&)?,86(:X;XY/=L?1?NYFO!OS?)'>;J_.Y]R0IS MUZMGEG>1Y*\_K?W$U\JR;_)TCI.T8DM"%]7`5%/Y,=53+`4_1<>KA%(JI,9N-(/K&9W0; M\A/OJ\B^=;S:#)G@X?60<^5[M0( M1N^HP#>00FVDY'YH'TBZ#O)%G>D&GKA+)91YHA>,XKCL3$CMHL3-N7+]!5^L M[N(U+=3#WU&Y^%,C->53JKSFJ1):AOPTSI)%1,WPF=7_X=X.?EF3/,>+P_`2 M:VF%EFI=4S*!:[0U()^RP?[";.3I$GJYWGI3+B3/_]VDR?]_XY7RR MA3"5RUW9"33F6DJ3#OG]'L^U87>;$2OZLEIG^=CQFC).P%1%(]7[+`B%J3#Q MCM`OW^\EGO&BK$YQX_R\K?S+TE$O!# M._$U=YG*M,.WUF"TNR+U$3^W,Q[@M_`')@0F>6MO,2,M55)F"&4&EF%&DYNA M!T>(9HX0ZRU(.(+?6C\DD0*-(I)_TW@+$?^F\18Q!DUEAQQ@R8**24H40_VR MM7>Z;.DD6/8@2U:%]N&$=(-V_-:4HGW(%:K"`#3J*MW]"OW?$^8B.O/YOO\. M_]#?8;!M%13F9NGDR>W-HGX?-S>Y!1&GI\PN1TK!N0?+WKT&7T]3\D12AV'F M+1;QTF6NSY_>&&_XSTL6)9#^_-6?KYY_>N/`']Z$__/1FYC$)>%."4GC%[CFHOWON?--SMHJX MFZGX>9YA,\T?JJA=S;>^\"7%D+`I)PY)?G_DAXYP=P$7C`ZW#@EL0))__<>M M=;&]3C;>7U:`7+F!JI%*6JD=MJ;7GE"=0A54P#1PA0Y1T.2@[,Z^9Q'.39[I MG9&^KQSEAUXAKN3(7'W,A4?F#LW<$[0SGFZJ]9*%Q&Y5Z^VC31OJ?3A_W;:A M3CX_S5@UTY_>_,]LYGF/CV]JJ:&F9=E*V[2YF5GW#KPU#.^E;&2?)1_VC'JN M=/^]:[.7=RSS7??ZD;]TI/I(]5Y3K63W[EB3_7/+7]#LX9FXBE-EPY^4=OST MQXCYL_J-#UC<_REQ#"D<0?@UD$DE5.Z\D$3EL"?K9KW@1&T\W7L2V>L:+D.E$-!PO MC/)%GS:WYZ&#-:OL>$+1LL.=[/,6MP\W"!^]55+82BRAX:7]/PY4J'M&"@PG MW7\&IQB14]O9O73_I:?GJ2I/O%Z?[^36;WN%I38#MQV7WWA=R?G)_QC\OW:K M93K#2N_A^^DL%+;?X]WFT3?^G6HH1%7%/%PS>WI4%370N'W/&:V.@:*P2&.% M"QVE1(IQ;AY9)J87Q-PYD%8XN6`5<7@CM?;'>5Q0Q<_OB ME65HARS':EY5EXBWZB[GU4%;&(Q3OMG,RZ@9D76"C;PSCS6"S8>+-\8[+WI; MEU]0U,WF_BU6Q"HORYKFRCWQRT>60%93XCXM$QMN%7]*2[Z67\=&9!9*R@2Q M\F%2^!`D=48KF`[KN"[%@ZWA&+>3EI1:)KC"_#(;!L2\MGX^)N?!!HE9K:M8 M=D+!N!,JO9!+=L4>=2"ZY^4P!27&ZK>E)198:8VDMU?C"O/CPM>]736M5%6] MZCU)@>ZLH0)[,BU.D)7V*+\FJ7XNO*=2%LKRN&:II/]-2R-TJ=%6]:Q0U2$I MIY`4AN<5CEA9<%8T)DZ*6S?10?=8YF[)V[HF)3^X^`8A%W+V/9;02J$5S7!9 M,8^D.A_?I!^]B-E`O.YK5H'YM`9H7*J]SV\1&)!G>DA@I336G_^=]+#EE(NY MPT55CQ4OVK],=)*0H_OHSE9AKC"JRF.W%24]^?-&>7U6__6+[_%Z24Q3//NL M^P.O,+2DUJ@_RX9A!@8OK<++$_WE+35,BFX%51SE;5-2$HFYMU6"DZGDR#RFH["ZIG0 MP5TVR2X=;+;:%)^L>@=O7U-4*"E1&2[]@`M#,F=^(D^I(,Q#7A0Q\"C'XJ1I M_3(*6>'<9/+3\EK4[F:L7>2U9_)25B51%A5Y0C@O59CN(B4N,T$M'(U)-1=6 MPS`NUS'.4]&32EGLG0$KX"5=?9?JI#\9_'N\#:'!C)%REV9VR\8-N<]Y>YR2 M'DQ[QN0M3!9)99JP@GYE"JD2?^Y!)N!D(MXGT2'&!DD=R>$[=9FS[=E+4\Q73O">%5NIHZM$3.C>60KL(:%WQW%;61\/EQ758HX6/Q;^[R MB)OM/PSK5]3D,-1GR?5;/ACT6F@/IO4P`H)^YP;945EICDZC@>%0U-:QZD_1JI^O['T1SX>`[W;SW_6)9?]G7/)2;?@*"/T(.V]K(WN:M3KGG79/UH'0M[TFLC3IRRC$ MZ[#[\*JH)5Y5(0EN2_JP/26.:CI*TKS1.[E=N$%C1_.!0WC.'G=`6:3]&29 MF(92RZW=-+S]\^POI;9M0MPK;Y53]-Y)(JVWJPZ@-``PZ4+XZ$51LJ;H&KSS M6$O1D_.3?V9OH0]Q"M/?7!2_B9^SSCOEYG)B/T+>[W-&[4.>A,DKE9S?79S8 M@.0!KD(%%/[\'VL6H/'NO;YZ5-*,78Y(W'RS568@;7 MG?][S56'7PHO3A@6%UT,F6KBM+.WLV9"J?H1^_ZQSHXGB_`K52C)>$L6M1IJ7HQ[I>8(5:9^R)XQ-!L:>QSUX*H*H6SDFI M0>^?`+9/D8D;D=0TYA*!\&(%/X@!^2WM*=IRI?BVPG7WC\C,06UI1G MV19I:#;=:"+OB4?2LW>#4YN04V"9R?*/-U$FW;4?6>0^:W56`KQ$80%1N/ODU\9Y+W0Y MT1$`+$\C2TD+YIP%V5Z3S3Z=CT>JW:CZG:]GJT2L$I(2G9_$O,=YO@3?(NGN M\2=(>&I:TFLWC'B'\9F[]%>L?S6=8KYOG#QY@1?13^CFM^0=D?,LI;6=)%UGWCN2*IWBBFXYKMEX/%< MGX([V0.5"7;54B/JO;+D(`N<&HC4"&8R:-W$)Y7$9,@^S9,,EFRC9R!@(:LK MUA1I6V(WL<3A@L]6(;3,)S7ST[;4%3A2$V=C"J:B4O\\[V;R^4&R+R?MDNE$ M+$[3SJF99-@_,('Y0BT=GYT;E[D9F#(P,^TXJ0=LWC6;=ISZ0S3O9$P[3OQ( MYAW`I[9AC&C>U9IVSBEQG!P(Y\%.S3L;6*<&0S057?3!9YE^=$_E(Z>R3-7) MA:!.;G-U6_,:/'2#<(.`I5-GK6?M7+F'D4^!LJ[P3+S3]9:EK::] MWGEFK,]7+N\-3Z=IPSQ*WC5/4;+%L'1]KA++QEBEZ;.]J2T66?HW??Z/=4C5 M7K#*NGQS*_"%.1#X-QF@;.`X_=<\,Z"J\EK35+.@#'F9>(_XXD_6>/%2D17I M&J9;=_H&0*C^G;NOJ6&3(.;/G-$O;]BWP8INB$N>R$=?F!GKQ4@;#"M]FQ/_ M["9-YQ_9QLKFZ?2$?Y)D+)YNO(X!9PLA8BQQV;J(5WG2,4O+I9-TQL9,#"EN MTJ2>B_JJ$R8^!3:JFSSZMF)\^NGF)D=_O_"]==74,6'E+]QVGI"D'`/#]/;D MO+89=AFOH`($2'1Y$X.52$IM'L8CL91>(_ITSNDNRN_;W"1UD?[UD@BHD"[Z MMN4XUJ+DV1\@J\60L3J7_ZHD:8K2\U[<*LN"[^>IZ<&I3$XCY9=+)7US$>'& M34-9$OL4.X9&`4GR?Q@(0422LA:)>%1O6[+2`4Z!@[5+QW52":1AG8%3#'$] M&SD7^J^U; MS"5)K:>\X?YCH+N-IJ)2_&ZLZK5FS05)7@3LE^*L\VM:I>0F^)35WW[/RF\? MX-V)'-.$*Q(E?FWF]1W[ON]G9_(C7*V%`(Y]WR<5!W/L^[YW'#WV?3_V?=]C MYA[[OD\A9O?8]UW#EXY4'ZG>:ZJ5[-XIMD\]]D88.R9]GWHC'.?V>\LW.,[X M<<:/,WXH^KO)3-F?(]BQ[_L4Y'Z?FBH>Y_:XBQUG_#CCQQG?3_TMZ7]6:>_6 M)5*A+7M7.KZD3[P%[!.D\IO0`OZ:M0WY5&I$_[W&L$#%&!99=O8)<3FVJA\G M".-XQY4KY&.K^EUMRL=6]<=6]8=;<.G8JG[,B\KM%78L"[=OV^_Q.O;HSO]. M-=2Q5;T.7X;LB;6OJP/V>#>/18TUL0H;SS*^260UJCX=A5\KN:EF-7 MR6,J0B=?UK&KY/'&_'AC?ISQ@_;8'[M*CB+<4^G3=E1;0\_L`;1IVQ^;[-A5 M>!FLJ,!>T,\C=W%--^]O_\][E7LU,UL0(`23 M9(#*5VV-Q$MP\T63!&C4,&P:.WP>WSP^((,.S`<]60=^\OOD MVV].YM[,?Z$2_M.;ZX]7E%Z`+`,8%BAA:AAT6(`/0M.0A[QIR`-_W<.OW'YI MIP$Z&)@F4:7@RE]XT065FZ?PM8$ZP[5KX^OH]XL.CK>W^Q*"_SF\#[^SJ8T[DX#^;W7ZF, MOE[Z3ZMGUK+H.;YD=>PKI>RWNP_B]!AO_H8L!!TZ-](X-F"OR]L'A7/KOD;A M8G'O?O/B3DM@&QS`"&$;".B:AQ.Q\1Y329/?\#QO8W+K^O/KX"+I8?+>"WAS M%'>1B'E<]`N^#Z]9H!$UUR^3-G,\N*9$#F7[XHM7XCCXX,V@89!FCCL$.AE) M.E!.A0L/Q8`/;,2'Z^`A'7-;=WR_?#*;EX")L?4]<*&GM$R-3Y24XV#3,0UP)=E\=<;"<<1KIMBW#05V.5WM#=D^!.%3&`*/%:T@H]F61@:T]Y;DCW[@55ZE]#YB3(0MUW&\ M9GTT_>G.JD.R_ZXL^\`>]"H0V(T457MH#:#8E]%<(83*A_F7J*/&H_>+_X?ZS].34^#8#3A!=`A$%8#KH-2 MQKX.6*W,A1O'_J-/-1<]'J<2FY7=?+T/+^D\K5ZE#ODMZL8FV+0*N!U&%V"S MDI\SRKH/_F*]\N:_A'%\ZT5I5"P+B%5!>GE[)X)EH>S&6Y"QMG5(97CWSY&G MC,_0CT_*@57-/&-WS)/!9T`5?!4F7$,?*)UT6BX#_PHV?V?9% M390/:4#Z+Z%+]ZYXI2M(VL)6$3G4-+X(D^F$XOA]$WUB"4V7W[QHYL?>;>2+ MA_/TMW&;:/S?.I`1#?`69H=!)1@CD?'PT5M]#:/_/-"9>KCR`[HG4TF@:W2V MCGBQY$ICIXK<8G+ZDELD)B2&\&\4.4A4D7&)R:4QE-+DT=T5C8C(\F")QIR-K;&R1SFB2B&EZJDR7 M5"*MDM/7;&=9A*Z):CS5HPZ,LEK7;E_H.,9.44IM7Q!8!`V"\F[].?;^6%,M MN2E\O%P\9`=4:7N>B`DV!3(4!'G04E)OR<'WB&.,P7P MV1XP=&Q@3XF4#O-@`\OH-0_7P8R5"?`^>,G?UT'JOL\L',K0F]6S%Z4E M5<[CV-/FL`,FM+/]5`W8L)0IWC5`#,B$J%!2LH/.A!#[EAOSP@WE[3IB#ZSN MPT_>TWK!?4\?JDX@#8$XS8Z3NE.7@PQ@YG2JPQR56*)&K`DA@,3:,V)-Q9DU M#`?BO$+*OE!KJ5$+D67:8,^F%AB*4PN`:1OFOE$+U*AU'(,8)IPDL?7Q]FI2 M;"`'6FCWI`X800]MVS9!'Y(VX[CT4]0W%YLX7+_M&8G,PKDD` M`OG]_IY0U%-03:I8'=++1-@!S9VO*ZG9MU-\HZAL8"NC6F!=5 MVQ>:.VM49K+O%8W-!3J`C6V`[/VBJ'>F)";6GMD[;6>NJ@(C5J_3Q]@DME0% M,!$V'7NOU$OO?'\3(6+#O;+@6L_+%<]W]"E=_C7 MA<0];6&^U"B'%;;9YOC=0:I=DYU!TRXB:8?$H[)JSS`]?1!%-*W)^MKF5"PP MT`%/&Q6Z9=$T3&);VZ>]"@A*4!4EDF"ZV6YK[J%0* MK][%R]8:\L;Q<#(9+EJV#94WV+_7>`O?GJSBM;>&[4U_V./ M0>1#1?N,(JDHM!#2.,I';W4;A3//F\Z MG%ZA7\QMQZ#&2K/$U&(2J+FEFQ6%X3[1_2HOVI#<[5^XBX4W?_^:?JO[!-#3 MF;>1B&J\S3V!\B/7P!62MV-NK%=Q^+]W9\V#8F5ZL`-X!0YD*/YP7!L)] M>)O6$Q*D3Q;SWV[)OPID[>\5<43>B[]^87X(!IHEEJW]^)G7P;EY9"7SM&TQ M!LG+AK>C*$/N%I*IT%-+",CL&'XI+L),"(1D:_IUL2ZE+IL4&)9M@(*$+IB& M(49M%S2)@:'A],:=RGR:RRZ(OE@`A53U3-@8 MX6(&.WO+>1`R^1._V2[M#Q_#X"$KE"KE"!?R\88!N0NJ[Y_]:#XMVJL[RIXS MR7CRF,)[_UH\*]5` MU<<7+Z)[T\],VE@ST?S%:ZT9=7 ME0`K*?\Y#.?,K*'R[:4;5N9N%G:9?[#[+LK]DEN:[0$J547JXOY)!=V]X>V$ MZ`H[KJYP`C)M$^-#H5N^@3:$-MI6"=,B6[5L3GW.$JI:V_W@C4]Q!^DF>,A% MO3."Y<7:0A`@HI'BLE,M^?V'-2M9DBCYBC2>2[8C5D5&JN;Q"(<523Q=*-@V M.NH):"M8*X]SRS88$F;?^!O3L<@T".D<5M,/]_9C5--G99ZHP<,\GP-6K'=, M(_=N=QM?._#>'?*(E:=43HVTSD*57]9/BY*V%J^(Y-=`$P/>OX$2-J:YZ*9FFWNJ>5Z)QA30TL]@T9R$Z7T:MQA,2:[)*CJL- M:=]6?\2Q[6V*T6=R4&`BF0TSW+6SLI:O:%`@Y]G2@ M]NY+[ABHW<`;BYBN0F-)6-7C8&^NN8&QXT`T%:B]>P(Y=+%.AIC.,H.F(C,M M)WL"H=UNUH\$M:]%3*`A8>R/14SGTSMLM^?'P=Y\7C=S>KK$WG\*A(_04WSG4OO8,.S5-AYC.1O!D)L)N/ITZXY^TZZ'V M/6K;CCD=OG>6&309[$ZS.G4@;&) M:8*)V#.]Z[O8A-AH(G:D0N$6RYJ*S#0'QR,$K:FHQ-Z55B@Q>"I*4Z&$RMA[ MDU+?*+'(PC@P=14]P89M6>.Z#(:K9H*'1WX=L*SC*/9^]:(GKR(T6/'>X`R9 MN`5LU=!:`?<4G3/D@):[OO%)ZAYDT;)%J9'0NYQ?BV%,@&W:+[)*AM9P7MQ\G=PN]=^=TV'05; M;D0"NPH<(1KE+K0CG7:UD# M8@$;M[ANY(".3+"J`P1B8AO[2+"BO8X<:#MMN=23)%C5M*>'1:LMF7^2!"L: M!@C;!FY+NGA]1-D":I"UTZ;P(C!ZCXX"+:BWAQ7&]*>MVL. M`K@M+F<\6CI?I`$-T*L$;<09.3,EA*L6XR@$=@[HT$M13>7Y7(T/F".-D=-J M+DG!&9FJONG4&-FP[>0Z2;J[9T2VW0!-D,R6HFK`=FS0.3F2U1SP@8J#5-8(I4]34/@&%0XNM&U! MWQ,DLZ6-G@D1VC_SH'=1`=,$)H![=T)1J#_`[AZTD7D51N>S/]9^S*=BB+QR M`"$UW:J"+(@^Q)V=TE7.SN[P1NA2PJ/P*FZ[JX`(D%,9 MSF5V^[9&*VI,H)/7NFO'H@Y\\``@0(\/ACTT\L'*3!2G@-;A-$#K7L!C!+BJ M::!":.A.P/7-N;/SE.+=P._L`44]9&%[E]92R!M@@JT-O=4^M$ZXO6^%)D90 M2U%LAQ0'X4G`[;M*IT906X%IA+%!IH2W=Y7IJ5'4?!.(++K/HBG![5W\8F($ M-5]J88L>MZ8D+GUOJR9'4//]#`%6<7:/5@F1E#S50,P3-8S9DIX^^X` M4Z.HQ6_.TO^),R&-V=LC/CV*FIW`#B8@#\:9!-R^$:2[(4BE]"I`-D!P_!.+ MKOJK@]'SB^]^]A?^ZK4$^[V[<(.9=Q[?/,K60C9,"]L;'J[\Y4KC5C26KF"$ MB:@2,+J/^X$RZ(N[\K]XUT&\BM8O7K"Z1+YI]?>K.5-_\]9!EK M[)N?W%5+O&S>]OSA_FOX\%#=@NP/@7/)#[IP"<,]YE*])BVQ MZ7+A?>DO3]CZ?CG52::*6KL'S*D!%-3W(%#]-=3>25,J!4K60/7ZVY5!D%(R M*J?D-CY%/F%SXGSZY,?_N:*BDA7;&\FLQ(P[AD'ZKK0J^&-P1=E::N<)WE>> MC&0;I6Q"WRF;9+>RE$V;MQ.'QJ9>5M%W(DJ]3*(]E*-1[:&4/U;?LW\#(2.R M29,QI'-K&XY)&Z$[MY$_HW^$G]/7*)M&G=D%.;M(3V9)D#-AIG6SG0Z98YK6 MY)%E1Q$;Q"8]\JRC\74H#/-8++4W/__B1>Z3=^]%@YI:O!TQW]53#?]F_`KB?0MYOVV`3CO9V@?=0_VS2 MQY'T.']M_HH/?CQ;A#'==]IC+1[8MQ[XURAVEWV)P8D?/GFS=<0"/#)W0CJ> M5,QL58Q&(]"N='V+_7>!O_CI#64?W5VUD2E^[SI8KNDW?J&2O@`U;/AQWPB! M0Q'2";F(`+4#;B1TQY+8&E6D98551B/M9(7U)7,R*TP7(?I76!7RT598/TDL M[W`?UVRXF\"DK>.S)]==OCN?S<(U79UIN[W[R)U[%W2ITU7?,RJ7-4,QX%]_E!AI M`$A2`;O0-DQ`U"#1G6)^&X6/7ASSR.DKSXN'890%>-JVW%C#X)(+;S9@'V#K M%]9GPYM_\)81?6W2`<9;+CSV#RJ.YR]AM/+_RS^G[UQZT>KUEF)$^1*:T%$(P M$0+6P='<-YEM.EPI9=(-4VC-)+;5C;02B'%HZ%V<;4)4JE"WY)@BTW:("%QJY-YH MI3P]TX&KE!]M(P/:T^%L,]J^/!5.7#>/;/=@7E#FA;B-O!=_(S#S)O#^O@[F MD3>G!S*Z*H/5*]6CJ^?NL)&-B06!`+X-2!/N*S^@1RH_>+H(XU6L"3*$)B`V MKH-& M:6#("R/I9,#V[J7@\:>[JN,0<157;5$M0TGMD98!#((MF9$&NM&S#&)9:'/` MZILRN7'EC`&;VLO&%DLKQ[UPXV=J\;*_V$W/%W?!SN#GJPLJ<:]4`K;K257Q MH;GNFVW8)A1/^U*##HI3SOHT;`")O5.@:H*U,X:V"2+30K8&G$EML>M@%GGT MO$UYQO_6=**3)*,:TT#4J)WV("N1VB[06I&K'+;.B&TBDY!!@"_ M1)^8!SJ+E2FVP@MWL?#F[U^S.+7TP:9-)PWTE[!';$)*MPL],8U,X,-';_4U MC*@=%G@/J;_%73P4KY8_NEG`0$07'Y*X)V8QWKK1372W8DXYKE(R,Z:KWKV\ MO=NB@>4R"PXTB5$'A%FMKS3#3";S?+UZ#B/_OQN7!&U5'&TGI#D.348)"%,<1A6&<0IAWPU#3D$N"Y, M&P;<$(8DQV)5`JDRQ:0'EPRO8M(C/WCN'O6@>F(5S>//X?A/&;MY-(2OW?A8J[+"B=0=&C4CR^-LR'_ M0]K<_G&(T>1O2P893M(BUTM:VW!BK*HFB<(8(TM0P^*0DF`4+^$L9/4:5N5, MA0EKER0QJ/_%GWO!/"[K!5VKVK`-HW2]6S-^=Y!J0U"CI=1%3=E)H(:$"L%%1"I=YP-("Y264KF\KS9>0OVB^1;>P8X\A6 M=G;O.YD`.#H6YP;_P/^M%Z_MH14`0QU@%"_=,;*U**YZ.'UGULP M\Q>)-9#G^+*$P2)=]V?7#WX)X_@Z2*X,KX/LCE#R#K,M!5E',OP9P(C8XE%[ M-*X,,QEQS;B2A__=5E;02OQ.^3N-O/HQ^>M3/-XO_AJD8*/7M]8!4(V)<2PA*.;'!8E_!H\6?U'5O9J]1]:S<.ED629H6,V MMD='O_RVHCIY[$); M1_4"+W(7K"[`_(7JVG@5\9)T5=DS`Z9-8!;-:PFGTQ8:[&6;=+\A(P!4\<19$-H0CH%.T9L#H6.:HE^^&\"(+E-6$\77I:HA)EAP MJPH#UB/1H7SE7J^N9N7>KZA0>X)O>_]F)-IU4%5;2)>`6":UX0L)D0/3FP`U M;7H&+8``'AVMTB6"Y1"`-$!E=92R4[?OZ4I(!'3;`@"TX-_`TA.]HE`0VT:F M,RI2)8$@`-JD)\ZDB8E>H\HV'-LP2JNL-&PS)@V[1X0#F.H[2)#$-$^ M!KL*8)8^E:WP)6]ZH\OZ)@@X1)23ZN$50*JI@I+3?D`TJK?PT-$"1ZV1/-0S M4XJ&,P)&5SAUREBAZ3M"!@1"KE.MQI4:4XY@8INF;78;D\5,L;NZYW`Q]Z*8 MN9-Z=[S?3IYK&W`H>&H)=\KHALG'@R:TQ/B![0'4`AX9E6:)T#(PY4=>%6$AO+@828[8I& M!G1BY;$[BF93$J+S9=1:JO",53@'HNE?&J+_Z`^?O)5+YWK^D,7IR(41#0)K MP`4#@(D1+!WME2`IEI0\8_7['&1I&UUQGH:!I5IJ^0P!0L_12-_PBFS1C:NY M\O`91A@32/0-K\@6W;B::WW2-6R9R";ZIH6H:CO=P,R6F`2;U;=P]`VOR!?= MN*R6:3'HE)92*X8>7U5>=`.SV\:'ID,LC>,K,T8S,*=E?(@@+-VR#3V^*F,T M`VLI2'3&"G+`4EN:H<=79243@]6S MG@`%BMK`2%07E(4MPQ;/9+V1J"T,:-B8&&0,CK1`080:*\CN@F3U[$7;`4O#7+HZ MA@F%;;IYK&%PR=W%(J=4$*<[L"3C*`QFPUQ.6Q5P-H;HA4(RAK0KBEOWE>

R/M1]Y1>2*+A6.6'PY$`-' MFD"TP)5K'SE@**'CP`IVM^,9A`ZUC:I\HSLR9+7`TM*%KC+B2*R>D!55^.2N M6*W'&7WT/5DNU5+)9D;1YS&'P M=2B9.CB^X>JF;K7$J!^N/ZP.+!L2UL#U4Q%![=AJ:Y0J`Y1GWI``AZBCRO#4 M@:FHIM$)@)S=[N!N`,*9Y\WCI.]'J8NIK@0#RS`MIS1CM1#JL5)[@86RL<:J MO*L5#RV_9C5*XW#!]C]*\OIS[,]]-](8WH@1*>LZ983UI+(2!+^R%K+^ZI45 MO@\7"V_&J[:P]VH_JK#8;6R#:B(EL343MU%?880C#*`G1JM&!%L0;9%2_5C_ M.BSL@3+7:T<:`I-D@@<6Z]C(8_KD\9(VU(I:O=Y';A"[,Z$C)N>[\'',:A:) M7^E]G-IP$?2$LTG;,CV=,2?#&"H4(ILX8M9A`X1-K+'G1C/60.,#*T\5\NG2 MFWJ((<8F0EB$VX!"%;"B8\"Q@"U6D]:"3;6.`\:0_J\9G-)Z0H0:&L:NV-96 M3AXZCMC:MA.XY!(ZNX,6ZG%]\![]F=]7K9\!@U@VMD17>/N@PX%4CBKN"I+M MH_$GRNY@[?%:X9O;SX#ZD)A8\"Q5C2R!34.2<]=QE#.=NPZDENX\&#E=!M(G M-LBQB%4M-HT2,X*PC"$GVD5$FW14ULP]9_4UGWC)R_>OQ2.IYYP7TDVKXUZ% MT:/'#V;Q=9`T#NO'B,PW,3#.GWF+JPPBKUBSN1*J*F>#AX_>U\7KP_ER&?KT MZ?G#^Y"^-'/2RW;H(F4WG@9B)L*M3][#)3NUJC(*'CBG\K[,6>EJ^2YO>-,9 MO/>\D5<&WXN4"$TC>-W^H_:1X5;>E:&W]MFW%28XXY/^CDU[K^RUQ<`[KSK& MAIN+6HQ9)Z6/8>"5NP/$@A?J'VLZ,?[J56R'67$)5=_-I5V6@$5J9*DOQ!V1 M+M^8]>`HE[]^A".2GH&77$[`XJU##!9]PJ*WZOJ;-"TQY2%;NZK(C%HW3)&' M+D?9QJ29IEVA]@?C>X%.*Q.*)&\E)C@8(M-V=#&A0#<*$Y`:$X!AFU1Y:><" M&H<+6)$+)D#(%AMKZ^$"'H<+1(T+T+(A=,1>&7JX0,;A@JG&!0PQH8I!NRR8 MXW#!4N2"@QP'BO?V>KA@C<,%6XT+!!G`,O3K!7L<+CB*UH*%`BYJNYSI/\+#^7SNLZ.ENWBX=?WYPW7P M<.$N_17]N3HE7`.&9NG0-:I<)T\-`\LFW[M-6%51F]NW!M M)`L"`XGI3UHP2@A?.8K)M'5#&JAO65:GU)@(E)'`MI!==<9!)@9%L`ZQ4LTE.PL&':#L!Z)['-N5I5"\&&FN=. M4;`@U>Z.7?+L#`^NN4@G(`1";.A5!F9/P2)4L`Q$]$YBF[^Z,C5"LPFA6N$4 M$:;N#+TF5G.94X!M!`C0*UA67\%R'-LN%9?0`K*S8#'OOV9,BJ66J6"9!M*K ML9K+Q`*J;PG1#:&G8)D$6S;0K-G;;E4JY)U=J&C&I%CQG3*,F(9><,UE=AUJ MO^A66$Y/N;(LYL&&>NW`MGNJJJQPK)UQ:G)E6I9C.7H9UE*E&!BFXQ"]QP=@ M]!0LQW0(=`RM9^?6J[^J\S34ZW^4N?ZKTJ..5G%7KCMMFZRD@=[C3EO/+L,` MCJ77O0!`7Y*:/!RJ'I#DQJEB`R$Z6ENB]7*8'=`N&*< M(T261<"FVMHGPI5#&S=BW_>,;M4`-LMV$-KR".P7X:HQ3F?[3[QJ4)Y-;+1E M.^T7X'JJ5:>\)U1GGQ^%4:L_^E@:86LBQ.P M9+56"8,*]BP]3W*66/U![X^U%ZP>+K^P/^63CCK,TA:Z#I1]]+[R7TEW=55; M;AVHR1%)4<$K;@YF(#>?(0WL(+/=')2#M`/J>IY/*?W$(9N>CWVBO^O)%VW? MS^X/N6U!!9:)MF[H]HBZOLX68J%2A<>]H[]SC`VR]G?M-@TQ^]^"+O:56X8*-'#;+.M1&3.J^5Q]4'MFTR`'3(A8CHOG@&P)U7' M6!5]O978`4:.9<%-S;8U?&>(:K77$:O>L\6__FB4^JW9R(";<4(R4(H6@VQZ M/GDK/ZIR&Y4`TNE[7E79FHK^*USECI,$ID+2=I^:>HJ:+65;`7=%%YOA8?=- M9+',J1+6^32C3LA??_SV.5K0?_Q_4$L#!!0````(`.F&:$%(:4/590T``*JO M```5`!P`<'9C="TR,#$R,#DS,%]C86PN>&UL550)``-&*IQ01BJ<4'5X"P`! M!"4.```$.0$``.U=2W/;.!*^;]7^!Z[FL,E!UL..$F?CG7(L.^4J9ZRRG=VY MI6`2DE!#D1J`]&-__3;XL/@""5*D"%%3.426T,WN_AJ-!M``O_SZLC*U)TP9 ML:VSWNAHV-.PI=L&L19G/9?U$=,)Z?WZ[[__[]CX:.3_8A+KCT?X20.!+7;66SK.^O-@\/S\?/3R2,TC MFRX&X^'P>!`V[/DM/[\P$FO]?!RV'0U^_WYSKR_Q"O6)Q1QDZ1LJSB:+;G1Z M>CKP?H6FC'QF'OV-K2/',V&A7)JP!?^K'S;K\Z_ZHW'_>'3TPHP>V$#3OE#; MQ'=XKGD"?'9>U_BLQ\AJ;7+!O>^6%,_/>NLGW0$.H_'P]'C(Z7^9!JB=6\:E MY1#G]=J:VW3E2=W3.-\?=]=OXG/Z(]U>#?@/@WS:P;:B?44F-_W]$F.'%(@II+[!`=F:4D25!N+=:]`UV+VYS=SF_7F'JV+C2.B*I6<>X=6_]C M:9L&]._+/UUPAS)B95'7*MX%8LLKTWXN(]2&I@9_8@0XSBAFP%NJ>V62;"W( M'=;1FCC()/_S6$+G_8XI!.8B<7((:[&.#@RGQ'1AZ+BQ&9MA>F&O5K9UOX0^ M)&.K`@9;"^F[Y0-%%D.Z5+_+HJ@!0),/KQ!98JR+X1.0;2W0%2+T/\AT\>W\ MBE@0^P@RKV'K:D9$74S8TN,=A`)C2*J!H2YP$]FE@B M9\NC;4@T220+B)L5[@&_.&YQ&B['HX%`,K--HI-B@/,H=Q20)4U9DEG3PLOU M'TDF@;`P.]-=TW.1&Q`M)C3HA2T#&Z'8G'VE&7'`E#B9$'R^L(&OQ5=@X!,#/S6\)9Z`B^:ST=[]L)!K M$/CEO;\P`?*:MAZ3T>1+(C:-^T`@HK?N,4?LT5O\<%E_@=!ZP'UC@$V'A=]X MWM(?CH(UD%^"KW^>,Q91QD2/V/2>]_;#H#6A+ES*%P(2LF6V^3DY/IE,3DGD]/A<43R"/SG-*X$HGK('S[&L$\O*@4M!LQ=^0[6!]A6(?V,9\L>^L-VH'$SZOAR[*_^-1^`F9 M/"2<.Q>(TE=B+;RX(XTA09Y!W/*B-.BUYC'N M-RSJG'DDZN"*(<@#"6@_(WY`D;UY:#K`6!<=Q77`QA/M&^@%A! MBP#&B7(PWCI+3`/9;4O/'1TSV^X+:/+"!UA]4@ZK&X(>B4DLP>7*]]:\IGL,D6A1+B@G50;HD3#9/AI7\$NHZ%4=M87V(Y6):)Z_3IQNN,\PEM1J/Y(6R+%MU^*% M?Z]\A^F!(@,7+/Z+*91&-T_&C/2TI)9-]UQ!*`4QJ1O?,H;1`80&"YD/Z"4U MSDE2=0#);33=F[[+E9M1>XX9\P2\PD4Q.9^H`[AOH>A^3$W\)5I?.^FA.)^H M0[!74+3IN8L@=L/4:HV(4H-N;W=L2.E4-RU\&B2J4 MYDI3$@M4M'>Q)[RON\Y&=/0BHL_=/(%:FE+&+W MR,3L#C]AR\7B2JM$*_60*[)_1N&$A$I[@=HWVS9RBN2RFJJ'GPP:^1CFZM8` MD(+9ZG=L\`G'%#\1'0>B9$W4.N M)2Q5$!&HAVCY0%E2NV)8^ZU5ES$,IN*U[^"=V+2]4NE@+4586)9#HQZZU1.8 M\HJJ"_0W;($93%#EW%@1BS"'&^4)YT-=0-4EL*NH6KSHWQKY>P)5?D=C[%CWD` MY]+M(;;E]5'VQ,BU]829PZ7WU;ZV'$SA&P&:HN9[!F(I-1HX02*8O&SBQL42 M60L0*W+<6J85EO57FX-/3$_5TJTVA,DRT@?PE6PH]%*/_LD_(S#&YC@+M2C!B>8O__C'Y7 MCKRE_5`N'

CT'4F("\I(NXBT' M7>',W>*5C0EK)"B+)Z0W!". M2FO!=]%%"58>28=]H++Z(?AUCMDY!P>Q+]@/?DV7X:U4L`<^,73IZU=BFL*C M@T5T'89V.QN$^!:LWOVU"[D?SE#+SN4X)RDK[PR"WNY/]2]?,-4)V\ST,WNX MJ&V'@2RO=PC>#I*QK]CR+K]")F00P+[(/SM\:T"PLUR..';*8C0>?3II M^QJQ>M'=SA`AW'5F90*X)8$]0`C+@K6#+"KVJH,EM=W%\IHQEY_=#/;!LK$K MHNH^E)4L$"![O(LA,R'/E4W#"N$L2,6MNPYE2/)EG$#ZL7(IM-?I`XES!%B/I?!=,=\XX: M#!'Z1JT+'**(D*AFN+:J7JA2C5.'/:%NJ[QM*ZL7,M):9MW\)JP6E2'NL*/4 M8(C0-]0[BYRI5.):J3*.D2`]5+>0,4/H%.KM@@ELY)][V**P,(.!.@[28&&A MK-[*5B:!0CK&!KL"2V7D2]&7%PD\H@0'=5RB)EC3?K*M-92]V@)&0O]-CO:Y M#AI07-I/I!D<@IML9PQUSW@G_?\[2M(ID&WZS(OY`LN_'/L9HP5R\5$.L9+JTH_FKA:(8Y)=Y2M.-2[-WA MY9U5N+:B-T/=NX^,&`31]%(L7\[)T]=YF=X=U MM"8.,@.CPDSW.Z:+S9K@1L!Q4L`DK88L0PNIZQ73>],3OZ*=F*[#TWC&]VZ" M07Z)*$Z+>YQE3]V3,>"B<38:\-%\1EK`J5[1_1L)'RBR&-)CRS$;64^2L@;7 M&,:IZD;>Y#%QAFA,NK1P']*X>Y2:1ZK%:.L5,7+W6#`^(//:8@YU8[O5&U$G M25$Y!\UCP3O2&Q,MQF7'KCK%#B)F2OI)98_5W@4L:[_KL@``H295<&A;BU&& M&JF87$8/;52[)NE8(H1`)J0T9W)!6FVDCW7<+P/.\Q&<#O[X/U!+`P04````"`#IAFA!2(6NX*\5``#LL@$` M%0`<`'!V8W0M,C`Q,C`Y,S!?9&5F+GAM;%54"0`#1BJ<4$8JG%!U>`L``00E M#@``!#D!``#M75MSX[BQ?D_5^0\\SD-V'VSYDMG=F622LF5[XXIG[)*UV>1I MBR9A"1F*U/)B6^?7'P`D)(H$0%`""9!B3=64+`&-[F9WXV.C`?SU[^\+SWH% M800#__/1V/3WO_W/'_[ZO\?'_[Z:W%MNX"0+ MX,>6$P([!J[UO+(F$^LZ\'W@>6!E3>W9#(24JG5V>H+_G9_]]!=K'"Q7(9S- M8^N[\?=;O8Z/LS&N[`C11/W(8./'T?DUZ.TZ5:C]^?0(\W.3T\O1I3F$24:019) MU/9L].\O]T_.'"SL8^A'L>T[FUZ(IANO.^:'^#!*?Z1-2TQS^8G@IX@,=Q\X M=DR>4&4WB]L"_W5,FQWCKX[/SH\OSD[>(_<(J=BR4B6'@08R!^O,\NX]-T;/X;QZLY_"<(% M8?W(PG1_F=RM9<#]3YQ@,<(_C,1]1TKX>XJ1O>)!HH>7ISAPOLT#ST56>O-[ M@@:LXK"JMQH>D?E#!RGA&GH)03@.%HO`?YK;(;@&L0V]J(I;>3IJ M^$ZU,`UM/[(=_-`B248%'=5P-@$>#E./=K@UC"1[5;W5\'AKP_!?MI>`AY=; MZ*/``FWO#H68D/B$K"IEJ;3)\YD:IL_:Y7H*WN/$]M3POB:F*HJAV$-F2>3- M2X`L,F>0DHS+T.+,N<&8C.@WCJ^4`DF2,2H9,\@V,7(H5%)-1G`^5Y M7U.!?CQ"34=9FQ&30--&>&:??&.2::.5Z` MQ3,(:W*[W;5I3FW/J$$^Q&YH?7 M91CVC]G7OZV!VM1^WCQ9SWX&'GFG838::>E0D9)!\CL<\>0F])X"8,%7\'9P(&T%$&(T#5Z)UW[RXAA]AM/NB:> M;WTAGA]9@ZL887PMRE)@YSJ;7IDR<-IJXWT<^*\@C"'RE$=$%H0A<`E&^Y)- M9$PI*GLU&0C*0$88!40&E@\*G"=3#`8-R;2-'E@"":TL+TCEPZD9W]A(X=+S M!E309U2`H2!!@E4_I>J:@!F,XM#VXZ_VHA@`^,U:Y7&,]!/B M')(+WO$5EPF2^U:XI):X12193"W_7/+/#TB)P^07[G7R-`$S!7:M<3E)1K: MQO:,P5WA]Y9U=PLCQ_92S=RB[XI.7-%6"[?_`78HQVNN94NDA@OPN*U:GZ@%';2 M_"XAADS\*+9C+\V`$9^--K)L1/'1"".?EF_'_L#/_BN9A.:J>R^7Z: M?\3Y,+PN.>3\AYS_WCG_QG+D=.V\S23Y3AGE^_;6GJLJZK;=Z^P".]BZ#_H\ M#OPH\*!+JE`WQ*S@QBUM_K][YNI:&'Q6G#%Z& MF4SKZG6-)6N9=>I6U]W7D+1BI;W43AO/EZY+H@5ZK[2A>^>/[26,;4_(?T4? M;;),<,6I#]P;._316T`D%(+7>*AR4/Y*)UWE(%?:8+X<#`K@ MFJ2L[Z(HV9ACD=^M)CMP6M[LA;])]9"2O4Y"-!&F"TK3X#9(2/:<#)PIBNQ' M*S"X,Y7&94A5QN:AAA!B,GHMOY7\$9^X;NL5%_39$N?Q(["E3JWX$,W MBZ47K`#8P7&*75OSEO7`.[A(KF_C_-[Y$X"/@0!?0#@#85T-L[NWI.7"X+4U M7>K?.-^W0?@$PE?HU+?E6M)P;N+:&M_JVH=T[A)31N/&CO<((>P_VB$N;7I*+;K38#FO)QRS5NB9XN\5OBB3%=U MW,H\5LP'SK,^O-`)$D6*<8`KZQU\7L_#LP=GI+20#Y*:&:==/9#',PVNP#I< M5F)#)63;E9*^IN?/9[H-@T4>*^TE;XT!&L>5CTF(;2Z>!A,P2SS"RU-=D"PB MTA(R9K)0&PYSJ*B38>/AN67O'/!F,7#-?1S[4-,L$W\.V(N<%G_A/Z`=B&CT MEVLE_G+=3+SFSQZVAVSE:^"3B3+P$-$9S93DS$8G;MIJ`#&G]"047$2% MO6E]*LH3<%#+&.ZT`B)!TS1=I,:J6!G21(U^\\GQ?`V>XU]A/-^(=`OL.`EY MZ15UY-O%=U?`!R\0'QBZ824[:W8:4-^^>\UC.=$0YNB-YKJ M$=J5?9,N>WAA/:C,./>2OMX8VN+$5Q#?^4ZP`/BH:HZS%]H8O>]15,1B3'VL MI`A;=2W&U,6*F=^YYL68,MG=Y1.7PW3D!(":A3`=.1V@;@5,1XX+J%2B,IE.NI04%Q$1>TR$I$M-Z*RF@Y0=JHQHL*9CE-VJRNB MTG4-K!2KD>A;=M>0";MZB4K3"40B4>M$Y>D$%)$IC*("F0X_]JB#HB)V`H/( M%DQ1H;H#0&0*JZA4G<`:S=144168#D'4U5=1B4W')4U46%'9NX9:9.NO:$Z] M:VA&NCB+"M@)@+-/Q185M!/(9Z\J+BJIZ9!HUQHO*E]W\%#-`C`J8">PD#/CAJ.#EW.`->ZQGP5W8$'81>KZ&7()?` M@0+!H>QU#2.B:WP&I!<5_?"'TPM\QP*,\*%V*$*B/P@I'2]!^L/9(OR$DYB\TSR\T(,P MD4Q$%N%YBXH'T;>#8#_VKU9L`H)0U^B(9AR`WX@%;J'^)G5HW/'[!QG&>NV8 MVO6([_H3@IGJ;GJWP&5+',(SW5D-M7&=O6P*&2ZTT7AS0<7U\DSN*WOI/TN_ MA:!2/4WEG2V'^JO6SE;85VQ"QEPEH$II0T`\:!??9U]_Y7.>(J-);._R M.2+E?071=J31U2!^N0@2OZ@#Q;2-A'YJ`KDB#15ALA$+;T/`'')FIN?,M*P% M&I\",7U1,5T;G8:V'Z')$^<^N*'DS\50DJW2YSL;$#8V@)XD"*Y68\^.(KFW M2$8/_7>O$6XRWF2*#LKM#5M'XSX7YA5M97&,6]+JH1,U97QMYOUSK`AG.E;# M?J]6M"I/]^Z-WGMU2^O-RCR7WF,4.ON/NLB30'7G,O5=93@+V@M-^ M2S(#%!Z@,#6_S+X>P@F4^VB&?)CN^&46"(B`C?'%TA4M]7JKHYKO!$_\6+HS\9!Q+YKK=1$W>BXX.C!'\]M M?P;N_%L;IJ?GK]\U[Z']#+WS8:Z0?TU\Y2OY9NTD,]6-#GI) MKU5#WW6UK#-UG-FIP(]VN&7H7#O_4+3SC(!%*.3-W8!)XREYCL#O"3[]\A6? M@"Y:?F(VU;>?J<`.&D\$#'FMS:CR$#R%K:4HGA3&;6$Z**=18GIZ^1=B+$%[ M4V00'W7';JN_S+/"D"I]A6V7`%T>ZRX!YH@RN:(1![X,7./J6J`J6[:GWT@+>O8RE6ZNY:__U MB#3^9++;`R-\;%P>'.';]2[]($;NG.]9X\G5IFQ68D@<8&L^1F,J%V6$5/I0 MZ^[O;&5!^)!FA2'QK[!%0Y[+L#R7%N]J++6S7U[AOKVEG5SQ_7K7 M])V/P')"KIGE.N,/16?$A"Q""5]-NZ9EY8@9X)9K<2^C",3X]!6ZUX#L$;>Q M,.Z#/\$UX!B7H09?`S^D?^*#P(7;EQ72U^;4:QFN5AG'^.G=AF1N<40Q2ZJG M$0M)RNT@'Q>DU&!<-A'.T5$^CY(K6_BDLC9'KJG^AJ89) M,L.-Z+D9LV93PSZKA"P_PZX5UAQJS!W0E\R\M/[X#PA"Y&+SU3UX!9[.2[D-%8N3)\,`5G>5B_Q3SG57KU2\R+@IB=V7%X MJ#AG>/4YS,LK^_B2U:CZC#O9^\`B5J^]4;L>E5\EVZ)$G;SJS?A;;[7A4ED# MK;ZVS,A3U0\L;`]`LQT=W5=4RRL>0\N>D4;TQ'RCW=^8C#FD7JG2AGAX\+Z^ MSZ8->J;G^D#=-:>;)RG:5%.OOSJ^KY&;O=H8D.2,2<1H18=V-;JK)K4CP<;B M?0T5&+GAXU!CYE`;MWMMG):"]C9+R`;/',HE>E8NH=MG6UG7-NMPW0-SX"&K MWJFLNI:`8&JJNF>U!6>,H'*V3U2QS@P`!D/:UXS7FCZN]_=Y8UL_H\'P`K_[ M"[SN%Y]A<]NPN:W_F]OZ&7<'%&92"JOG6*R/&]SZ&1:&K&T36=MA4]6PJM7KMD=KU.&S'&;;C&()/A^TX?0O=`^`\ M@#+]84O.L"5GB(F'X^\Z="5FG_#[BQ\\1R!\Q1Y(\E/HYP"9@`<)DAK;GI-X MY.,D\+S;('RS0[=*?\V-JU^GN2P@OH2D)$>T+4@T*9A'MI>%T*J1W%8P5N=T MQQ'G9P1J[X,HNO-3\'_G4[2O6)\[C&]*KKKQV5ZM:9IWYI9I"MS!%CN\,ZZ? MT&4HKMN]N$[W3IMA=US_O7.HM5!?:Z';;X<=,KL9[3ITY3MX[Q1)U=$M:;UVO89/5(LDX\,EA4Y7W#8N[J#NI:OH63.=!$MF^ M.P4^/7R)624BT;X1OFX\A-WKL<;NHK^>1<:DV0&+907&%*/(V/?Z@"^Q!75> M)K;I]?/"W]Y./7U!?1/;GP'!?)G[O8MX+L=^1S>P]=:#=K:\MGD4%L1NM=#& MYQ?['2Z2A9#30AM]O"+7J>1UNXU^6%8RUE*0,0Z>,&PWSW3!'#K#]K9E*$%- M6BN4>QO?^X*0"!,92_<5E8*Z%)0?\+ZNR&(E=O)59_D*0GL&IB!H81>`RA@_X+GC,R$SL6G8;?S'#ZM7+SO@0.>EC_"G#)!>N!]&L"IW]O0X!:Q2`$4:S:!MCTS92[@>$D)6G9)!KY-8R2'%^4>A+C#EFZ?:= MJ]6FS:.]PM]=XM,$))>H]J6O<=)[`6'(Y1OO.K[S7?@*7?0H2R(@L:;81AY> M-HV$$W\S@YE6C*3&VK;GY68T9UP1^P&%IQZZ7HO:*_B`]#B8:`Z7T^#& MC_'KM`C`UZ:B+@?\%;QYJ\OE,D`1![A7`7+_U*_X)>N57=1Q-P$W'DDP23$F M:JV.IYO%T@M6``B*^DM-]%>+->OF^4FBMC$;4^>UHS.OTT>5CM$;246>9LPJ MR+Y"EKQ8R2[8ABK[#@BQ#"]4U3JBMOL$PE?H`(X@'N&`["''1SC-?/A_2`P0 MP@"UB^+*4PB5CZ*E*K$A77'J&?'_?!Y6SG[5$.:9D M1VV1O#)@\.+%0[H^^S-9T;SSTP?P[.I%EX(27['O_WC'A#W_P_4$L#!!0````(`.F&:$%?\1*N\T8` M`/\E!``5`!P`<'9C="TR,#$R,#DS,%]L86(N>&UL550)``-&*IQ01BJ<4'5X M"P`!!"4.```$.0$``.U]_W/=-I+G[U=U_P,N.W?G5#W'ECV33.;+;LF2G-.= M8NELS62W4EM3U'N0Q!V*?"'Y9&O^^L,7@@1)?"5!-I2]W=J-+*&!_H#=C4:C MT?C3OWQYR-`C+JNTR/_\U=$WK[]".-\6NS2_^_-7A^IE4FW3]*M_^>?_^E_^ M]-]>OOS7=Q\OT*[8'AYP7J-MB9,:[]#-$_KX$9T6>8ZS##^AZ^3N#I>B5W3T M^AOZOV^.WOX1G13[IS*]NZ_1BY.O>U0O7S9CO$LJTB>A8X.]^>:(_R5+\[_? MD#\APG!>_?FK^[K>_^'5J\^?/W_SY:;,OBG*NU=O7K]^^THT_(JW_,.7*NVU M_OQ6M#UZ]:\_7GS:WN.'Y&6:5W62;SLJVHV*[NC[[[]_Q?Y*FE;I'RI&?U%L MDYI-H96O__%/7T[_2/[?\1\1^1]M<_JOEX+F)?W5RZ,W+]\>??.EVGU%)@2A M/Y5%AC_B6\2X^4/]M,=__JI*'_891<%^=U_B6S5+65F^HO2O$=FX2Y(][R1+;G#VJJ5YM1I_UT6=9%.8 M;`@;3HG8!>?V>_J]CKX=<7M!V1BS/)2`[WL=RI2O_IEIQ`(3K&!Y$KG_A+C?,=E1;^6TIOT![^!:G6L4YIM\6VUV%&5;`H^\CWC]N:(#MZ M\_K[MZ\9+OJ;OYTV)NPXWYWE=5H_G>>W1?G`5/CXIJK+9%N+CAC[O"='NEG!*7!6'ET MM)D`7:-UIC#>)4J",CAH40`@K6`,=I\9"DN0:\IBV, M(!D9EP5(V7!UP3%P,1*8H92@GWES0#$Y*7*R(:M38@6O2+>X+/'N4UUL__XC M?KC!I0:TE0I&=!S!R$)D(5E$G,B`-T6%+PQ2Y<362+Y^_]_1MB-$>T&)*DHZ M%+(@6&JRFU\`B42%6C+$Z-#/G'*D-(NK^GI0`/P/LA/#Y^1'J],A-03V-$8L M*]V+MA6<3S%@P>2/TJ:(M9TM%!7>?G-7/+[:X93+`_EA*`;D5W_CNZ*/^"ZE M.Z&\_I`\##&!]Z(FV6?M;7N$R+79G^>Z4+"T&_@?MX+ZNDN'A9^XU M`OG>"@[T'YXW1J0UHLW7DH%C,OB.,O`^2^X46`9_7_^;*QD4W[KWQU6_L6+D MT;=MVR#::&VM?I]6VR3C8O6>_&[HK%O:PFFWEO&AAH\:@FBYA@N]IG,"H?", M!$8V_@TGI9MD2"VAY6+$M%HJVF:`,C'@P2H1M/VZ\G!R*,L>NWHG0-]T?8FP ML2U$0M=N59DP,S$.`?'F/9E8VRG@FXSW:8;+$S+L75'JMWF#5E";/"6S_2U> MKPG`!D\QOFY[QYHBT7;E_7WQ\%#D+.;XZ3XATW!YJ&EB$\WGTF]>C41@.W\' M*(,P@($"(B9@94<;(&"4/'2\09P82=011)$O;]^G>9)O4^(]%55J2)SQ(P6. M-#O`4L:>#71PT6@K4ZHCC!W.:?XE^:DJLG3'$CS?)1G-C222B#$[\89/I3FN M*L**1>2&C6"$2\VJ+$;]%E!'D2HNQMMBUFCU$SD/WB(2S\8==)+245M(8=4P M/I;904-8T54RH_710279C57>=H,$RS%(]DE2W1_G._H?FN7RF&0L>:H^2G5`&Y34Z`;?I7E.ND#%+>+<+`CT+-_!P,3D#\L"-*;6A,#%?C@;X!(] M(-9%)$N_RR(0Q5)O7>(7,6"U=*W%/E$:L6!W8U!,R[K;ZAEVLZ3,L=XW]YXN3V4>5K= M$_M'!"S#5862[?;P<,C8!GZ']R7>IOPF##'^O_GMFZ/-V^^^8Z2_^>W1MYOO MOO_]ZCHS`;0@V2!&Q"_["+(-(H1PZO0^S=,:7Z2/>'>>UX1KF@G*=5ZO4#8B M&)5R@R(KE9D"2JU;S??$O7Y[JA1GV\W M1T>_I]JT003&'F]K,EXV"OPOKDZ3P'*BEXP*=61(K%6@&G59W^.R04"$UNA2 M:=K"Z(^1<5EME`VAM,7`S$AN6%N4P#A;_HRVXMPVA]X@&/U(V"V!?B\`N0DP M>O^@7K]7J'P].;M(DYLT2^L45\2Y8H>)]T6VPV7%KZ=9PM+NY#"RZ@M/EF97 M6BA+[,??2/(D.0'W\ MSH0D0DC]<&-:(HCKB.AXNRT.9`=UE3S1H@O79;+#EGBHB0+(%;*#Z/E'^N9@ MAZ(VEL8>2T.!]IP$O40UI5K?KYK.>D.R08RH58PIVJ`I'D2&*@]X1R_WX[SB MM6GR'1F7P,JNDR]XZ-L[4P$4#G('TY8-LI.L6S3(E1^5S%!")%,RWZ*A18QX M$>$WJ&\83-LAIGV#J5X,DZ@+R,8$`/4-Z(I'&;PJBUM8]LAH(4( M;-US@#)8^@P4@*N?E2N#H.75(:OI:3+^0D4.9`F M.(%;?``FC.PL)?V$DKAB`AZQ@!GY)9J=ST])2>N6B,&&]\HT;0!V-3I&VSW, ML,&Z.Q;UZ*./VC1#F6@'LA6)BEGK'F,JMX";!TEW[68@`E-OL?'@QMUHU2.Q MYG8S#GG'S_.D,+ZS0;_3P/C._[Q/QZ(XX0O"-3JNZS*].=0L`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`.)3W0J^\QVF&R*!3\]A19,.[6/]Z;C$P0(D&)7DBTJ"$> M>8N0X0/G[6(\X0*W,`%,J$O'AR;BM5IHP/$"OS/[[]K[^$W](;C;^,X\GS'? M4;8GC]FBKA@P\DFZ$XW-?`3SF;N#*'HA_/G<4`MZW6#4Y MK7,MNGO@Y.<,-SEXQ](55^VM;-U&(%CW8`EO0:=GD!H7I._5:PB&95R5IR9Y MK%W_&]2.P!1)'F.#!I?_-_W;_VL?C@-,5;^,0\Y*^RA+0$19!$%"(D^(9EJG M=!1=L00+9,<""II>(BRJ8.14\<2"7%@A1WM>>"&FP@E^@&S%%&1=EKN+Y423 M./R7)2L?NV.AZ"MN(8SCUMT/1'H3K*.$Y'S=S9#DPWW9$,\/'B M9!S-T0FA1T6)>`_$(4^TL&+9\>B7[R2]W%[O.4T,V.B&/1)!T6O1T.*./1' MS95=;T8I!,#ZXXVC7US^6(L#5E?X4:C'#`B">'2D#\&F'[QU3+HA<^2L%ZGR M"!M$)P+R#ZL+^J<\G*GBT0K-8QZ.)#'IA_U5#YV0%?H7/4`T91$D@=>QIOZ-K%1HD(=&/M%2I3S##\X48)GM(=$$?2-`TC48'C%MP MI?0`Q0\6XQQ0YNUA@YC>__2!852!"*(%$QX`58H49)Q@!0SKZ<9YOBT>50=-T]2PB(Q^NCX^VY!5]?.%RCTNV>XWCG<=/28:KC_@1 MYP?\`=LD2ML:*.W=S'PO]UW=%.Q^O(D=Q94)UG#]Q!(_-EEKU#1G+V]$)^(_ M%,7.$B-NBF\<`_9UDFV:!>#6/=Y&5UA`A2@4G^S^415712M':0@>]%C#2K6!2%F?I MSS#F><3`Z/NS%M17)TU6EU97]JZ4[*U8')R'=?*[LZ:>M"628F@/5!+Y3M`>L_SV994$0173E(ZXP$;-[LI:<=D5)&A8UT"TT4*5G M'(#TJ\X8".`*SEB94H07.0U;VZ7*,@`U968R+U$)+0%T3W!.-#:CUV=W#VF> M4E6EQ=S,NF&E`G)CW,#T7!LS"92&.+$U]C(X%9.RI$>WODLT&T"?#EY3VJ6- MG[==$(?.MFC*+8$=IC'32E>I:P;CZ&L9T<1BBM;?R$A3./?(RF[G&/&FZ`5M M_#5X:.:'),TI)Y(("U#[&@<+<,4&(R.6P7,[<+9"-"I`M":N7Z/N*HI M+]RM.<]K3&9/G^RG:PZ5[6=FOY_NIVX+I>EF?D:RU#5'*6N_NA9,9YBWWR!! M$3"=I5NT3^[)Z(2I]TE:LOM&E[`%93CCT2G3I^ M3-*,BE.UBMYMJ[@#G6F,2D5K-0LM]GZ59( M[+:Y"4BO`#:]P.K>+(`#[11=4:!RA8BFMPUB_07<$++^Z-E^FAVH9T$SNW#9 MX%#427$E`MCX.4-I-WM6BG4W>([LC-\TH70\UX)3\AT>K1\B9$A51F257=Q\ M3+L&$S,%]'$_V0#`[-<6!C5I4Z;1[Y]P>G=/"TV3#Y73H>LT;U2!>@ENAD:`A@[%O.,0%XY$\4!+F\G/%OO1`OU))T' ML/XK=0Z$JU>"\.!*51="5PU"^8Q9#&G=_?*J/V*J5YJI43>-H5)OGVU]>5[> M+HZ:O#(OMNKGP$5W?5A%/_/6@"(M;9B-\JQH!UY"2B_)HT81%(LR"H8<:E@F MU$IL:7!.M?*[N,X%Y1;\#7:CYEEHHGJ/7:^11H+(WF8WF_#FH?/(7F@W\CQ\ MI_V\?:<]`IT8OIEM5`9=XS@>9M>+O[IE+`^PFX5G_`XY^+OJ1H;';ZG#"[E# MH=H8JM/:2M(N7H?6];5Q>QG7T3OCXE4DP/?&[5SW7QI?E&7CQM[.*6^R0>>3 M*^-J`N;,5^.]GAY*,AM7;&ZOB_?%@OVC;PAWA7B?='#6M$;DKOC*94@P>Y@L&D?U!A0D+<"Y.*'[];0 M=>#/R@MLHQW_K/OVLRH1\WS*D*=T&C34R*N9MXS(X+7)O=,?41A>&Q M,^AC>9K#-IT!BLGT3`!NM3V+>BA3;=#D+ZPT0E7[A94S`'I,IH3/C.T'_)G] M19!<&@66)W/D^U?'?H9P_[ MK'C">,*V?$@:CU.L@V7?@/?IHG!^U4QY;K7;+F+<7COA:_U:80$H+"PHHW)F MO;Z8;A?=0EM]Y]PR/\%_EVCC,0=:8*X;XY8P"H.@X6K:%OAL40V:N>VU(33; MA*@WNFX?S[*[;:&N8!W.V"D41D+[^^GM!$$UFXZ(_0V?3VGR.4:85S`B[XM2O-/A MZW2,2>,Q'3I8-JLQI(O"8*B9\K$5MT79/<<2G7_AB&^\'Z&PJH8R*KO@]<64 M)D&&MK)'(3'O;0I[M/&8`RTP-R]"(HS"(&BXFN`]R(8A)I/@BM!L$R+V&5P_ MGLE?D*&NXRJ(RE=7R1.M"3+!8U#W$(^EL(!T\!]4Y%%8#2-OOMY$6P.MZ2I* MK\(#KMJ0M`7I]KR'J`S)E.^I]36&2-?W.098IEC441?QV!4;3&='9$`?A64Q M,S?1+1E:F)ALBR=@-^,2M[?B\VEM3LL0>=#R0KR@[+1(APC;#N:8LE5!(&/4)\NGN!'PQ%[[IBVN-Q3[-79 M%UQNTPKO?#<[COW%XZ)X38#-7W'J+`KGQ8-3'T]&=,N?PF;MFIY1VW5\FZ8Y MDR$:]2P51<]=GH)W%95W,__;*^V7'CW"[;=?=X,EPR-H!?`6J;=+:.\P'LOF M-P5N6S%;;U'8-A]6)VS3^F:-"GMK]=K.8[)NLZ;#S;Q%O(F;)0:F+5W?PM$I M:>>G-7?0M\(^XCV9[?N$L$*P?\1U6BKN[@SF=%(/@'=:_$".+K:XD4,](^+- MXKA244/*1+1DM.(1-R;",+==9D'BRBEUP;`UG2AOE\6NA]Q6S9HPT47,FMB' MZ:^*G#YN791Y]%9&V"MH\[!Y::4:9IA]P/NB/-[^6\D`=MF./&DV;=*ILOHL&CB'9CZZ MSP.CH=B)7QU*_#*]';^SN^*F.QA0]5GR,NDP)J8MT387TABM@RGZ9J>+S#XX M1'6L!@(Z+A<`GX^)B"`^%PZQ*>\DI+%P<8I$)O;EK7#SWA?E29&S1Q@/279Y MDZ5W;&+T%PR6&0?`#"TY8:W-6F*0=0W<<@BF^^-(OE+0[EBH29$&1=*H@"[6 MBO.GO6BQE6:EZ/J"L:]P`I5T`K7O/_G&C+1MZM:VUFPIN2[>X?:PR'K[*TBW MD=IBQ^GP,KV6/N.SM$X,SS"LW'TA;6ZP?$@D^1E\UT[CT^Z^G) M^@P[*D9"\E"(?L?!E9.X#>K<"6NG83N:A@BNU`&(C,':8L>Y6NW:W=6AI$YQ M?5U\Q'?TM5B:H^1[A]C423S7Z^Q0;5?J]#U$<8W.QI[/U3G1%Y7GKC?T"?H< M(P!J>0>]Y>_,<]W;:S"#IQ`&^,C*`*4,N)0_\KJ7?I60/*;$V$L\]LL+D?'`K>DZ!72B%IV):GP2K#%G MIS!F;%'T/3.NG812EH/@?M8D@/H,DUG=/1?3ILE$F='7,S!NQOR&F=8-,)-E MV;GPL&^P[MJRT^!OZ(`"67J7;4(G\6PD/1PT[QZBV$9Z+\/^@2Q('RP4ZF?E M>H7]U#[AK`7<+._M\&F03?5I3%;(`>ST<-9I%';(RE^X<-8R6AD\G*7#_2R] MI,!??4)0:YIC%+#.E>:.Q`F[_541%JD'V=X$^X2WI&6=F@M?3>\3L!+6W(D8 ME<::VN%JAB\@MQYFL"GOMD%=UWR7V5TW['I?VR8N.2571'5Q20MK\[4.]Q4A]*717;<-W'6Y+`9WI\*Q6X]!US`0-W_D>Z M]0[G^#;=IDDF&Y029[10*&)FY1E4-9@Q`1[%#F2K0H?A91\DR].,M'+F=_<) M.U8^\@]X78C'G9SP1L M24X(P7&\46Z>+A@;W-7VO[Q5+52-CS_+"ON-$:D=GC)17I;89X#X;+$_]S.L M<3<852NU"]T,N(0YMC\OLN:T]2=#[?K=JG?J\5CD\.)CL,FE^XS-,,JACEN( MC%%09*U*JOOW6?&Y.KZI6#$2;5#:1`)U5&*'T3\(T;<'./^T,3,21B*Y.[JQ MVE&35!59NF-;K[:GBCF2I#-$>T,_B^[^'4[2/N":,G15%H_I#N_>/?V%L'^> M7^YQ250[OSO>UNDC.UBPR-^4CF"DX$*KD_E="S>0G(K1&_!H[8' MU'6Q>N0\&#K2$==-T16Z>4(O:&]D%?E:"38*#>XMM!\Q58`TPP3->;XM'O!% M49'?A]'Q98:*X#@N\+1IC^8"C1/%,5U0+#:_KA2#H9RH:48&HK^E/V^IRAZX MEJ*B5=($SB+!S5([&*+&C`^'7M`!OZ9_?H[6[13OR;=/5=L,=1,8:Z)B4[8" M\M^AM'?,PTB>Y":KZ\U,_E9<<1^*LD[_P;BXO*41Q-.TVA:'O+XJ\4-Z>-`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`/N$:&`0R^BD]+ZSFUHJ"4`UTP!!H9R* MUE#ZJ67%*!F]]]8CT=)I2'H/?<>BJP&A+*ZQ)\H7V9WQZ>$%R6*@M@L0 M\S`;',&UO2>_I1%8=$L1/@J$C1*A;!F$KI9A-L2L^7X6=$$=BGQ+DSCP*>;_ M/<^;Q,DFRE<=Y[O+^AZ7)X>R)."/JPJKTS"F]@3A9LP"W7D-X MX6HZ0Z(WJHHBQ5ETR-Z58%VBID_$.X7Q2D+B%U"Q#+5@4+<-U&0!J,Z>"0A6 MP'.P,>#C+;M355TE3\E-AJ_+9*<[%W,EACDG\X,FGYNY44*=H_EPITI%9$W1 MGK==_>1L%O>M]7PAR+^F]K,%U72Q0:R3R+2J/!`CVS@@^GBBTB8E;\JT7OK`@;#O<>B2&^]Z36*0I`Z>0SDGS?SX=!![^2:57KE3+Z)= M=5$GF4FW?/E3EC&*KR9*$%B>]4NBT\+S_!%7(8JJ&3N*2BL=(#MHIZ&7R(JJ M63FU%E5K>XBPJ)H_.HO:JL!&47:(L+O%>%?13_(IR3"]V4L-:?U$D]%JLJ4] M^^60[NG&6#.%7CW`Z.P$D+*R>I!#::DWBXJ`!.\!T:E#%>F#!D=OTR]$@A>, MNIB4,S2H3PTHT(CI3 MA]5#>S!T*H>*59(7<6;[QEU*BS0#*-Y<%*(#5NB<=Q&OU@VLS(^T,G9:/Q&8 M)T66X2T[)+Z\Y4LX@^5HKYQZBF-%]`!M6AD=NHEEA71FU6&E9.6NTXX0?*4, M!8[VM4&B-Z:Q4G\4];D>->#"Z:"K1I)(%D>;]AG:1[,`.HA<\UH!O!9-X%VQ MT$6A$NX;V]D[X_@C,?,B,%'%1[7\Z>.C+PXB"K&78A-I&Y&(+UKJ!](S[!*= M3K85GN9&2XT=1:6C#I`==-702V314BNGUFAI5P8LOFBI/SJ+VJK`SHR6:O+S M"".R[WQ1)#EWHNG%H/LBV^%R,!?N9`"9=QYPVC0[!YIU<^J<&5**57\#PXB; MO4Q'#E+"81ZL?0]6UL&J%H9E38M;'A=@"IR,;/"8IL-6?$0!'^S1@-`%=0;- M8PC>*%FRQ#&&3Y."!FBF`!@^RKO<$DA#/A6K[\O+IS(U/LYWIA*!WEW`+XVN M,'7+I(T>=,ET8\YA^?PD@IMM5\W==1H)!*U,&`[Q7AW.W;>(JQ8Q;"U#4,@A M+\6H@=!G!(I\NKG1T4=C:\P`+89&31R#E3%QYF-B>#]QVQ=OK!I-VW*L*UF6 M&I?+(OVAI#?K^ECW9?J8U#3?@M@4NI4WP68O&M-"R#M6_YC')HLR*D.[^++-L(=IN>F4.J`#* M->A@K.T"<+$,][,,=_GJ@%8+`X<7,);R$>^;T])>Y5U#+,5(`1-+<0`AQU(, MS:%.Z*TLJ<\BV&U5]D!M30^YP2,J_C`ZBF'U[<`1%79&0J;K?5&>-CLJ&A55 MO2/DT!ZBQJ8#@*ZZIJ'QRG4UK9RH19O2L`(Q@HH=&ZC?VUE:2VQN4LDB?B:"I`H>TNF_LBF)IA24_L M10!TQSP.A+"YI79(J@Q3/15TGJF-,VVV*=L:<6>6/4,[B,R`)9_Z`Q).+5TN M.])A2/4YI+W-3CN*/\U-I67NU%&EHFKYTZ>BR@FHMVV25WP)J'[0/#/9X#21 M,DJOA)#_T(M7CTE&#<<5+M-B-ZP7HIDPORY@M'$*3%D??>AA--*?0[5.M@4? MF7;2%9']@+L^5]?(`-!.!!CV@]3+!O%^D*+"#:Q6TDS?#T2RR8]=\GN^4]BA MT[3:9D5U*+$E27Q^MW#:&V(ZAAH]IT^HO+Y,,=53496Q& MDFY.4$52+6-_`#$-"\Q&FVJ_\4`O3]LBF>G'#[1LW4>\S9*J2F]3O*.'1<-R MM]<%-6_JDM*^/4"\V#T)9/=VMQ?YRJ]X3^!-]1@\Z03)O?#3OE'1:7HTP[L" M.<`-B;8]]0\$%#(J=IG1_D^^J?L:AQE9K6\,X%1;FJ44A MU*Y<+ZE.1C9&,M2VI('40?[FVK'N6#DW6.J)+&^&^=!P6GE9WB5Y^@]FJ4Z* MO"JR=,?^09PBPF0EK-CE;>/%)-DG\AOF_-FNF0;J&T;C@TZ,L`^+S,ABDAUJ M"D:/82=5*FX%M)U$4'>5IZ'5Y@ M?IQT:=7U;P60\A`;U!N$;;![=H3,13L0ZD;J;;CI8(B-!FALWAVJ-,=5=5(\ MW!"&67JE944UD\`8`1<80J%]^%],8"T,C]/^MKRF7B.`3.)^Q.4=+J-8LQ1P MW%FUP!F+A_RM:NYG?TI.C3?6(] M'=$WAU$5&_M".5SY7DR,#(RJ?)LM$_?3-#O4+*^6B-$5?;JJR4RA/41AA8>P M;(;7T#X.`=*:5V?.E[:H)HXGBM*J!M6'?]&6<=Q(?1QFDX65;<9RT`A(PI6L MMF)MY'$Y(1@R-?KRK`%]="JODJ9N:@P&[R/.:"#W*BGK)YDYBRC8R:#N9;G! M$>+BBV,Q`7)@?.Q1,A+$:&3)BEJPW#D?U0.8OEJJOR M0AB"QI\T*1]\J9`'U6F*O3E`,H<#^VWFAJ'MNFD:5D;<%G2#0*R2?Q$$!DPN MQ636:XD$,"^B?8R\,Q`V)\I,`K.BN<`02Y@/_XL9>@O#0Z&AS=%?Q:/OW0G# M>4Y(#OR(89%$OF'\[SC?\>@?%?-#DFEDQ9,6P-[[`FN-OROANBN!'U=>QPPO MFBZ^-DC8*LO$KP&C=4%9`N0#ZR#DS7,6T2*L-?$L&LZZPF5SW4^$DRSFP;\/ M`#,Q%6AK+GP[6-=L3.-N\:X!DKHD>`BWO(M+/('%M; MZ,9"$X]KJPW/>"%8.B!CXWR"D[MJ,&8&_Q+%NO$6RYKK0!1-[,6TJEHI8HC# MV,VH*AH3S1KY+$%-#-@XHXHD;/-I>X]W!_JH,,O@?_=T0F_A7"[JNY$" M9F5S`"'6-0_N%UL.S.R.;JDVK>E2QDN4WCPA1D$6!$H#>,C5YJ4R?AH\QU]2 M70D30WL@R;$!:.7&E?/EI,;`ZN@N+Q./5F!^ILT`Q43F^+1X2-*A034U!+I^ MKV592(2=U\5$0[G[:RL[MU6"57^5!#+##\(;6[C2<*=?=<7BR M-9(H%J!_67/KD.2AM78YLSJ"L"WY&LVY,/0Q$^?F#D<[RGA#O M"AWVU,MI.POY4((9RG7Q#I^(^;XNI%*X_.\J1V!VEQ#/+829ANY%AGG]K?QH M0PAF?<1;2#?1WAN,VK[IOWM/T'U:3K5M3ONB'DKZN!ZK(O&7O+BIA$M(,A-MH& MR>,A-B`:S#<_+4-1W#=M9_*XJC![ZS-L.J0-V#^PZ0HU02-[ M%7IFEM>Z`%-A4C7>/.1-!\LD<#8\J^TBS#@4 MNX)F"?V9MUDFG]%'71RXUN@+<<3M>$"\@?;'_Y7BDDCG_=,%?B1"[N00&(G! M?0(':`JWP`/3&IZ!&81)_%J"*-V!:@S,VS$P]!&1R;8!-=IN5X3KVD$#)'># M*#FRDJC&XTVP8$G%M.W(S8E040`+HA[$2.SLW*_F*2BY'B7ET#^C(V#WP(E5 M60DXP0;9V(>5^#?>$O\F/HE_XR[Q&NXA)/Z-1>+?Q"/Q>E;U$J]G'U;BWWI+ M_-OX)/ZMN\1KN(>0^+<6B7\;C\3K6=5+O)[]YW6PXHWAN M$*6:%6C2Y"M??RZN[XM#19:E:YPW5XLJY;;"H3U`IK$+@#:-V-1XW1QA.RL#2JJ(ZT*V=CU<=YX\GJB(ICC7<\?G4`1874DPW*7X:UFOX55PM"7QW)-#%$.WEWO::7G,G M.=_AWB[4OZD[C3W$O4[IEV]PQ9WVA4>GU MQ5\GL=_$#0NZ=_LT93U"7;E=`EC:5`Q@7[,R2Z"^ M8XH=3YR80*'ZCWO'*/1*[#;)MH.H#C!;6II6,(E"`?F$J'`] M4[W=BF*'&02ZCG;(J1J7WEYBCI83^M"38BKP'6BE@+^'/7.N+BPI>.&Z?Y8^ MYFAZ`KF9VGF)U>6Z,*3;!=.EBQC2['CB4E+AW0]%L:MX[B%^V&?%$R8S5SZF M6UQ)&]7_>T@(_OKI\K:#SK>XNB4LX`!`RU?P*6J7KL7F9G'7,N2<##6,_B$A MGX47;)4"(*R`6%X=LCI9^ZVE10&SSE_>T-X1ZUZDYHH!D!A!CMEMD!B$55[O M+-&Y,O(U(]@\';PX$U>:B,!]`P2F0T],&ZX.U?&Z0>RP7*O5!+WS5).>EK2Y M(VH=627JO?`LR=939):L83FM0?%5I(,;T;M6.G)).BHA'5*H'/TB24<[73S2 M'C(?YX3//O$!3XJ*5L*@"0#5==%`T]M'1T*8PKKND.3RN7:JU8ODNK*D*H/: MT")&C!IJJG'BF!S0U@2"MF70MD3#[@BTLLE>(1"%QH!5M@V'KNP^G'B/(KP9 MF&\#WQ?E+4[KI9PIJ?MGZ4^-IB>@2]7V_=R\J@'CBSI6[5C/U+>RS57S]T/9 M<[">JT?E)AEAG*I;,19@=H)X+Z4:5$*O];F,9A*8D)0+#!%D\N%_Z;"1A6_W MM![ZAE26X@,+$275/=J)GJF828\2K/^TCR?&MOE&\5*(BOGUE$63XGSV98_S M"E!96%IQYZ,?/665/+%*J%1=MYTO M+I:3554V/#KM#88-$KWR*^2?2<>H1QIPZR&6_/:QOC8W^C2MMEE!\YA- M]X+\Z`$V#U,`MKL#'^)UW7]_SG3Y^E7W6J9&(`:M,5L-"`&`FG""T=L'8>EU#X,#*V+ML:9!$ M!*WG,Y&D'=$?8%0V'("0RNEB2*8:H&A7]$DK>7PK^,R5.]KEVG69CG?I76W) MC>Y-NY/NOL3'(LO>%^7GI-3E>:TP;OS7@V=-Z`)/W[G-Y-+!@S5F\/\_BA=@ MTI9Y(6^#)`;0SY0%U/`00T57J:H^#>R,YK+JHZGZ4]^N'*POFVT,.U8\CS0$ MFSC38P[!9VRV[NZ)2U_L/M5)65MM7^#9&JKNNR1C25_$BOWO)#\DY1,ZVB`J M^XM8+8[\+-]%A/L3$5QV*PR]?;T@=*O!7ABQ[DDQ%CP>&^-J8(U[3RDU)KS; M7+!^GY]1UDSA#TF:7Q15=9[SJQGGN;B'$=A03QC_>1GOR1,\UZ#/GMG5G-L5 M9G1H"C[@&MT1`I0VK>FQ.&[:/POC%V(69AI$DSW<(,H)>D%Y^1J=2[-\IIGE M^>&[=G!5D%&N)7]XX)>A?\+IW7V-=\=$4I,[?(W+!T.L(TSW<,'`D-,SC!F& MZ!LDM!B.<6VDKO,1E&<*)@5`S$J)#048KEYPJ@35IL-9+874-;*X@ M%UTD9:D-IVA M+#/<<[*V[M,WW_K:QWHFUM@52'#KW)"+D1$;&DEC(SKX\[+7LR<3B]G8L]G8 M=\3/S)C/GHFIQMTZD:@D@\=@[FDVWI:L0W\M:'QZ"0NO&^$9&77S),VVX^KN MGX?I-O$>VEJ+L5`WV/,SSUX3=D7L![6,=^RRS6-+\KSL\"09F6AZL9"1;K(B MM[4_)E_2AT/0D(5EH&=O>0=3MI`!;D9YSG:X!V$M?/ MPR+K.0]MB.E(B`Z%Q%C/SRWVF"T&]Y;"307<L/_D:8SQ,W6!IPM/6.,\R_\-5"E$ M,65T>@P/R)M)@"J%.,!H*X5X\+]8)I&%8:<+CMPF0;]]WK%V4N3L9N`U&=+X M[KF9!%J"]##&$F3G?P4)4C)LD"#1'E&"64^?; MX4[T:A+G7$Q- MU2*)$'647>7[@!NOX]U_'*J:FOSKXGBW2^F827:5I+OS_(0_C_8IH6]L?"AR MIMQ%1CJ]$^[-<;X3USA57E3(W@&V6>$GI]U=A>MZW4U5:+['CT.T`]`ZHMT0 MB(Y!\X:;41`=AD;-R4`OM]U(W1Z*UMD3@X'LH1:?*S$%^6`*VIT`F:ZK0XE? MIK?IEJS-Y;XHN56A7%E04HZ0=HW@M2\_HBJ;A:1UZM++ONF1UU!C*N!M159VK4).P54/OM0?-03G$G"Y3R1W"OB" MUT-1ULV;M0P^`9;>9#0*A4=NF"L1T&M;3E#:-[2\,"RMDU;>1PN21+"(ZA"I M78A=JA5[H@)KOQDTF^F.!'$:.+5MW!7CZZR#-C!*J614Z*"1PZ55;LB9MJ(0 MR".LCMS->GE5LXMO3R(N;]^G>9)OTR23ZJI=XR_U(P#8C4\#V>ZX M_,-!?A20;UO(IG=R3*;=<2QJ)\O'HT.RK4DYRFB9@+`F:,\`.\ZPD]+N1,-TN^X.-23/[F^]6)]Z:<8P/_FRRH9VT0FR M//7##CB;F:"G..)I.9A][BJBLF>B(K^8AWNB4H]$14Q0*?<`N%=FN3[\@=73 M`ZV==L5KH;)'VOCOWQ>E>(-0X\OX=@+CRTR#*GR9>1B7]F6\L2D?B)1?Y<-? MMO>D`6;:#O*:UWQ,[+U!WA+Q+A#O8\,SV,C>O?DK!?E)`W*&/T.K#E[F)VPB MSW,I]#9,[%=9,`]B`*_$&UKK>#A3KNM;>+(UDC9689*L`+P'JD+]P/#H>@Z( M@Q`*Y;9%>=N+!7\>WB.!6?U7AQGR&N(5F8[[I"GT='G+7T]EQHQZ*:9,5U=* M`'OA!ZHU%FYDZUH*'Y[&3G1#W)1H([+4O([+5ROF)(+FBX9!MQ?HMO+;OPP= M;,;G:O``G?J/U&@9+KA)?P=ZA'?(8/N^A'U%])MJUCRQ'X]2*W^<3"HR17O.B#XCH MPMC*ID#!:@/;;4C:@=_EHK-J!D%Z->'HV+3*!R_9`+SE4O!OK/=A:!^-G*@K?3ASOJ:L:&M\:*0%O,#' M`(-Q@Z1I&X6T[J\/4NVXN17>60\M2N(-(MYL+N\BVG]K)R(,8=)RS,8(BN#YT6*'A'+ M!F]>0R.M:*\B70,F6R/H%)SGM`1-45:HQ%NQH+?6B1Q M=#FPXEMCZ5MC^JV;28@^8_LDJ>YU.S:/#F+.U)8A^F5IJ[`M'K_PP31>*!_V M2?Z$DBV=.EIVE+B7VS+EU;X%3O M)$NJJLTAO2P_TK>//QQHP.;R]A-]?9[=C3M)L@SOWCV)9+*FH2Z",KM7&"4- M-!E"

[--"Z0#=8"/[`YUC2W=#I^`)P:8]R7CS1;M9X@WB_ M]&]=SXAWC6Z>VNS8EB+DC8VSJDX?Z,VLR]M;3*V1N#"F/"O7-X;(,;&QWF64 MZ%JNG#]B9F.<6"#:(T'0WLR$R0KQY5_<#<0M$+JF?2[*O[,M<%,)EA9ZY9<$ M[W".2_*;;5/M$J/]@?RT%%Y[;LCD#U:(#R;N1\YVH"N\_>:N>'RUPRE?P,D/ MPW6;_.IO%\0ARL[R.JV?%,?\RA;KZJZ!R;:TCYG#Q:S^F*U1'1S:`O$F@4[M M73\L'U1Y+#_^\_J?5,6>^)XFWA;[F`.&1KK:?,,99^F:)?4#KJF)N\QQ6W"L M6]>51^7N9`#+K`><=L%UH%EWZ75F2%6VF5(B0BK5NI,7U./A19Y.>#$US7;9B?)5",/5W_2( MS8S8BC47R"R;_#D=09S9S8'Q-Z67E\[_I+%JWLMW.M-NWM[<][;O7=0X5 M`^)O02IO10(=0"[Q?3]+WZYDWQ>/H(_:!#W5U%2U\;HKX]]'/$6OW&_-^'80 M12$KWZL6^I)5,=ZB^56"GEJ(:BKJ4BYD4+K7%A2]+AD/;A4AH M&1VG@&>O3$)Y7="(>=X>I',/"'%61[>B96BKR6^!S6`)\U/:X7\#>MA]U M3IJ*QH)\PO3!*;+?/A%NLSYVIV\+8!ULC+>V0-=P7Y M!`W"34-PO"H&JZ[.`Q%!$2#ED;WAIJNA?40))JKC,6?.%W/J3*PZ)SZ`WWI5 MHC#>>S521"0UZF,X#^[7E1SM(9U!=A;8,O0"[96(M#V;O#;28*7:T8-6K(-0\4KK,;F`\,R\!X$HUXFF?!!U'L MCO\*R"!3TNGVXUU2X1U-5"9LLHFP/(!B(P)*/7>"TJ:;>V%8;!&Q,JW,NG[) M*)!,$L7S.J=IMNUN53Q\H9-@.@9_4S[1JQS MR,H3:C-&/=T[3!E]]S2:E6.RT]Y=\GLPEX>ZJLGRF.9W/(7<;^69,TY4B]7\ M";.L;^%F:K:*[?E=HSHI:YT166*61FE6W94%VA5]$I)&FHF.)34ZQ5L6.D)O MCS:(R/[1(L:&S\19OHMV'C[1NVM\(EZSB7BS[CVU%?#+UK5GA:5A:'Q>8841 M&VN#+L6E/FD\<2?F^=KF'U@X]#SG=_M^*(M*6U!HB9&>IWTV3%HH"^TP6TL[ M>O-V7AUX61`9]>KB4EC4;>RF"1],:FD=OM& M3!(F)D4C)H^MF/`]#&`D^SACG>.=>@J;`+[&DO*)+K]Y&W"JY/U/TG2U M[@YH$:Q-IZVOH=#^35-%IMW9B-Z;UQ?0S'"_U^Y&A=)T/6E*+]'L4ES`6G8B MIBYBV&W8^7/?4?3$5)+29:_L:(,S@5'#6J6)NX3)GU?A5,E@JQ9MT*3TJ3L= M_DC1>4Z`L5FJ&L@?BISO?G["-*\.[X[)@I;<818;.B4^5_N6<-"-5PAVHC&" MJT[__+C.?%YB,,LK`ET@8M2\&2;QUJX*A#L12!+\H89!'K%%E$7IL?7U3U:$V]:T6;>V^_AI6U?](9 MQ\KJS=.O866=^"&66UD]&7KF*^LDM.NNK,-DDO]4*VN8[^.XLC[+U)4U)'NA MA768_[+DPAI'-OC[HKS%:7V@#\2HDQD7'>EY9H,;)BU4-KC#;,6>#:Z>)5N^ M'CI)R/?+GEF*M!O6D"G2THCZM,Z8''R)X3B\>S^&?@VN_91/L)Q?[\/-,W?J M_:&NZ]'+QN0_DS,?X+LX>O*+KFKK^_+!!'HA1_Y6$FB`X!C-MAE-MT-!<$=" MB+7(!U*W9KA0K6S;W5G27.13V.`7L13V?M[H['9L-KRQO0'-/ MN'Q,MUAMI=L.B9F##G8,N[8D/OT&\ M.G?/JE,62,L:/>$:=5P,;BR$+7R?%KONK9?KXHI\DWO"_PE_1;X>7S7R(80I M=^\.2:YT;Z=:OES?$]CFOR=@6V[9Y@3$_=`?] M.H3,L/%1"%5#>%%2/P%AYW45T=`^^#`0@?"//`@3:'C,:=0$8%W7L-DNZ(._ MK[N2*P?71E*`'V>*BEGK2NW++=E5UO<8W:;EP_)':UZO[GIW$<5ETZMKG75:9L\5T<;%)&L5T:#NJE5U+\/WUB'<*E^W_ M:,#@/MU?%V=YG5HVW]Z]P*C#1+!"SF>B7$R`_6&Y2.9GT@F2>Z$'9KR?62&! M%=.)FHJEY*?+V^[4GQ\%LH>)+M(^U5E]TW75U<:'XE`%-10Q*>D4&+B! M`:^:BW^$-:,<9?I(/M,CKJZ*+-T^69^6-1!`11ML$+J(@2OO"^[Z#3=\?O9L`S_8=Z,U_>1>'!U9H M0_CNO_[S7__EYW\[./C'Q=/=Q/'M>`F\:&('P(J`,WE>3YZ>)E>^YP'7!>O) MS)K/09#W.ID>O[\_H3Q,T8"_\VUL(?WFWB*+5WPX/?_SX\?['R7L_F!\>'QU-#__Q M]>Z;O0!+ZP!Z861Y-G@W0>W_%B:_O/-M*TJX+9&_/0=NWL')8?$M:@O\?P=Y MLP/\JX/I\<')]/U;Z+Q+A\C1_[N<&?P+$CO3L[.SP^2O[Y`,)I.?`]\%3^!E MDOSN;]%Z!7YY%\+ERL5]);];!.#EEW>K5SM"PYH>'YV='.%!_>4JT]JYYUQ[ M$8S6M]Z+'RP34;R;X'Y_?;HMQH#IW]O^\A#_X9!->]AW:!>6BY7T;0%`%+:- MI=98[L'P,0HKZYIA>1 MI/=`GH!MK6!DN?#/I$LT>;^"`!GFMN$P"*5(QT8=7D$W1DO'G1^&CR"X])=+ MW_NV0'.(1U8M'?0>9`K+66!YH65SS3L2A00%NGAY19:ETG6[^BADO0=T8\'@ M[Y8;@X>7&^@AVP'1=@MC3<&7B+XO;57K"S+0U^*F?8TT&L)B<>&(1#V5#.D;51#[=& M(.^VT)#8]/3O]>'QZ=G3ZX7-I[&4DG`=5/JS`SK^`?JS` MH'F:D[4X7"5'``?V`KH%@EX"?RDDVFP4OA!/?H!VT[^\.SYZ-XE#-%1_A3O% MDW$50#]`W_KEW52QVM*YB0V'[V'/X_P-AFU:)-%HHU0!_3"4RLTB7<QK;YJY-9(4ZO\G+)F+'@!08!VG:D4J:PE?"6B5@.!2]][!4$$ M$>@?\S$G'L)7L'P&`04,+50587WZ\/'3YQ.UL.!7:1,.77B5!0STX6<_!'?J M\%%,*.1F@5OT8ZNY+QIJAX)^-I[-5Z;Q#S(->PCL]W/_]=`!,%48^J&N)_2K M[ZDC\@3F$/L?7G1O+>NN%:V9OCIBBWNC)R'.AEA^Q;1TB5@+\.&-`][^!ZRI M:JJU,TE//*RIG$ZYBS]#W1+T4_ZS&6IIY2C3QD>5VG@$:!.$]ES.%>*0H99* M.[/TT\Y:IJC/*A1UCH;HX&'>N-:%3L0_>6O8B$XR<=EI42- M1S^$C(@=&@TGF8KSO_,P1&*E#)W<2)N9Q2_9YK$?!TOF'/*FS&9>,I>N:VVU M4;F`^F@ZYV%M&-4K#_/B!.ISS\'_P1&35\M-0F?1I14$:^2Z)2EHM)`0#ZVF M..%1.2$PU)EC0^%3$2:/^3`*#NV^9'EZJ+TQ\!?@2!:/R(W+,F* M05-AA1?<>T##`(M$4T@(8D&80WJ\8]06`;EHQGU#A(>6=Z#69HFL$+ M(UHT8@_A#EK/T$4[;A"BI;!Y<[1EP\E+K@TZ^AP[]&)V&"=",63X3B7H!-K` M0HJ*F8C9X9.+<]OV8P]?X%_CW+Y98#F@92-*I]`9,AWWIH+,:H<2R@49Q%<0 M5R\RH3F%N$1?=V?6&Z@[%)Q4YB"@#\.&;DHS::`]^@L(PX2C&P#:SJV81.;@ MI0>_1F]04W$TQT0T%GWDK!*2./%G1NO7CKR;.@FE52^E=,A-0\:G#P:OTDENO$= M@[+:H62X[2P__[*,B:X`VB2N,*XZM+0W`",<7&9(.%$9J:>$U'ZS`EQ"(V>@ M;@"(;;29[1RBKX7&N%C1;G])T1W:+Z^0-WS]AL-\"8B3<_G\[):4825`IS[3 MJD/HDX^U?#Y.WQ^?#JWCK5ZKJSUHD'59W+&;]KUC-_FI\H7]G3M)`>K-W@3! M`HTL+=&Z^YS>D,+1;-P;/ZB^)LRPV M\4Q_2D=&8$X2VX8>>%8/_='R\A`D@G:2H]]'$&0/A'"$16C$1J"H!ZN&'HA6 M)9(6'CF/HP4:U9\;UXF)F#J1@4CA8M'0!Q3+'8NJK%@@INA?+DX M'2*,/G28CO;(=RU$=\Q9!G/3W<1_F6PZ5%T0\]9#'(-B=(QX'+6ED@0YRP7A M$W@%7@SN05OU`4IKK2QSBR(J"7$"[)A3!+/,]1??=Q@5JDA-M5%V%RVR,1LT@J^`#986*N/@ MTH5?0[<&A2A3.WR'EM*VY633TCA@\/)HY*VV+Q;T,,Q#!A%`VJ(!@=9\K/H7XF>@I#$I!\4;^W:YL+PY8N3&@D&2 MUO3PPG,[5JB#L:E;$H<#Y8"IF?Q"U[@4J;<:JUW8FI&5C=3\ZI!CL"RN$-C[M@&Z,X8)/0$&09101\G3YB,:F MR1Y'$NO=U_`C^0O=^>.@'3]R^K-K4%H4,NIJ/6A=D@$>)ZH)11^2C)KJ]T\S2XB0U!1C]^BU<0=<<$90)D MW!>/13XDPP^OWT!@PS`KA2U@1KCZ,P0YTD60@VG2 MM;D4R2>*=.KU@E#:Q:YAB,%U#B*E-VO;ES7D_)W;?\0P+?'=LF15&X]?V1WX M*Y+0M%EJ1'5,G.P\)*;KNWTR?]#>8U-F#,>?+GTON3(;6^[#LPOGZR<^1>@V`&V!@HE=+M#D.LBB1QA^OC88O&@QSC`\RR:^4]@ M'KN)(K^)1A3IG1B"'CE\%Q?\1HJ5=/4G,BT<,"3V8C9:1!G/X:*]1[59JDL5 MNDH14!++5U0;T[TW0^`C60`YC+3W@3KQ3=^Z]>ANEX'4OL7[J&,!3X$5FFYZ MA#LQ!"AR^,[AH7WNI?#Z?"7%O;DR&RVBC.?%_?3QAH>O97#I>_BF5%+N,/TY MPO4.OP$;M8Q@IQH'K7V.'W;#B2$'H0$/@S"GI63@<79J//+ZR"&'GHZ/D_"< MEET`#[Q`&UKNAO\GX.*$KYE?>\"AUP&E\(?&#[LMRR:'HO:>FUC@H#07\+K7#FB#WISI M+)'\(%;[;%(>*>2%9/%L!EZ8:/<&*:%<)Z/7$1CW!\:/OBW)),]F'E$@@)[- M;;G@X>7>]Y)+`[Z+.IWG$9%2$A0;?/U['S/,^G.?&[3N3WAJL])67R=E.END MIMK9H#ZN%C>#1>VUH>W)-I_SO+3"Q8WK_R@DDS_B^8'PB*>#0Z\.ZSE/W-T$ M]Z?1&YXYBR'?TYV$YHH"'G@DCX&/7Q1V+M:_(M'?>L43M>=V!%^3C`P*6]T[ MTF9ZMVN&&"V1P:ZL,S;UMG[\D3-)*NT16=/GVLH`.^TG8/N>#5U0$56TRAV.\L%$S#>`?#Y(;[[' M3$<9#1,5&1HJ"/PK"SIX@QV[45(F+4EW;D<-C7(/H/[B&NBQ4ZCUD--`KY,.8+!L.P`I6[]Z^'@O.:`)9P&PPCA87T#7)<-=O6+(Q#!?IN2!V'RGVJI5N#[F^ MPNK_BJILR%$L%^8,\Y46GMW48B-9*UK;/5RZ"&@TSZF2;ME4+H'E@6$29KB) M]R"2(K'1O,/*B9\]4NA($<6$]FYT.:=IM@C\>+[8W#I-,A'($&FCVB.FGZCZ M/\VY)6^FQDS+`[[TUA4IG!V='$T_[R9@!$74_W7.K0.E5'R8#RL$@CU<.DNI M_]N=*A%#+E?-C1\R^1Y-DF36_RE/?<]]TJUFFJ:+Q(X$':T?72N];+G"NF(< M_K03[S$H16+]'__/UCJ_#XI?@PV`,-BX M.]@AK/6326];IDT!N?JD^XIOKB.X(Q%<^JX+[&1S_?"2BCR1&:=-X^AIA_`F M23C:I?H.9.,XX,8@V2%V>]\RPN+4BQIH5+2D2D'F3:*EZS,VG%H M5TF8NM_,1T$T$`UV(E+3H)*4N,#_U^W8A\58C)]6.8*&C(`:ZKZ@RFH!F0_FM MJ))_UA)3H!.:CZ&>LNA_IU$;&/&+MO=Q[^[`JJ=,I%UNU"K`@"6"(\'H/SCO MX!7M)]',2]^?O?5L7-X`N7+I?RE8$^E"&[1U"2KT9E36WKN,('U`S;Z M<1/P]QS"VHRK$KI^&`>@)>+=M]O1VR#IS/??N0_XIOP2EZI\`K9KA2%\@<#! M)YSUVRTSG_B":8<>M$''H!JO[>\EB,C0Z'GIT!RG\9*+1+(;?S_>N6MI[0+) MX:)/O%Q^ML453*8J?K8+9^&FM51NO?*;'M_BYQ`ZT`J:.WZ\.O3JS:B]?F]I MY&O+9'@'8'X20@G2)13)N5CU:;I,%35LHY6\9Q3L%#M`#!91Q@M1#- M3X^>M/'$!15<\ZTE,M_;Q];SMCY#MOG>@YX'WZ(<8@=[`]4JHMQ*F;:?:\KA MW$X>PP@?K;6%'(!98#FT_1T?\5CL%F-NE?=P/9@V]$R`*)$@1LQL)"J"H!KI M+N"'A^6M9=0/_0CHA17"-!6\Z*X05/8&*$+:Y&"R.;Q#_Y-0X8<^*W0*X/X0 MS"TOVRIM]M<8?IY3'EOQ^(+E;EXJ9:S:DOI580%Z#7VCY1D"T87;S!WJ+1WB M)U29$*GXR?T9^>(9\AG2H2T,\B/3%[8SB2`A?`7!?'-3<&-GCNMVIDX[L3QG MDE$KF%H7<0@]$(:7_O(9:2[)5F<8$79S%;:!,"*^&<]+J&H>\V@FGYZ\O(QY MTN$%VD8S[0JZ,=Y-HYW;(]K%I\F,"R3*YN0[(2WR=C+CLEXFN)L)ZF>2=C1) M>U*`XVLK\)"7AWE*QL"8A/2F*B9@?32L.<=HJVJ:MF_@_;3IT">4D(2U/`Q6S@,(&RZ5K)U%S MB9`\*C[?3HA:U;SCU56^`@DQ-69/KU16N=A-WGI(*'&EFMAF3GZLSTGU5S3P>/>2SKH4%8WR_UNW5 M%8@LZ#9FW\?.NZS)3UF7?]WOMT12).T%<&)<6_?VL)KORE!3UN0)5)5*%B"Q.+#9&R$/32<[GT MS5>P?&Z44$ROXC0;Z:7+)C"+)8,P]B%W7#I,4VYD(R\4W$9@.<#Z4.IZOQBP MY4-/YU!R-W%3T*A:HH]J'EHIQF(K6AF1]E)/*?==SIOA;5M"O`^.+9>R=>K8 MAUYZ[6[U-F^!"XO`T$2^GA).;TW*7U3R?E4`K]<\D[1HY/P;BKKL6BUUH:G] M72_S0U]6:L,NGN`U[[P_<90:YXZGG4[])S^EO2DYL;AO/61]\LL7,,$+5]1`ZF=&%6R0RKDYS_:)R$<6 MP@R&D(EQK);%A!K%ZK::J(Q@F;.<9%-6=3@WO>"*H0I02R)?8]JUO=G M5Z^CY(*QBW7&!IYY-P'X(P:>O::$H;BHE.M5%NP;(&!QK:EZ20.F!H6XJ)2K MMQVQ#<6Q^-%?<6$!6>IFFX],N>K:T#,G/1TYC2UW,FA09@P.6TW MV*36RK4F`LZ&\D@<&6BH2VP>"ZGYV#@U']?4;-*)6(G-$R$UGQBGYA/9D77U M:MYG<>KKX&TC@9,`X;&>V#42)22?VMVISQ$;?B\A1S[T=S3TL7'[[&!]LH,I M>6+YHY=%Y7+"R34K1TR,?LR3NF'[BB0Q,1EHEZI#0<85"."KA8%9BIJQH-!" MH"Q%JPO$"]VV,#469?+(H.OT5JA:+HP*S5,-5;I/I1-.I1OD<$"/[(1.#(6F`SH=6*>C"P; M)VWWRFRKZDF:5CEO5-(Z?KW"4Z1%^PF&OU,.M-C--5=-.P-Z39?-6"]]+YG[ M,_1)ZAZ>W5R5;G@`UE0.B8.!-]^S'_YLX<>AY3DSX.7N*=%%XVBO7MQTS!0^ M.)L%[7SO=L5=N^!54'=DDK&IC\R%#M$YBM+:KJJT7X@4[4'I6X@T9Z"F45&> MBO=Y-9^B]1<928M"^5@P7J8E`7X#<+Z(@'..!FC-P0P$2\;!B)SNE9V?=)L2 M]0,5.4+0(7U#-I92NNLW$-@P!(\!M-&__.>LFR74V;-=78YS(M M6BX'!GSA\ZG2Q4A2'7O+FP-"5(+P=\W#$(01LXK.*$Y52$9)/$DEME!YRM:` M2$/:M8-1XKF98GEG-IDI\5H;Y3*O#K8L]=I(M0LI2-(9]-IU5FVCL\ZJ(S7F M.5.^E)XI(9FG\<:I4#+/=)_&LR]JLB]J,BA&]D5-]D5-]D5-M%;7EFO';O+CD^^Z-W[PPPH<%N"&^^:80=B8JP.\HT"3 MFSE.-6GC\1N,%@W!A%7)A$\U960I'4E?G+MG"=]1#N"A[0%K@RY!?K*`O`(! M])UOD15$(P0S149?D/N$W^.Z]5)W^-;+_5^)`._P[3WHY/>78)$J)L>L7WO.5NO87/\1(VYF:)L:6G;",/7AG@_U+)>4=E(F5OM03SH@ M1A9+O<&^_$RGV4N6\P@+SB`G*DI,0?D"-N60FM%6\X3BEM'KI9+R^*B'O*1& MRI30AJ'B?6K"H#63O3F/A]-A)/I<>._]6O?GPF5I-7G?F*I':KOO'T\^?/QX M-CT]._UX_.G#QT^?3W15J!@/L@[B56MV)&&3]KE(#I2@G-/ZN0 M-`,4N72K@V2M.;*+[MR#Z(*"PB:H2:^-Q46F2M@D1!1W(KE&;N@5 M))[2FG5;K4$$56"'0QFYK-@F91(UST_.'0>FG^`H4B9$KL/Z38P$BK,REL)D M:),0QFX$O?FE'T;U"4-NHNS*>`.N5[O#5 M"R&0="=`/$JM"O"WM6NGIS!5^A`SP'UR]Y M!(&-53;IYOR&53$0$$!M.4:E4YG1HD"4U$U,9LP> M@B=$NC>Z]C@(HWQ'%K$NC0Z.0U5 M3G,.*F5&&W\E._O=.AH;0OKPFH-"LF0%*4 M/[D^8X7`^>+[3I@F.(/ERO77`'P#P2M"?<2!)!)+5O50\@B:-(.MO:&2^^(\4GX**-63CS,X[H M&.$D')'Z.3D:YJABD(#:8^#;`#@AOLWYS7(!\I]**0D(WSEN*9$U;OI*7L/9 MT^!#DC4N[UX&J4V M]"K&&>R/Z<4A++MLW412N+3"!>5@1*2#<8"G"V>%>ZH-/"BV9G.X6QC2@A\< M,'_P\KT[+BY@+[*I0+(KG;L:!PSZ\9@#0GM_Y#$.[(55'-64%E=\\X7EB?!2 MCDG=G"SEVOUTJKEVK\,(+I&_[#R\H%$A&X;?'?%"0%0HH_&(=,C@HE#;I_?: M*&[0>)9@4$N_R%:W>%8UJ'4L^>&"07;[Y%L&Z6(S\R]`U@0X,[]DE=*_4\X! M^G4Y#A#(X;5X.4$;H`Q\5:?LP_ZZ\KVT88AX)F5[=NEE'/#IS%Z.&'VV@QS^ M_OE\'H`Y6AI3SFHAVS87OXUZ'!H79JOP&3Z_GQX;YC408_N,YW$8[37/_>;@ M()_2)!WKJ*>V>Z_DUAH\8$V'6RU+G\P!/2MM038N^GD'?V1S1SOQ\SU[RZRA+&0_AN%8Q'HYR90Z??S5T&9(T M].<\6D%%4-1:)*?U6B19!Y.DAW))$K4522A\L5[::2=1$DR(G\/D*8/H^A7] MBU2NA-U4E=GDU4`E/$#D8)"[F<-H!WV/X>M16ZOT(%@`8^FF&/RXU$-T\3C: MZZ2B&LI:M#3H%>=!],2LED%IJYE^Z)4R*./GU,[8;@[4N+VCW(!N;ZZ3?CE- MY%WC,C0Q1T[V\11EX>7(L>:EU$@7#4`5KCPO,]I-/#&U"MUZ%^]C#-YC1]:T MRUL==.>31VQQTE]9H#@(7R;AWQCQ]ZCL`*#KG,D/S7IS/I84^VI"<,W&MN=$ M-PA&J7$>QK1+B=YFRF*>X-DK;7'3B6X@D9:_N&%1N_D_[.G:Q;K\%\9)B$@' M&GF;5,]?A)\B,T*_?7AYL,R#$E)#E7H2!R1->TH*PB&7(LNA9Y1_:S;21>*T MLF_-$6MG#RD:F2U@X'"IA=92<]W0AJW=IDAL-\SRS,\]/UJ`@+'9D=KSB+P; MJ7QO#4'#AT9M:P4CRX5_IKKSG*\@F(.`&AP];@9'JUU,+,^9I)VH#8]>Q"'T M0!A>^LMGZ%EMH5%V# M.I]E\T(^WQT:>Z MI4T(#Q+*2854:=F3\D@H!HR72,T-F%S"R;VM8E39@I_4#MB,^]%:)R^Z8X!? MN,V4,6F]*CT0X-)M>7/9F]VM!:C43.[D3*7A3)WR3_')3VD72API8^9Z*>F; M.+I$^@^KU'-!Z\XKSJS$,E\$Q9\+`6"<]=0LE,.M5[I\TF/:M MA4_:(,?:477I91R3M#-[LBKG;ZON3440.)M]GCR6=K%N.!OG^-W.-%?^UD/L MQHD'D@GBWO?^#D+DJ/P&\+T'X)PC*V+-P1><'W^%/)BBV#4_CK8T'&5[O^YS ML`6A6Q*X.HLUD^*7M/:=EX9]OP1^2`V&#_&ED2)Z4)EHEY&Q M+YEEX3"-%M";2H[^Q9`CV,\&D*UTDE*5)S]@BE3V-1%;',\9YCV2[/.B71@KJ0662 M0W7X0T/=['1)''H8:;$!C13,.HA.OT=/]##/#W$41I;G0&^>/BPTD'%N?$?I M0PAZ&&>B3%A9W^)':M\B*XC&XT>/]A!YQ&C6071Y%+-OC3>IH-]Q`SU:0`\H MD=R+Z'V0QA'P4!IPSY(/"7'WJ7#@?9)UMJL!^.WDW91P'=*`S2P*):__<03X M!V"<%?I77:0\LTX4SO`MC5MDZEZA@V9J,\WP8CW#)N#A9=.(<6MSJ(\I!9;L M^5?)_1Q(8!J7!5S-_.OD22#F_5+A7E1":-@Y6,:3L%BV>8LU MOTK(*.[::*)2;1V1NGD4H\Z,=ID(7IZ`[<\]^">" M>.(.)RGN=RV5OZ1_Q=A%1;JDMEFA2JT/-%$VASE\(M#N4J`> M!RX[F[HG,N.VE:W7&YP#9U$39294:D^XBW'LKKOQEF^@#7OK([/EP"'++RN= M0+$RO,2:&0ZN2FJB/!JZ9'$Y!/?X"20<44EL9SCS(\LM_QT[!?=^]$\0;=R% M\I%Y'W^Z_[?'C,XMB6@L)77NP0]W?;Y:^=!#[%[XB-UT9\NH2=5&,N;]?2MS MLD+ZP]=*NG:!S:M35NLQJY/%5Z;)T]'7SVB^>//HN]"&S0OV'XX^U"-^*7'Y M#9=P\E-.KR3*EXZ(49BHWD!-"":`KTAS:)E(A+5N+8#!(%!5H(@LZ6HL@SYJ MM24J?C[$@WU&*S?ZG_\'4$L#!!0````(`.F&:$&?`:)ZD@X``!BA```1`!P` M<'9C="TR,#$R,#DS,"YX!E%UC`'W]Y7OC.(^:",'K6Z1\==QQ, M7>81.COKA**+A$M(YY>?__ZWCS]TN[]?W-\Z'G/#!::!XW*,`NPYDY5S?^\, M&*78]_'*&:/9#',MU>D?'\G_3OJG_W8NV7+%R6P>.&\N?\QQ=;MQ&1=(@$S@ M4X6='/6C+\*=XP5R0%TJSCKS(%A^Z/6>GIZ.GDZ/&)_U3HZ/^[W?/]\^*+I. M1/CA><)]DB.7;S3#:8]0$2#J8DWO$_JUAEQ^GH!^B?@U^EB;_OOW[WOJ:\<) M$)_AX`XML%@B%R?DRTX! M!>;$31@`UV8>1KN:#S!VG(^(4A:@`)J-^BW?+)>$3EG\$U[(2OW`F8_'(,*1 M#U_N;]:K2W[H77T+2;`:4410?0JL?TI_5\Y)C`0"K>KB% M%S%W3%+'Z2+?#?T-&%/-JOGBM[KN-X/D(6#N5]7'+]EBB:&R9*$#'"#BBS%^ M#J"51N`84=;"]-/QO_I%G)34>)#)RG7>Q)*=6/0!,S/,#,!J1*DU2`=P&L`9 MHXF/:[&)*6JA>=<&FDC@`9D&9.HPJ4?CQ!R-`P@:A'OLHB4)P/7YGU+SG'J? M,3AD/#=\-5(UC&`G16"*`AU$/2<2>1C$RE#R92@Q0CSGCA4PJJ5I0.C=.D)* MG*/D9?VV`SXFCG0.FNK/#:B8N=$'/(IX7"/"?T5^B(?3:T(A@B7(OX%8EJO( M7-=^/T+'E+@!JY_6?&DIV%&2'39U$ME.1GCJ5O*T[GE&7 M:XJ7-^EL!X0:@K+::*P)$?,P[(!#=?!5%74UU;Y)N'6H=^,YQG!R:4)ETUGE M@%3C(E_#ZEX3,FV6]0YH9/N-&$Y'&1/3GE+\T(#`VIJ#DB$G[ZR40]VG>PXP MFRH_9CB]1&)^[;,GO>-0\J6V]OMOC]460\P'SY>,>IA&FPU4,)]X:NY.14M@ MI'!'2G?>?*$H]`B0'/S>4H34]LV<^1[F(IJ*U[$JH:E'[;0$M2JLLL+_H;V! M`VP-L`V7F*.,(U;QK1ZFDXTZ5RK^`%/YW./+?*Z'.<:!@)@"[)SC@+AZ&;7F M>SU<_;X97'$!3E1"%B3G3:Z\`VCEH)7@U`2-84^JAN8`A89B$"=W@HM\10.8 M#6[HE/%%QHFKI:@%2L*DN;./TH>.1#D967\!3.0_,IWT'D\=E2SZ0:9%GG4$ M62Q]F62JWLTYGIYU)$Q=G0/Z!YA[]+SP-8F47Y.VJI`MUE!N6.[(<\4\'^:!I[\6,!\3:&E\`^95LOTQ+>273 M?31I:SJP8/\5C;Z5\E_)7.AB;-FL9?N6SFC^"W8P' M#EU+":]+4(\2X&^9JP35L,A?78Y+0O)>0M+_22NB3ED8-XSUM'\3-8I< M)6ILI$/F&$%+/1B]VU"5\M,2ACU$,\A2WVW0*?"S.V_=*Q(F]=2Z7^1DN2RD M`5^UUB'+IW]LJ4G((:AR-U`ERYC\VDX9BH@KI,!^&TU2KNBQFPK80`=!W-8: M:![YL&7IP9*W+UXSJ:)C3TJ#^C#D?"("CMP@"EBD2_&'&7GDEZA#8Q_@ M':&S&P@JI><.AH1`1H)0= M@(<@BA+?EPD=^GBS7<+1X[&V.K'D?#;C:A2_)=]"&=E"$>!T3[%LOU*X MJIXFJJRE"T9Q@/C*V-:B_NNV1^Y'H#]-HLC[K.-R#!'W&J2)<9_A,_CJ`_Q( M7'#<'C$-$Y/*O[VR(2F(+2TQV#R,S#(@C&R$*4ZJIMZ]BH55IOR&Y8E-[)T_ M8HYF&&;,">;#:49%,0P#";@\-EJP1YNYI9!BSD>Y? MJ%SV4TN&8LPQ$B%?74#!(C'5B-;6L4>.(4-Z]8RY2P0>3G]#G".54Q595_W= M4N@N,(6(6V9J07.+SY7+/B:?`P)%WM``9C81)(.J.8.E)M<8MU]F9$X(&H-*R7:*]N@8RD_ M/43^<.*3F=[CK;&TBL5:NZF\M4/@`8[^?T/C>3R>O04X7<-@#@ZH"HB#@E$VF[KJ>QM?5"WUN0<"$5E]Y<`'%3 M2,0\3D09X$F00ME,::N5JI')L1=[@U`NR8PBJ>R:A2I65,%CG,.D4ONUU9MP M[EDM1(%SN44-U5#/NN-XNT'GJ\729RN,36W,T-MIV`V5"UI3:4Z[+&1#: M"E6=ZGFT3"AMZ$L0#<:JKH\"ZP.E`;6MT#7J7]+;3,CMZ'7F#DP+!ENA//?^ M&XH@NKN!G7N>&@61+Z/D&WH9G?-KL>B7JY[7D;W/-:EZPIA=X&3N*6U7+R)J MG^M)QZK9_9!DH3%>;&M=8RV$VEIW%2[F*.2R%P5C=H]G=<&+3KLGW>^$:),=-!1[PYT;K3;"#'? M2##7,]06DURSU'VNO7N\#+D[1S*?HJSA7&,4A+Q](VPGU](]F(K1IV(K*0EV M3(9Q0QFV-JW:<3EK4!I#I+89#>[-0FR('\WFYX=-)_:'?6X&I09M/+$_V`IX M9IO&;!NO2&XKN#*9,,Q?]`T=<816G/G^&#WC7-IA$^4K6[EIYG8\KMP2-"&^ MNL@BMTZ0>6^I`9\0H5%BY.4(.07 MNK82L>,!J9#;\X!\'%U3%*6"%$VI2`EJ9K/4.RNWHQS&>MNK>"PU/.V]K;KZ M7Z>+Y^;A;21\MUJI.>D0TN`>NSX20OT5+-ELB_"!3Q'?PI2<>&C%92OXZS=% MRBN\+_Q,^G4M2617]#>]/@3Z_7<%L/(.O_@R\O007V2/.7WQ=%YN,FIW"/`E M#&T\#U9A<'L^RPPO;X$EEAH06F9::[]R#WQ*\_,K>8](Y^1=X)A$KJ9F9I2\ M6[FUF!V[EN,G-IZS4"#JC3'54^5G+$\_:AOK:7)CK\<6X(;LRH(K7YZZ;32B MG&S7=E1<6%TY?9A16S;09#I`M&+RA7J8%^?"_%72R?&KUIR[7D>21:J_??:) M,4\N;M[!^!*8R9Z7Y[9&FRT/1B\G9<,?&97&A\Z@1#U)9A MK,SE;&1&6!-B2Z>9[3&[9GR*2?"2S2`CTHZT'I'X"XDKD5ZJ7!SZVO%8-@`. M@/H1:!YQYD\Z%"UL(++,)!,\VF!G[0ILT;W) M#`\7VL*O3*YIO52%54G],]719_1,%N'6G;%!^'[6V#T17Z\Y3FYP>(DV52[S MSU,_+]2>:D7OMK;2C*#JY%?DX^$47%*5*VF/\Q7 M'N*WY;+,+:Q8H=`W,(,X;5+Y8;M,NFWJI#3:ESHV/W_\NNO6U_W10,]XNJ&&QK)/G%V<>H$#\ M+02*JT=,L_=!U1%9NG)36'>J6(ZR5OU1Y!U`<)B_Q%#MDD.)V?O5KI"K>U#2 MW39EWZU_<@4%+.1P/YQ.L>P->H)(.ELU@:5`WN'@B?&O0XH3+^`!NR$G\@+X M_!Z'$6GY"+*[?8]+F;N0KDT.^;U-0$\=NAYX'H%87C%V6;T!6?[>M1[:Y<-5Y,NFUWZWV/T6;X''7VAT$K?78L;_RXA60'^-V!T1K/?YL0,29`"', M*KM#H9T2NX9`SE]KUE_R3MP8K+=FLVP4N,-/_NI\ MN62$PH!\P6``CQ`JKCDUD-D&YSV^\M5V?:5)=12[M.9C+_IC5?#X?U!+`0(> M`Q0````(`.F&:$'WQ'@1:%(``*AK!``1`!@```````$```"D@0````!P=F-T M+3(P,3(P.3,P+GAM;%54!0`#1BJ<4'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`.F&:$%(:4/590T``*JO```5`!@```````$```"D@;-2``!P=F-T+3(P M,3(P.3,P7V-A;"YX;6Q55`4``T8JG%!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`#IAFA!2(6NX*\5``#LL@$`%0`8```````!````I(%G8```<'9C="TR M,#$R,#DS,%]D968N>&UL550%``-&*IQ0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`Z89H05_Q$J[S1@``_R4$`!4`&````````0```*2!978``'!V8W0M M,C`Q,C`Y,S!?;&%B+GAM;%54!0`#1BJ<4'5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`.F&:$&-#&YNJR<``!W8`@`5`!@```````$```"D@:>]``!P=F-T M+3(P,3(P.3,P7W!R92YX;6Q55`4``T8JG%!U>`L``00E#@``!#D!``!02P$" M'@,4````"`#IAFA!GP&B>I(.```8H0``$0`8```````!````I(&AY0``<'9C M="TR,#$R,#DS,"YX`L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``?O0````` ` end XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 22 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation
9 Months Ended

Sep. 30, 2012

Basis of Presentation [Abstract]

Basis of Presentation
1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)

Sep. 30, 2012

Dec. 31, 2011

Condensed Consolidated Balance Sheets [Abstract]

Accumulated depreciation on equipment and furnishings $ 421,377 $ 416,798

Amortization on patents 6,621,717 6,118,377

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 25,000,000 25,000,000

Preferred stock, shares issued 2,941,665 2,941,665

Preferred stock, shares outstanding 3,531,665 3,531,665

Aggregate liquidation preference $ 2,250,133 $ 2,702,134

Preferred stock, liquidation preference per share $ 0.75 $ 0.75

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 113,701,071 113,701,071

Common stock, shares outstanding 110,596,798 110,596,798

X

- Definition

Aggregate liquidation preference.

+ References

No definition available.

+ Details

Name: pvct_AggregateLiquidationPreference

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

+ Details

Name: us-gaap_PreferredStockLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Recapitalization and Merger (Details)
9 Months Ended

Sep. 30, 2012

Recapitalization and Merger (Textual) [Abstract]

Common stock shares issued 6,680,000

X

- Definition

Common stock issued under recapitalization transactions.

+ References

No definition available.

+ Details

Name: pvct_CommonStockIssuedUnderRecapitalizationTransactions

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pvct_RecapitalizationAndMergerTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
9 Months Ended

Sep. 30, 2012

Entity Registrant Name PROVECTUS PHARMACEUTICALS INC

Entity Central Index Key 0000315545

Document Type 10-Q

Document Period End Date Sep. 30, 2012

Amendment Flag false

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2012

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 113,701,071

8% convertible preferred stock

Entity Common Stock, Shares Outstanding 2,941,665

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basic and Diluted Loss Per Common Share (Details)
9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Stock Options [Member]

Basic and Diluted Loss Per Common Share (Textual) [Abstract]

Common shares excluded from the calculation 15,140,956 15,390,956

Warrants [Member]

Basic and Diluted Loss Per Common Share (Textual) [Abstract]

Common shares excluded from the calculation 26,042,116 24,575,302

Convertible Preferred Stock [Member]

Basic and Diluted Loss Per Common Share (Textual) [Abstract]

Common shares excluded from the calculation 2,941,665 3,848,332

X

- Details

Name: pvct_BasicAndDilutedLossPerCommonShareTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Statements of Operations (Unaudited) (USD $)
3 Months Ended 9 Months Ended 128 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Revenues

OTC product revenue $ 25,648

Medical device revenue 14,109

Total revenues 39,757

Cost of sales 15,216

Gross profit 24,541

Operating expenses

Research and development 1,129,921 3,442,344 4,352,940 6,971,816 42,446,334

General and administrative 2,296,637 3,860,755 7,228,225 9,568,240 64,753,074

Amortization 167,780 167,780 503,340 503,340 6,621,717

Total operating loss (3,594,338) (7,470,879) (12,084,505) (17,043,396) (113,796,584)

Gain on sale of fixed assets 55,075

Loss on extinguishment of debt (825,867)

Investment income 310 529 1,325 898 653,195

Gain on change in fair value of warrant liability 1,246,917 1,027,554 1,435,898 1,059,730 5,580,181

Net interest expense (8,098,004)

Net loss (2,347,111) (6,442,796) (10,647,282) (15,982,768) (116,432,004)

Dividends on preferred stock (43,884) (59,465) (145,709) (193,623) (10,800,584)

Net loss applicable to common shareholders $ (2,390,995) $ (6,502,261) $ (10,792,991) $ (16,176,391) $ (127,232,588)

Basic and diluted loss per common share $ (0.02) $ (0.06) $ (0.10) $ (0.16)

Weighted average number of common shares outstanding - basic and diluted 113,166,988 109,100,408 112,073,836 104,277,935

X

- Definition

Basic and diluted loss per common share.

+ References

No definition available.

+ Details

Name: pvct_BasicAndDilutedLossPerCommonShare

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gain loss on change in fair value of warrant liability.

+ References

No definition available.

+ Details

Name: pvct_GainLossOnChangeInFairValueOfWarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Medical device revenue.

+ References

No definition available.

+ Details

Name: pvct_MedicalDeviceRevenue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Weighted average number of common shares outstanding - basic and diluted.

+ References

No definition available.

+ Details

Name: pvct_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Equity impact of aggregate cash, stock, and paid-in-kind dividends declared for preferred shareholders during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 26

-Paragraph 20, 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments
9 Months Ended

Sep. 30, 2012

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments
6. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2012 for the 2010 warrants include a weighted average term of 3.0 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.51%. Significant assumptions used at June 30, 2012 for the 2010 warrants include a weighted average term of 2.7 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 64.2% to 65.8% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2010 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%.

Significant assumptions used at March 31, 2012 for the 2011 warrants include a weighted average term of 3.8 years, a 5% probability that the warrant exercise price would be reset, volatility of 66.4% and a risk free interest rate of 0.78%. Significant assumptions used at June 30, 2012 for the 2011 warrants include a weighted average term of 3.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 0.41%. Significant assumptions used at September 30, 2012 for the 2011 warrants include a weighted average term of 3.3 years, a 5% probability that the warrant exercise price would be reset, a volatility range of 57.1% to 64.7% and a risk free interest rate range of 0.23% to 0.31%.

The warrant liability measured at fair value on a recurring basis is as follows:

Total Level 1 Level 2 Level 3

Derivative instruments:

Warrant liability at September 30, 2012
$ 1,631,590 $ — $ — $ 1,631,590

Warrant liability at December 31, 2011
$ 3,067,488 $ — $ — $ 3,067,488

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2012 to September 30, 2012 follows:

Balance at January 1, 2012
$ 3,067,488

Net gain included in earnings
(1,435,898 )

Balance at September 30, 2012
$ 1,631,590

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Transaction
9 Months Ended

Sep. 30, 2012

Related Party Transaction [Abstract]

Related Party Transaction
5. Related Party Transaction

The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2012. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2012 and issued 100,000 fully vested warrants in exchange for services. Consulting costs charged to operations were $47,520 for the services for which these warrants were issued. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2012.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments (Details Textual)
3 Months Ended 6 Months Ended 9 Months Ended

Mar. 31, 2012

Jun. 30, 2012

Sep. 30, 2012

2010 Warrants [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Weighted average term 3 years 2 years 8 months 12 days 2 years 6 months

Warrant exercise price probability 5.00% 5.00% 5.00%

Percentage of volatility 66.40%

Risk free interest rate 0.51% 0.41%

2010 Warrants [Member] | Maximum [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Percentage of volatility 65.80% 64.70%

Risk free interest rate 0.31%

2010 Warrants [Member] | Minimum [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Percentage of volatility 64.20% 57.10%

Risk free interest rate 0.23%

2011 Warrants [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Weighted average term 3 years 9 months 18 days 3 years 6 months 3 years 3 months 18 days

Warrant exercise price probability 5.00% 5.00% 5.00%

Percentage of volatility, maximum 66.40% 64.60%

Risk free interest rate, maximum 0.78% 0.41%

2011 Warrants [Member] | Maximum [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Percentage of volatility 64.70%

Risk free interest rate 0.31%

2011 Warrants [Member] | Minimum [Member]

Fair Value of Financial Instruments (Textual) [Abstract]

Percentage of volatility 57.10%

Risk free interest rate 0.23%

X

- Details

Name: pvct_FairValueOfFinancialInstrumentsTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions expected volatility rate.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions expected volatility rate maximum.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions risk free interest rate.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions risk free interest rate maximum.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions warrant exercise price probability rate.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsWarrantExercisePriceProbabilityRate

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant liability derivative instrument fair value assumptions weighted average term.

+ References

No definition available.

+ Details

Name: pvct_WarrantLiabilityDerivativeInstrumentFairValueAssumptionsWeightedAverageTerm

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Equity Transactions (Details) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 128 Months Ended

Jul. 31, 2012

Apr. 30, 2012

Jan. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Equity Transactions (Additional Textual) [Abstract]

Dividends on preferred stock $ 61,424 $ 58,490 $ 43,884 $ 59,465 $ 145,709 $ 193,623 $ 10,800,584

Common Stock to be Issued on Exercise of Warrant 1,855,176

Exercise price of common stock $ 1.25

Equity Transactions (Textual) [Abstract]

Issuance of common stock to consultants 225,000 75,000 175,000

Issuance of warrants to consultants 1,732,135 454,500 1,003,000

Consulting costs charges related to warrants 721,753 183,908 475,668

Gross proceeds from private offering of common stock and warrants to accredited investors 2,077,796 2,077,796 9,486,071 40,101,773

Forfeiture of warrants 122,833 4,368,644 1,500

Company accepted subscriptions, in the aggregate 1,855,176

Period of warrants to purchase common stock 5 years

Investors received five year warrants 100.00%

Purchase price of common stock with warrants $ 1.12

Expenses estimated for working capital and other general corporate purposes 25,000

Total number of shares of common stock sold to investors 20.00%

Common stock shares issued in lieu of cash dividends for Preferred stock 64,183

Converted redeemable preferred stock 490,000 100,000

Redeemable preferred stock converted into shares 490,000 100,000 490,000 490,000

Network 1 Financial Securities [Member]

Equity Transactions (Additional Textual) [Abstract]

Common Stock to be Issued on Exercise of Warrant 371,035

Exercise price of common stock $ 1.12

Series A and C Warrants [Member]

Equity Transactions (Additional Textual) [Abstract]

Gain on change in fair value of warrant liability 429,818 222,546

Convertible Preferred Stock [Member]

Equity Transactions (Additional Textual) [Abstract]

Loss on change in fair value of warrant liability 114,800

Rate of convertible preferred stock 8.00%

Dividends on preferred stock 43,884 51,194 50,631

Common Stock [Member]

Equity Transactions (Additional Textual) [Abstract]

Consulting costs charges 184,750 64,500 160,000

Warrants [Member]

Equity Transactions (Additional Textual) [Abstract]

Loss on change in fair value of warrant liability 148,364

Gain on change in fair value of warrant liability $ 817,099 $ 229,599

X

- Definition

Class of warrants or right exercise price of warrants or rights.

+ References

No definition available.

+ Details

Name: pvct_ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Consulting costs.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCosts

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Consulting costs relates to warrant issued.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCostsRelatesToWarrantIssued

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Convertible preferred stock shares to be converted to common stock shares.

+ References

No definition available.

+ Details

Name: pvct_ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pvct_EquityTransactionsAdditionalTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pvct_EquityTransactionsTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Estimated offering expenses.

+ References

No definition available.

+ Details

Name: pvct_EstimatedOfferingExpenses

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Gain on change in fair value of warrant liability.

+ References

No definition available.

+ Details

Name: pvct_GainOnChangeInFairValueOfWarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Loss on change in fair value of warrant liability.

+ References

No definition available.

+ Details

Name: pvct_LossOnChangeInFairValueOfWarrantLiability

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from sales of common stock and warrants.

+ References

No definition available.

+ Details

Name: pvct_NetProceedsFromSalesOfCommonStockAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage of aggregate shares called by warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfAggregateSharesCalledByWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of common shares issuable on exercise of each warrant.

+ References

No definition available.

+ Details

Name: pvct_PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant

Namespace Prefix: pvct_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of warrants to purchase common stock.

+ References

No definition available.

+ Details

Name: pvct_PeriodOfWarrantsToPurchaseCommonStock

Namespace Prefix: pvct_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Purchase price of common stock with warrants.

+ References

No definition available.

+ Details

Name: pvct_PurchasePriceOfCommonStockWithWarrants

Namespace Prefix: pvct_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants forfeited.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based goods and nonemployee services transaction quantity of warrants issued.

+ References

No definition available.

+ Details

Name: pvct_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued for each share of convertible preferred stock that is converted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Equity impact of aggregate cash, stock, and paid-in-kind dividends declared for preferred shareholders during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Equity impact of stock dividends for preferred shareholders declared by an entity during the period. This element includes paid and unpaid dividends declared during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStockStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares or units of entity securities issued in the transaction in which equity securities were issued to pay for goods or nonemployee services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 65

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued as consideration for cash.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForCash

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments (Tables)
9 Months Ended

Sep. 30, 2012

Fair Value of Financial Instruments [Abstract]

Warrant liability measured at fair value on a recurring basis

Total Level 1 Level 2 Level 3

Derivative instruments:

Warrant liability at September 30, 2012
$ 1,631,590 $ — $ — $ 1,631,590

Warrant liability at December 31, 2011
$ 3,067,488 $ — $ — $ 3,067,488

Reconciliation of the warranty liability measured at fair value on a recurring basis

Balance at January 1, 2012
$ 3,067,488

Net gain included in earnings
(1,435,898 )

Balance at September 30, 2012
$ 1,631,590

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 6

-Footnote 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation
9 Months Ended

Sep. 30, 2012

Stock-Based Compensation [Abstract]

Stock-Based Compensation
7. Stock-Based Compensation

On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On July 6, 2011, the Company issued 250,000 stock options to its re-elected members of the board. On July 12, 2011, the Company issued 50,000 stock options to a newly appointed member of the board. On September 6, 2011, the Company issued 4,000,000 stock options to its employees. All of the stock options issued in 2011 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.

The compensation cost relating to stock options issued in 2012 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for both the three and nine months ended September 30, 2011 is $3,368,950 of stock-based compensation expense which relates to the fair value of stock options.

The following is a summary of nonvested stock option activity for the nine months ended September 30, 2012:

Number of Shares Weighted Average
Grant-Date
Fair Value

Nonvested at December 31, 2011
— $ —

Granted
250,000 $ 0.73

Vested
(250,000 ) $ 0.73

Canceled
— —

Nonvested at September 30, 2012
— $ —

As of September 30, 2012, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Equity Transactions (Policies)
9 Months Ended

Sep. 30, 2012

Equity Transactions [Abstract]

Derivatives Policies
(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $148,364. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $222,546. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $429,818.

During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

(d) The Company determined that warrants issued in March and April, 2010 with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $114,800. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $229,599. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $817,099.

Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock.

X

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph n

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 39

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41675-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2012

Stock-Based Compensation [Abstract]

Summary of nonvested stock option activity

Number of Shares Weighted Average
Grant-Date
Fair Value

Nonvested at December 31, 2011
— $ —

Granted
250,000 $ 0.73

Vested
(250,000 ) $ 0.73

Canceled
— —

Nonvested at September 30, 2012
— $ —

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value of Financial Instruments (Details) (Recurring [Member], Warrants [Member], USD $)

Sep. 30, 2012

Dec. 31, 2011

Derivative instruments:

Warrant liability $ 1,631,590 $ 3,067,488

Level 1 [Member]

Derivative instruments:

Warrant liability

Level 2 [Member]

Derivative instruments:

Warrant liability

Level 3 [Member]

Derivative instruments:

Warrant liability $ 1,631,590 $ 3,067,488

X

- Details

Name: pvct_DerivativeInstrumentsAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants liability fair value.

+ References

No definition available.

+ Details

Name: pvct_WarrantsLiabilityFairValueDisclosure

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)

Total

Preferred Stock

Common Stock

Paid in capital

Accumulated Deficit

Beginning Balance at Jan. 17, 2002

Beginning Balance, Shares at Jan. 17, 2002

Issuance to founding shareholders 6,000 (6,000)

Issuance to founding shareholders, Shares 6,000,000

Sale of stock 25,000 50 24,950

Sale of stock, Shares 50,000

Issuance of stock to employees 932,000 510 931,490

Issuance of stock to employees, Shares 510,000

Issuance of stock for services 360,000 120 359,880

Issuance of stock for services, Shares 120,000

Net loss (1,316,198) (1,316,198)

Ending Balance at Apr. 23, 2002 802 6,680 1,310,320 (1,316,198)

Ending Balance, Shares at Apr. 23, 2002 6,680,000

Shares issued in reverse merger (3,645) 266 (3,911)

Shares issued in reverse merger, Shares 265,763

Issuance of stock for services 5,144,000 1,900 5,142,100

Issuance of stock for services, Shares 1,900,000

Purchase and retirement of stock (48,000) (400) (47,600)

Purchase and retirement of stock, Shares (400,000)

Stock issued for acquisition of Valley Pharmaceuticals 12,226,320 500 12,225,820

Stock issued for acquisition of Valley Pharmaceuticals, Shares 500,007

Exercise of warrants 453 453

Exercise of warrants, Shares 452,919

Warrants issued in connection with convertible debt 126,587 126,587

Stock and warrants issued for acquisition of Pure-ific 27,000 25 26,975

Stock and warrants issued for acquisition of Pure-ific, Shares 25,000

Net loss (5,749,937) (5,749,937)

Ending Balance at Dec. 31, 2002 11,723,580 9,424 18,780,291 (7,066,135)

Ending Balance, Shares at Dec. 31, 2002 9,423,689

Issuance of stock for services 239,800 764 239,036

Issuance of stock for services, Shares 764,000

Issuance of warrants for services 145,479 145,479

Stock to be issued for services 281,500 281,500

Employee compensation from stock options 34,659 34,659

Issuance of common stock pursuant to Regulation S 380,347 680 379,667

Issuance of common stock pursuant to Regulation S, Shares 679,820

Beneficial conversion related to convertible debt 601,000 601,000

Net loss (3,155,313) (3,155,313)

Ending Balance at Dec. 31, 2003 10,251,052 10,868 20,461,632 (10,221,448)

Ending Balance, Shares at Dec. 31, 2003 10,867,509

Issuance of stock for services 449,923 734 449,190

Issuance of stock for services, Shares 733,872

Issuance of warrants for services 495,480 495,480

Exercise of warrants 5,000 133 4,867

Exercise of warrants, Shares 132,608

Employee compensation from stock options 15,612 15,612

Issuance of common stock pursuant to Regulation S 793,137 2,469 790,668

Issuance of common stock pursuant to Regulation S, Shares 2,469,723

Issuance of stock and warrants pursuant to Regulation D 1,288,861 1,930 1,286,930

Issuance of stock and warrants pursuant to Regulation D, Shares 1,930,164

Beneficial conversion related to convertible debt 360,256 360,256

Issuance of convertible debt with warrants 105,250 105,250

Repurchase of beneficial conversion feature (258,345) (258,345)

Net loss (4,344,525) (4,344,525)

Ending Balance at Dec. 31, 2004 9,161,701 16,134 23,711,540 (14,565,973)

Ending Balance, Shares at Dec. 31, 2004 16,133,876

Issuance of stock for services 152,285 227 152,058

Issuance of stock for services, Shares 226,733

Issuance of stock for interest payable 196,031 264 195,767

Issuance of stock for interest payable, Shares 263,721

Issuance of warrants for services 1,534,405 1,534,405

Exercise of warrants and stock options 1,439,795 1,572 1,438,223

Exercise of warrants and stock options, Shares 1,571,849

Warrants issued in connection with convertible debt 1,574,900 1,574,900

Issuance of warrants for contractual obligations 985,010 985,010

Employee compensation from stock options 15,752 15,752

Issuance of stock and warrants pursuant to Regulation D 6,513,176 6,221 6,506,955

Issuance of stock and warrants pursuant to Regulation D, Shares 6,221,257

Preferred stock conversion into common stock 3,049,362 3,405 3,045,957

Preferred stock conversion into common stock, Shares 3,405,541

Beneficial conversion related to convertible debt 1,633,176 1,633,176

Beneficial conversion related to interest expense 39,529 39,529

Repurchase of beneficial conversion feature (144,128) (144,128)

Net loss (11,763,853) (11,763,853)

Ending Balance at Dec. 31, 2005 14,387,141 27,823 40,689,144 (26,329,826)

Ending Balance, Shares at Dec. 31, 2005 27,822,977

Issuance of stock for services 676,743 719 676,024

Issuance of stock for services, Shares 719,246

Issuance of stock for interest payable 183,596 195 183,401

Issuance of stock for interest payable, Shares 194,327

Issuance of warrants for services 370,023 370,023

Exercise of warrants and stock options 1,189,816 1,246 1,188,570

Exercise of warrants and stock options, Shares 1,245,809

Employee compensation from stock options 1,862,456 1,862,456

Issuance of stock and warrants pursuant to Regulation D 4,130,421 10,092 4,120,329

Issuance of stock and warrants pursuant to Regulation D, Shares 10,092,495

Preferred stock conversion into common stock 1,576,336 2,377 1,573,959

Preferred stock conversion into common stock, Shares 2,377,512

Beneficial conversion related to interest expense 16,447 16,447

Net loss (8,870,579) (8,870,579)

Ending Balance at Dec. 31, 2006 15,522,400 42,452 50,680,353 (35,200,405)

Ending Balance, Shares at Dec. 31, 2006 42,452,366

Issuance of stock for services 298,950 150 298,800

Issuance of stock for services, Shares 150,000

Issuance of stock for interest payable 1,258 1 1,257

Issuance of stock for interest payable, Shares 1,141

Issuance of warrants for services 472,635 472,635

Exercise of warrants and stock options 3,985,641 3,929 3,981,712

Exercise of warrants and stock options, Shares 3,928,957

Employee compensation from stock options 2,340,619 2,340,619

Issuance of stock and warrants pursuant to Regulation D 1,848,138 2,377 1,845,761

Issuance of stock and warrants pursuant to Regulation D, Shares 2,376,817

Preferred stock conversion into common stock 367,500 490 367,010

Preferred stock conversion into common stock, Shares 490,000

Net loss (10,005,631) (10,005,631)

Ending Balance at Dec. 31, 2007 14,831,510 49,399 59,988,147 (45,206,036)

Ending Balance, Shares at Dec. 31, 2007 49,399,281

Issuance of stock for services 390,000 350 389,650

Issuance of stock for services, Shares 350,000

Issuance of warrants for services 517,820 517,820

Exercise of warrants and stock options 2,639,711 3,268 2,636,443

Exercise of warrants and stock options, Shares 3,267,795

Employee compensation from stock options 1,946,066 1,946,066

Net loss (10,269,571) (10,269,571)

Ending Balance at Dec. 31, 2008 10,055,536 53,017 65,478,126 (55,475,607)

Ending Balance, Shares at Dec. 31, 2008 53,017,076

Issuance of stock for services 695,000 796 694,204

Issuance of stock for services, Shares 796,012

Issuance of warrants for services 1,064,210 1,064,210

Exercise of warrants and stock options 2,524,453 3,480 2,520,973

Exercise of warrants and stock options, Shares 3,480,485

Employee compensation from stock options 870,937 870,937

Issuance of stock and warrants pursuant to Regulation D 6,518,688 10,117 6,508,571

Issuance of stock and warrants pursuant to Regulation D, Shares 10,116,653

Net loss (12,322,314) (12,322,314)

Ending Balance at Dec. 31, 2009 9,406,510 67,410 77,137,021 (67,797,921)

Ending Balance, Shares at Dec. 31, 2009 67,410,226

Issuance of stock for services 856,613 776 855,837

Issuance of stock for services, Shares 776,250

Issuance of warrants for services 1,141,593 1,141,593

Exercise of warrants and stock options 3,103,680 3,491 3,100,189

Exercise of warrants and stock options, Shares 3,491,014

Employee compensation from stock options 3,759,650 3,759,650

Issuance of common stock pursuant to Regulation S 419,250 559 418,691

Issuance of common stock pursuant to Regulation S, Shares 559,000

Issuance of stock and warrants pursuant to Regulation D 6,346,989 11,169 6,335,820

Issuance of stock and warrants pursuant to Regulation D, Shares 11,168,067

Issuance of stock and warrants pursuant to Regulation D 4,217,390 13,283 4,204,107

Issuance of stock and warrants pursuant to Regulation D, Shares 13,283,324

Preferred stock conversion into common stock (7,893) 7,893

Preferred stock conversion into common stock, Shares (7,893,326) 7,893,326

Net loss (18,552,102) (18,552,102)

Ending Balance at Dec. 31, 2010 10,699,573 5,390 91,298 96,952,908 (86,350,023)

Ending Balance, Shares at Dec. 31, 2010 5,389,998 91,297,883

Issuance of stock for services 332,750 350 332,400

Issuance of stock for services, Shares 350,000

Issuance of warrants for services 945,116 945,116

Exercise of warrants and stock options 6,623,311 7,185 6,616,126

Exercise of warrants and stock options, Shares 7,185,522

Employee compensation from stock options 3,368,950 3,368,950

Issuance of stock and warrants pursuant to Regulation D 7,041,239 9,905 7,031,334

Issuance of stock and warrants pursuant to Regulation D, Shares 9,905,062

Sale of non-controlling interest in Pure-ific Corporation and warrants 443,500 443,500

Preferred stock conversion into common stock (1,859) 1,859

Preferred stock conversion into common stock, Shares (1,858,333) 1,858,331

Net loss (19,434,699) (19,434,699)

Ending Balance at Dec. 31, 2011 10,019,740 3,531 110,597 115,690,334 (105,784,722)

Ending Balance, Shares at Dec. 31, 2011 3,531,665 110,596,798

Issuance of stock for services 409,250 475 408,775

Issuance of stock for services, Shares 475,000

Issuance of warrants for services 1,381,329 1,381,329

Employee compensation from stock options 183,028 183,028

Issuance of stock and warrants pursuant to Regulation D 2,077,796 2,039 2,075,757

Issuance of stock and warrants pursuant to Regulation D, Shares 2,039,273

Preferred stock conversion into common stock (590) 590

Preferred stock conversion into common stock, Shares (590,000) 590,000

Net loss (10,647,282) (10,647,282)

Ending Balance at Sep. 30, 2012 $ 3,423,861 $ 2,941 $ 113,701 $ 119,739,223 $ (116,432,004)

Ending Balance, Shares at Sep. 30, 2012 2,941,665 113,701,071

X

- Definition

Adjustments to additional paid in capital beneficial conversion related to interest expense value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionRelatedToInterestExpenseValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital employee compensation from stock options value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalEmployeeCompensationFromStockOptionsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital issuance of convertible debt with warrants value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertibleDebtWithWarrantsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital issuance of warrants for contractual.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsForContractualObligationsValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital repurchase of beneficial conversion feature value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalRepurchaseOfBeneficialConversionFeatureValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Adjustments to additional paid in capital stock to be issued for services value.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentsToAdditionalPaidInCapitalStockToBeIssuedForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment to additional paid in capital sale of non controlling interest and warrants.

+ References

No definition available.

+ Details

Name: pvct_AdjustmentToAdditionalPaidInCapitalSaleOfNonControllingInterestAndWarrants

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance of common stock and warrants pursuant to regulation D.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfCommonStockAndWarrantsPursuantToRegulationDShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance of common stock and warrants pursuant to regulation D value.

+ References

No definition available.

+ Details

Name: pvct_IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock and warrant issued during period shares.

+ References

No definition available.

+ Details

Name: pvct_StockAndWarrantIssuedDuringPeriodShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock and warrant issued during period value.

+ References

No definition available.

+ Details

Name: pvct_StockAndWarrantIssuedDuringPeriodValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period for interest payable value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodForInterestPayableValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period for services value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period in reverse merger value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodInReverseMergerValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period pursuant to regulation D value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodPursuantToRegulationDValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period pursuant to regulation S value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodPursuantToRegulationSValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period shares for interest payable.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesForInterestPayable

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares for services.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesForServices

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares in reverse merger.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesInReverseMerger

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares pursuant to regulation D.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesPursuantToRegulationD

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares pursuant to regulation S.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesPursuantToRegulationS

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares stock options and warrants exercised.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares to employees.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesToEmployees

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period shares to founding shareholders.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodSharesToFoundingShareholders

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock issued during period to employees value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodToEmployeesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period to founding shareholders value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodToFoundingShareholdersValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued during period warrants and stock options exercised value.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for acquisition.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedForAcquisition

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock issued for acquisition shares.

+ References

No definition available.

+ Details

Name: pvct_StockIssuedForAcquisitionShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant exercised during period shares.

+ References

No definition available.

+ Details

Name: pvct_WarrantExercisedDuringPeriodShares

Namespace Prefix: pvct_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant exercised during period value.

+ References

No definition available.

+ Details

Name: pvct_WarrantExercisedDuringPeriodValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Warrant issued during period for services value.

+ References

No definition available.

+ Details

Name: pvct_WarrantIssuedDuringPeriodForServicesValue

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 05-8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=21917533&loc=d3e34017-109320

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 14

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7656322&loc=d3e4724-112606

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares that have been repurchased and retired during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Equity Transactions
9 Months Ended

Sep. 30, 2012

Equity Transactions [Abstract]

Equity Transactions
4. Equity Transactions

(a) During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(b) During the three months ended March 31, 2012, the Company issued 1,003,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants expired. During the three months ended June 30, 2012, the Company issued 454,500 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants expired. During the three months ended September 30, 2012, the Company issued 1,732,135 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants expired. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $148,364. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $222,546. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $429,818.

During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company intends to use the proceeds, after deducting offering expenses estimated to be $25,000, for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

(d) The Company determined that warrants issued in March and April, 2010 with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2012 there was a loss recognized from the revaluation of the warrant liability of $114,800. For the three months ended June 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $229,599. For the three months ended September 30, 2012 there was a gain recognized from the revaluation of the warrant liability of $817,099.

Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock.

X

- Definition

Equity transactions.

+ References

No definition available.

+ Details

Name: pvct_EquityTransactionsTextBlock

Namespace Prefix: pvct_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 178 194 1 false 27 0 false 4 false false R1.htm 00 - Document - Document and Entity Information Sheet http://pvct.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://pvct.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) false false R3.htm 0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://pvct.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) false false R4.htm 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://pvct.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R5.htm 0130 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://pvct.com/role/StatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity (Unaudited) false false R6.htm 0140 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) Sheet http://pvct.com/role/StatementsOfCashFlow Condensed Consolidated Statements of Cash Flow (Unaudited) false false R7.htm 0201 - Disclosure - Basis of Presentation Sheet http://pvct.com/role/BasisOfPresentation Basis of Presentation false false R8.htm 0202 - Disclosure - Recapitalization and Merger Sheet http://pvct.com/role/RecapitalizationAndMerger Recapitalization and Merger false false R9.htm 0203 - Disclosure - Basic and Diluted Loss Per Common Share Sheet http://pvct.com/role/BasicAndDilutedLossPerCommonShare Basic and Diluted Loss Per Common Share false false R10.htm 0204 - Disclosure - Equity Transactions Sheet http://pvct.com/role/EquityTransactions Equity Transactions false false R11.htm 0205 - Disclosure - Related Party Transaction Sheet http://pvct.com/role/RelatedPartyTransaction Related Party Transaction false false R12.htm 0206 - Disclosure - Fair Value of Financial Instruments Sheet http://pvct.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments false false R13.htm 0207 - Disclosure - Stock-Based Compensation Sheet http://pvct.com/role/StockBasedCompensation Stock-Based Compensation false false R14.htm 0404 - Disclosure - Equity Transactions (Policies) Sheet http://pvct.com/role/EquityTransactionsPolicies Equity Transactions (Policies) false false R15.htm 0506 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://pvct.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) false false R16.htm 0507 - Disclosure - Stock-Based Compensation (Tables) Sheet http://pvct.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R17.htm 0602 - Disclosure - Recapitalization and Merger (Details) Sheet http://pvct.com/role/RecapitalizationAndMergerDetails Recapitalization and Merger (Details) false false R18.htm 0603 - Disclosure - Basic and Diluted Loss Per Common Share (Details) Sheet http://pvct.com/role/BasicAndDilutedLossPerCommonShareDetails Basic and Diluted Loss Per Common Share (Details) false false R19.htm 0604 - Disclosure - Equity Transactions (Details) Sheet http://pvct.com/role/EquityTransactionsDetails Equity Transactions (Details) false false R20.htm 0605 - Disclosure - Related Party Transaction (Details) Sheet http://pvct.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) false false R21.htm 0606 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://pvct.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) false false R22.htm 06061 - Disclosure - Fair Value of Financial Instruments (Details 1) Sheet http://pvct.com/role/FairValueOfFinancialInstrumentsDetails1 Fair Value of Financial Instruments (Details 1) false false R23.htm 06062 - Disclosure - Fair Value of Financial Instruments (Details Textual) Sheet http://pvct.com/role/FairValueOfFinancialInstrumentsDetailsTextual Fair Value of Financial Instruments (Details Textual) false false R24.htm 0607 - Disclosure - Stock-Based Compensation (Details) Sheet http://pvct.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) false false R25.htm 06071 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://pvct.com/role/StockBasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false All Reports Book All Reports Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: Removing column 'Dec. 31, 2008' Process Flow-Through: Removing column 'Dec. 31, 2007' Process Flow-Through: Removing column 'Dec. 31, 2006' Process Flow-Through: Removing column 'Dec. 31, 2005' Process Flow-Through: Removing column 'Dec. 31, 2004' Process Flow-Through: Removing column 'Dec. 31, 2003' Process Flow-Through: Removing column 'Dec. 31, 2002' Process Flow-Through: Removing column 'Apr. 23, 2002' Process Flow-Through: Removing column 'Jan. 17, 2002' Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: Removing column '1 Months Ended Jul. 31, 2012' Process Flow-Through: Removing column '1 Months Ended Apr. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Apr. 23, 2002' Process Flow-Through: Removing column '9 Months Ended Dec. 31, 2002' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2003' Process Flow-Through: 0140 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) pvct-20120930.xml pvct-20120930.xsd pvct-20120930_cal.xml pvct-20120930_def.xml pvct-20120930_lab.xml pvct-20120930_pre.xml true true XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Transaction (Details) (USD $)
9 Months Ended

Sep. 30, 2012

Related Party Transaction (Additional Textual) [Abstract]

Payment for consulting services $ 48,000

Consulting costs charges 47,520

Non Employee [Member]

Related Party Transaction (Textual) [Abstract]

Payment for consulting services to another non-employee 75,000

Third Non Employee [Member]

Related Party Transaction (Textual) [Abstract]

Payment for consulting services to another non-employee $ 75,000

Subsequent Event [Member]

Related Party Transaction (Textual) [Abstract]

Shares issued in exchange for services 100,000

X

- Definition

Consulting cost subsequent event.

+ References

No definition available.

+ Details

Name: pvct_ConsultingCostSubsequentEvent

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: pvct_RelatedPartyTransactionAdditionalTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Related party transaction expenses from transactions with another related party.

+ References

No definition available.

+ Details

Name: pvct_RelatedPartyTransactionExpensesFromTransactionsWithAnotherRelatedParty

Namespace Prefix: pvct_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: pvct_RelatedPartyTransactionTextualAbstract

Namespace Prefix: pvct_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Condensed Consolidated Balance Sheets [Abstract]
Accumulated depreciation on equipment and furnishings	$ 421,377	$ 416,798
Amortization on patents	6,621,717	6,118,377
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	2,941,665	2,941,665
Preferred stock, shares outstanding	3,531,665	3,531,665
Aggregate liquidation preference	$ 2,250,133	$ 2,702,134
Preferred stock, liquidation preference per share	$ 0.75	$ 0.75
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	113,701,071	113,701,071
Common stock, shares outstanding	110,596,798	110,596,798

Recapitalization and Merger (Details)	9 Months Ended
Recapitalization and Merger (Details)	Sep. 30, 2012
Recapitalization and Merger (Textual) [Abstract]
Common stock shares issued	6,680,000

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012
Entity Registrant Name	PROVECTUS PHARMACEUTICALS INC
Entity Central Index Key	0000315545
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2012
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	113,701,071
8% convertible preferred stock
Entity Common Stock, Shares Outstanding	2,941,665

Fair Value of Financial Instruments (Details Textual)	3 Months Ended	6 Months Ended	9 Months Ended
Fair Value of Financial Instruments (Details Textual)	Mar. 31, 2012	Jun. 30, 2012	Sep. 30, 2012
2010 Warrants [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Weighted average term	3 years	2 years 8 months 12 days	2 years 6 months
Warrant exercise price probability	5.00%	5.00%	5.00%
Percentage of volatility	66.40%
Risk free interest rate	0.51%	0.41%
2010 Warrants [Member] \| Maximum [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Percentage of volatility		65.80%	64.70%
Risk free interest rate			0.31%
2010 Warrants [Member] \| Minimum [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Percentage of volatility		64.20%	57.10%
Risk free interest rate			0.23%
2011 Warrants [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Weighted average term	3 years 9 months 18 days	3 years 6 months	3 years 3 months 18 days
Warrant exercise price probability	5.00%	5.00%	5.00%
Percentage of volatility, maximum	66.40%	64.60%
Risk free interest rate, maximum	0.78%	0.41%
2011 Warrants [Member] \| Maximum [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Percentage of volatility			64.70%
Risk free interest rate			0.31%
2011 Warrants [Member] \| Minimum [Member]
Fair Value of Financial Instruments (Textual) [Abstract]
Percentage of volatility			57.10%
Risk free interest rate			0.23%

Equity Transactions (Details) (USD $)	1 Months Ended			3 Months Ended				9 Months Ended		128 Months Ended
Equity Transactions (Details) (USD $)	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Equity Transactions (Additional Textual) [Abstract]
Dividends on preferred stock	$ 61,424	$ 58,490		$ 43,884			$ 59,465	$ 145,709	$ 193,623	$ 10,800,584
Common Stock to be Issued on Exercise of Warrant					1,855,176
Exercise price of common stock					$ 1.25
Equity Transactions (Textual) [Abstract]
Issuance of common stock to consultants				225,000	75,000	175,000
Issuance of warrants to consultants				1,732,135	454,500	1,003,000
Consulting costs charges related to warrants				721,753	183,908	475,668
Gross proceeds from private offering of common stock and warrants to accredited investors					2,077,796			2,077,796	9,486,071	40,101,773
Forfeiture of warrants				122,833	4,368,644	1,500
Company accepted subscriptions, in the aggregate					1,855,176
Period of warrants to purchase common stock					5 years
Investors received five year warrants					100.00%
Purchase price of common stock with warrants					$ 1.12
Expenses estimated for working capital and other general corporate purposes					25,000
Total number of shares of common stock sold to investors					20.00%
Common stock shares issued in lieu of cash dividends for Preferred stock			64,183
Converted redeemable preferred stock				490,000		100,000
Redeemable preferred stock converted into shares				490,000		100,000		490,000		490,000
Network 1 Financial Securities [Member]
Equity Transactions (Additional Textual) [Abstract]
Common Stock to be Issued on Exercise of Warrant					371,035
Exercise price of common stock					$ 1.12
Series A and C Warrants [Member]
Equity Transactions (Additional Textual) [Abstract]
Gain on change in fair value of warrant liability				429,818	222,546
Convertible Preferred Stock [Member]
Equity Transactions (Additional Textual) [Abstract]
Loss on change in fair value of warrant liability						114,800
Rate of convertible preferred stock								8.00%
Dividends on preferred stock				43,884	51,194	50,631
Common Stock [Member]
Equity Transactions (Additional Textual) [Abstract]
Consulting costs charges				184,750	64,500	160,000
Warrants [Member]
Equity Transactions (Additional Textual) [Abstract]
Loss on change in fair value of warrant liability						148,364
Gain on change in fair value of warrant liability				$ 817,099	$ 229,599

Fair Value of Financial Instruments (Details) (Recurring [Member], Warrants [Member], USD $)	Sep. 30, 2012	Dec. 31, 2011
Derivative instruments:
Warrant liability	$ 1,631,590	$ 3,067,488
Level 1 [Member]
Derivative instruments:
Warrant liability
Level 2 [Member]
Derivative instruments:
Warrant liability
Level 3 [Member]
Derivative instruments:
Warrant liability	$ 1,631,590	$ 3,067,488

Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)	Total	Preferred Stock	Common Stock	Paid in capital	Accumulated Deficit
Beginning Balance at Jan. 17, 2002
Beginning Balance, Shares at Jan. 17, 2002
Issuance to founding shareholders			6,000	(6,000)
Issuance to founding shareholders, Shares			6,000,000
Sale of stock	25,000		50	24,950
Sale of stock, Shares			50,000
Issuance of stock to employees	932,000		510	931,490
Issuance of stock to employees, Shares			510,000
Issuance of stock for services	360,000		120	359,880
Issuance of stock for services, Shares			120,000
Net loss	(1,316,198)				(1,316,198)
Ending Balance at Apr. 23, 2002	802		6,680	1,310,320	(1,316,198)
Ending Balance, Shares at Apr. 23, 2002			6,680,000
Shares issued in reverse merger	(3,645)		266	(3,911)
Shares issued in reverse merger, Shares			265,763
Issuance of stock for services	5,144,000		1,900	5,142,100
Issuance of stock for services, Shares			1,900,000
Purchase and retirement of stock	(48,000)		(400)	(47,600)
Purchase and retirement of stock, Shares			(400,000)
Stock issued for acquisition of Valley Pharmaceuticals	12,226,320		500	12,225,820
Stock issued for acquisition of Valley Pharmaceuticals, Shares			500,007
Exercise of warrants	453		453
Exercise of warrants, Shares			452,919
Warrants issued in connection with convertible debt	126,587			126,587
Stock and warrants issued for acquisition of Pure-ific	27,000		25	26,975
Stock and warrants issued for acquisition of Pure-ific, Shares			25,000
Net loss	(5,749,937)				(5,749,937)
Ending Balance at Dec. 31, 2002	11,723,580		9,424	18,780,291	(7,066,135)
Ending Balance, Shares at Dec. 31, 2002			9,423,689
Issuance of stock for services	239,800		764	239,036
Issuance of stock for services, Shares			764,000
Issuance of warrants for services	145,479			145,479
Stock to be issued for services	281,500			281,500
Employee compensation from stock options	34,659			34,659
Issuance of common stock pursuant to Regulation S	380,347		680	379,667
Issuance of common stock pursuant to Regulation S, Shares			679,820
Beneficial conversion related to convertible debt	601,000			601,000
Net loss	(3,155,313)				(3,155,313)
Ending Balance at Dec. 31, 2003	10,251,052		10,868	20,461,632	(10,221,448)
Ending Balance, Shares at Dec. 31, 2003			10,867,509
Issuance of stock for services	449,923		734	449,190
Issuance of stock for services, Shares			733,872
Issuance of warrants for services	495,480			495,480
Exercise of warrants	5,000		133	4,867
Exercise of warrants, Shares			132,608
Employee compensation from stock options	15,612			15,612
Issuance of common stock pursuant to Regulation S	793,137		2,469	790,668
Issuance of common stock pursuant to Regulation S, Shares			2,469,723
Issuance of stock and warrants pursuant to Regulation D	1,288,861		1,930	1,286,930
Issuance of stock and warrants pursuant to Regulation D, Shares			1,930,164
Beneficial conversion related to convertible debt	360,256			360,256
Issuance of convertible debt with warrants	105,250			105,250
Repurchase of beneficial conversion feature	(258,345)			(258,345)
Net loss	(4,344,525)				(4,344,525)
Ending Balance at Dec. 31, 2004	9,161,701		16,134	23,711,540	(14,565,973)
Ending Balance, Shares at Dec. 31, 2004			16,133,876
Issuance of stock for services	152,285		227	152,058
Issuance of stock for services, Shares			226,733
Issuance of stock for interest payable	196,031		264	195,767
Issuance of stock for interest payable, Shares			263,721
Issuance of warrants for services	1,534,405			1,534,405
Exercise of warrants and stock options	1,439,795		1,572	1,438,223
Exercise of warrants and stock options, Shares			1,571,849
Warrants issued in connection with convertible debt	1,574,900			1,574,900
Issuance of warrants for contractual obligations	985,010			985,010
Employee compensation from stock options	15,752			15,752
Issuance of stock and warrants pursuant to Regulation D	6,513,176		6,221	6,506,955
Issuance of stock and warrants pursuant to Regulation D, Shares			6,221,257
Preferred stock conversion into common stock	3,049,362		3,405	3,045,957
Preferred stock conversion into common stock, Shares			3,405,541
Beneficial conversion related to convertible debt	1,633,176			1,633,176
Beneficial conversion related to interest expense	39,529			39,529
Repurchase of beneficial conversion feature	(144,128)			(144,128)
Net loss	(11,763,853)				(11,763,853)
Ending Balance at Dec. 31, 2005	14,387,141		27,823	40,689,144	(26,329,826)
Ending Balance, Shares at Dec. 31, 2005			27,822,977
Issuance of stock for services	676,743		719	676,024
Issuance of stock for services, Shares			719,246
Issuance of stock for interest payable	183,596		195	183,401
Issuance of stock for interest payable, Shares			194,327
Issuance of warrants for services	370,023			370,023
Exercise of warrants and stock options	1,189,816		1,246	1,188,570
Exercise of warrants and stock options, Shares			1,245,809
Employee compensation from stock options	1,862,456			1,862,456
Issuance of stock and warrants pursuant to Regulation D	4,130,421		10,092	4,120,329
Issuance of stock and warrants pursuant to Regulation D, Shares			10,092,495
Preferred stock conversion into common stock	1,576,336		2,377	1,573,959
Preferred stock conversion into common stock, Shares			2,377,512
Beneficial conversion related to interest expense	16,447			16,447
Net loss	(8,870,579)				(8,870,579)
Ending Balance at Dec. 31, 2006	15,522,400		42,452	50,680,353	(35,200,405)
Ending Balance, Shares at Dec. 31, 2006			42,452,366
Issuance of stock for services	298,950		150	298,800
Issuance of stock for services, Shares			150,000
Issuance of stock for interest payable	1,258		1	1,257
Issuance of stock for interest payable, Shares			1,141
Issuance of warrants for services	472,635			472,635
Exercise of warrants and stock options	3,985,641		3,929	3,981,712
Exercise of warrants and stock options, Shares			3,928,957
Employee compensation from stock options	2,340,619			2,340,619
Issuance of stock and warrants pursuant to Regulation D	1,848,138		2,377	1,845,761
Issuance of stock and warrants pursuant to Regulation D, Shares			2,376,817
Preferred stock conversion into common stock	367,500		490	367,010
Preferred stock conversion into common stock, Shares			490,000
Net loss	(10,005,631)				(10,005,631)
Ending Balance at Dec. 31, 2007	14,831,510		49,399	59,988,147	(45,206,036)
Ending Balance, Shares at Dec. 31, 2007			49,399,281
Issuance of stock for services	390,000		350	389,650
Issuance of stock for services, Shares			350,000
Issuance of warrants for services	517,820			517,820
Exercise of warrants and stock options	2,639,711		3,268	2,636,443
Exercise of warrants and stock options, Shares			3,267,795
Employee compensation from stock options	1,946,066			1,946,066
Net loss	(10,269,571)				(10,269,571)
Ending Balance at Dec. 31, 2008	10,055,536		53,017	65,478,126	(55,475,607)
Ending Balance, Shares at Dec. 31, 2008			53,017,076
Issuance of stock for services	695,000		796	694,204
Issuance of stock for services, Shares			796,012
Issuance of warrants for services	1,064,210			1,064,210
Exercise of warrants and stock options	2,524,453		3,480	2,520,973
Exercise of warrants and stock options, Shares			3,480,485
Employee compensation from stock options	870,937			870,937
Issuance of stock and warrants pursuant to Regulation D	6,518,688		10,117	6,508,571
Issuance of stock and warrants pursuant to Regulation D, Shares			10,116,653
Net loss	(12,322,314)				(12,322,314)
Ending Balance at Dec. 31, 2009	9,406,510		67,410	77,137,021	(67,797,921)
Ending Balance, Shares at Dec. 31, 2009			67,410,226
Issuance of stock for services	856,613		776	855,837
Issuance of stock for services, Shares			776,250
Issuance of warrants for services	1,141,593			1,141,593
Exercise of warrants and stock options	3,103,680		3,491	3,100,189
Exercise of warrants and stock options, Shares			3,491,014
Employee compensation from stock options	3,759,650			3,759,650
Issuance of common stock pursuant to Regulation S	419,250		559	418,691
Issuance of common stock pursuant to Regulation S, Shares			559,000
Issuance of stock and warrants pursuant to Regulation D	6,346,989		11,169	6,335,820
Issuance of stock and warrants pursuant to Regulation D, Shares			11,168,067
Issuance of stock and warrants pursuant to Regulation D	4,217,390	13,283		4,204,107
Issuance of stock and warrants pursuant to Regulation D, Shares		13,283,324
Preferred stock conversion into common stock		(7,893)	7,893
Preferred stock conversion into common stock, Shares		(7,893,326)	7,893,326
Net loss	(18,552,102)				(18,552,102)
Ending Balance at Dec. 31, 2010	10,699,573	5,390	91,298	96,952,908	(86,350,023)
Ending Balance, Shares at Dec. 31, 2010		5,389,998	91,297,883
Issuance of stock for services	332,750		350	332,400
Issuance of stock for services, Shares			350,000
Issuance of warrants for services	945,116			945,116
Exercise of warrants and stock options	6,623,311		7,185	6,616,126
Exercise of warrants and stock options, Shares			7,185,522
Employee compensation from stock options	3,368,950			3,368,950
Issuance of stock and warrants pursuant to Regulation D	7,041,239		9,905	7,031,334
Issuance of stock and warrants pursuant to Regulation D, Shares			9,905,062
Sale of non-controlling interest in Pure-ific Corporation and warrants	443,500			443,500
Preferred stock conversion into common stock		(1,859)	1,859
Preferred stock conversion into common stock, Shares		(1,858,333)	1,858,331
Net loss	(19,434,699)				(19,434,699)
Ending Balance at Dec. 31, 2011	10,019,740	3,531	110,597	115,690,334	(105,784,722)
Ending Balance, Shares at Dec. 31, 2011		3,531,665	110,596,798
Issuance of stock for services	409,250		475	408,775
Issuance of stock for services, Shares			475,000
Issuance of warrants for services	1,381,329			1,381,329
Employee compensation from stock options	183,028			183,028
Issuance of stock and warrants pursuant to Regulation D	2,077,796		2,039	2,075,757
Issuance of stock and warrants pursuant to Regulation D, Shares			2,039,273
Preferred stock conversion into common stock		(590)	590
Preferred stock conversion into common stock, Shares		(590,000)	590,000
Net loss	(10,647,282)				(10,647,282)
Ending Balance at Sep. 30, 2012	$ 3,423,861	$ 2,941	$ 113,701	$ 119,739,223	$ (116,432,004)
Ending Balance, Shares at Sep. 30, 2012		2,941,665	113,701,071

Related Party Transaction (Details) (USD $)	9 Months Ended
Related Party Transaction (Details) (USD $)	Sep. 30, 2012
Related Party Transaction (Additional Textual) [Abstract]
Payment for consulting services	$ 48,000
Consulting costs charges	47,520
Non Employee [Member]
Related Party Transaction (Textual) [Abstract]
Payment for consulting services to another non-employee	75,000
Third Non Employee [Member]
Related Party Transaction (Textual) [Abstract]
Payment for consulting services to another non-employee	$ 75,000
Subsequent Event [Member]
Related Party Transaction (Textual) [Abstract]
Shares issued in exchange for services	100,000